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1.1 Metal-Catalyzed C–H bonds Functionalization 
During the past few decades, transition-metal catalysis has experienced an exponential growth 
in organic synthesis. It was shown great importance in many research areas and applied fileds, 
such as petroleum, chemical, energy, environmental and pharmaceutical sectors.1 Especially 
the transition-metal-catalyzed C–C bond formation reactions have attracted significant 
attention around the world for almost half a century. The most famous transformation in this 
research area is arguably the transition-metal-catalyzed cross-coupling reaction.2 Today, 
traditional cross-coupling chemistry is widely applied as a powerful synthetic tool in 
preparative organic chemistry. However, the formation of stoichiometric amounts of 
potentially harmful metal salts as by-products and the necessity of pre-functionalization of the 
substrates prove to be disadvantageous. To improve the atom- and setp-economy3 of organic 
synthesis, more and more attentions are paid on direct functionalization of the otherwise inert 
C–H bonds (438.9 kJ·mol–1 for sp³-hybridized bond in CH4, 472.4 kJ·mol–1 for sp²-hybridized 
bond in PhH)4 in the past decade.5  
 
                                                             
1 a) Modern Arylation Methods, (Eds: L. Ackermann), Wiley-VCH, Weinheim, 2009; b) Transition Metals for 
Organic Synthesis (Eds: M. Beller, C. Bolm, C.), 2nd ed., Wiley-VCH, Weinheim, 2004. 
2 For selected reviews on C–C bond formation via traditional cross-coupling reactions, see: a) C. C. C. J. Seechurn, 
M. O. Kitching, T. J. Colacot, V. Snieckus, Angew. Chem. Int. Ed. 2012, 51, 5062–5085; b) H. Li, C. C. C. J. Seechurn T. 
J. Colacot, ACS Catal. 2012, 2, 1147–1164; c) Chem. Soc. Rev. 2011, 40, 4877–5208, Special Issue 10 "Cross 
coupling reactions in organic synthesis"; d) B. M. Rosen, K. W. Quasdorf, D. A. Wilson, N. Zhang, A.-M. Resmerita, 
N. K. Garg, V. Percec, Chem. Rev. 2011, 111, 1346–1416; e) G. Cahiez and A. Moyeux, Chem. Rev. 2010, 110, 
1435–1462; f) Acc. Chem. Res. 2008, 41, 1439–1564, Special Issue 11 "Cross Coupling"; g) A. Roglans, A. 
Pla-Quintana, M. Moreno-Mañas, Chem. Rev. 2006, 106, 4622–4643; h) J.-P. Corbet, G. Mignani, Chem. Rev. 2006, 
106, 2651–2710, and references cited therein. 
3 For atom-economy conception, see: B. M. Trost, Acc. Chem. Res. 2002, 35, 695–705. 
4 a) S. J. Blanksby, G. B. Ellison, Acc. Chem. Res. 2003, 36, 255–263; b) F. G. Bordwell, Acc. Chem. Res. 1988, 21, 
456–463; c) D. F. McMillen, D. M. Golden, Annu. Rev. Phys. Chem. 1982, 33, 493–532; d) J. D. Cox, G. Pilcher, 
Thermochemistry of Organic and Organometallic Compounds, Academic Press, London, 1970. 
5
 Selected reviews on C−H bond functionalizations: a) N. Kuhl, M. N. Hopkinson, J. Wencel-Delord, F. Glorius, 
Angew. Chem. Int. Ed. 2012, 51, 10236–10254; b) J. Yamaguchi, A. D. Yamaguchi, K. Itami, Angew. Chem. Int. Ed. 
2012, 51, 8960–9009; c) K. M. Engle, T.-S. Mei, M. Wasa, J.-Q. Yu, Acc. Chem. Res., 2012, 45, 788–802; d) L. 
McMurray, F. O'Hara, M. J. Gaunt, Chem. Soc. Rev. 2011, 40, 1885−1898; e) L. Ackermann, Chem. Rev. 2011, 111, 
1315−1345; f) D. A. Colby, R. G. Bergman, J. A. Ellman, Chem. Rev. 2010, 110, 624–655; g) P. Thansandote, M. 





Scheme 1.1 Traditional cross-coupling reactions versus direct C–H bond cleavages. 
In recent years, most attention has been paid to the development of late transition metals, 
mainly due to some advantages in terms of the diversity and tunability of the catalysts and 
their robustness. However, the relatively high price, low natural abundance and partly strong 
toxicity limited their application. Cobalt and nickel, comparing to their 4d and 5d analogues, 
are easily available in the earth’s crust (Table 1.1).6 In spite of showing great potential in the 
direct C–H bond functionalizations because of their low cost and unique reactivity profiles, 
these metals were comparatively underutilized. 
Transition-Metal Nickel Cobalt Palladium Platinum Ruthenium Rhodium 
Abundance 
(g / ton) 
84 25 0.015 0.005 0.001 0.001 
Table 1.1 Abundance of selected transition metals in the earth’s crust. 
Cobalt-catalyzed traditional cross-coupling chemistry has been well studied since the middle 
of the last century.7 However, the cobalt-catalyzed C–H bond functionalizations were still in 
its infancy. In 1955, the first example of directed C–H bond functionalization reactions was 
reported by Murahashi,8 which set the stage for this research area. The treatment of a benzene 
solution of benzaldimine 1 with catalytic dicobalt octacarbonyl at high temperature and 
pressure led to the isolation of isoindoline 2 in good yield (Scheme 1.2). Therefore, seminal 
contributions were made by the Kisch, Brookhart and Klein group, which imply a 
                                                             
6 P. Enghag, Encyclopedia of the elements; Wiley, Weinheim, 2004. 
7 G. Cahiez, A. Moyeux, Chem. Rev. 2010, 110, 1435–1462, and references cited therein. 




high-potential catalytic activity of cobalt complexes towards C–H bond activation.9 However, 
most of these studies were limited either by harsh reaction condition or by the need of 
stoichiometric cobalt species.10 
  
Scheme 1.2 Cobalt-mediated synthesis of isoindoline 2. 
In 2010, Yoshikai and coworkers reported on the cobalt-catalyzed direct hydroarylation of 
alkynes through a chelation-assisted C–H bond activation (Scheme 1.3).11 The catalytic 
system consisting of the cobalt salt and stoichiometric amounts of Grignard reagents showed 
high potential for further C–H bond functionalization. Based on this result, the alkynes 4 were 
efficiently converted with varies other substrates, such as imines, aldimines or indoles.12  
 
Scheme 1.3 Cobalt-catalyzed hydroarylation of alkynes 4. 
In 2011, the Nakamura group disclosed the cobalt-catalyzed direct alkylation of benzamide 
with unreactivated primary alkyl chlorides,13 which work was extended applying imines as 
                                                             
9 Selected review: N. Yoshikai, Synlett 2011, 1047–1051. 
10 A. A. Kuulkarni, O. Daugulis, Syntheis 2009, 4087–4109, and references cited therein. 
11
 K. Gao, P. Lee, T. Fujita, N. Yoshikai, J. Am. Chem. Soc. 2010, 132, 12249–12251. 
12 a) T. Yamakawa, N. Yoshikai, Tetrahedron 2013, 69, 4459–4465; b) T. Yamakawa, N. Yoshikai, Org. Lett. 2013, 15, 
196–199; c) B.-H. Tan, Z. Ding, N. Yoshikai, Angew. Chem. Int. Ed. 2012, 51, 9610–9614; d) Z. Ding, N. Yoshikai, 
Angew. Chem. Int. Ed. 2012, 51, 4698–4701; e) P.-S. Lee, T. Fujita, N. Yoshikai, J. Am. Chem. Soc. 2011, 133, 17283–
17295; f) Z. Ding, N. Yoshikai, Synthesis 2011, 2561–2566; g). Z. Ding, N. Yoshikai, Org. Lett. 2010, 12, 4180–4183. 




substrates by Yoshikai and coworkers in 2012 (Scheme 1.4a).14  In the meantime, the 
alkylation was also achieved with alkenes using the corresponding arenes (Scheme 1.4b).15 
Moreover, the Grignard reagents could even be coupled directly into the ortho-position 
through cobalt-catalyzed chelation-assisted C–H bond activation, which was reported by the 
Shi and Nakamura groups (Scheme 1.4c).16  
  
Scheme 1.4 Cobalt-catalyzed C–H bond functionalization. 
Nickel-catalyzed C–H bond functionalization was reported by Kleiman and Dubeck in 1964 
(Scheme 1.5).17 The purple-blue organonickel species 8 was formed by heating a mixture of 
dicyclopentadienylnickel 6 with excess amount of azobenzene 7.  
 
Scheme 1.5 Nickel-mediated aromatic C–H bond activation. 
                                                             
14 K. Gao, P.-S. Lee, C. Long, N. Yoshikai, Org. Lett. 2012, 14, 4234–4237. 
15 a) Z. Ding, N. Yoshikai, Angew. Chem. Int. Ed. 2013, 52, 8574–8578; b) K. Gao, N. Yoshikai, Chem. Commun. 
2012, 48, 4305–4307; c) L. Ilies, Q. Chen, X. Zeng, E. Nakamura, J. Am. Chem. Soc. 2011, 133, 5221–5223; d) K. 
Gao, N. Yoshikai, Angew. Chem. Int. Ed. 2011, 50, 6888–6892; e) K. Gao, N. Yoshikai, J. Am. Chem. Soc. 2011, 133, 
400–402. 
16 a) B. Li, Z. Wu, Y. Gu, C. Sun, B. Wang, Z.-J. Shi, Angew. Chem. Int. Ed. 2011, 50, 1109–1113; b) Q. Chen, L. Ilies, 
N. Yoshikai, E. Nakamura, Org. Lett., 2011, 13, 3232–3234. 




During the recent years, much effort has been dedicated towards the nickel-catalyzed direct 
arylations and even more challenging direct alkylations. In 2009, Itami and coworkers 
reported the nickel-catalyzed direct arylation of azoles 9, where aryl halides and triflates were 
used as the electrophiles.18 Similar results were also reported by Miura group applying aryl 
bromides. 19  One year later, Miura developed a nickel-catalyzed direct arylation of 
heteroarenes using organosilicon species as the aryl sources.20 In 2012, Itami developed a 
direct arylation of heteroarenes with various phenol derivatives.21 Aryl carbonates and 
triflates as well as less reactive sulfamates and tosylates were efficiently converted (Scheme 
1.6).  
Scheme 1.6 Nickel-catalyzed C–H bond arylations. 
In the meantime, the nickel-catalyzed direct alkylation of heterocycles 9 with alkyl halides 12 
employing nickel pincer complexes and CuI was achieved by the Hu group in 2010.22 
Ackermann and coworkers reported the analogous direct alkylation employing the 
user-friendly nickel complex (Scheme 1.7a).23 Moreover, the C–H bond alkylation with 
terminal alkenes 15 through nickel-catalyzed hydroarylation with pyridones 14 was 
developed by the Hiyama group in 2012 (Scheme 1.7b).24 
Despite of these seminal contributions, the aforementioned transformations were still limited 
to the activation of more acidic C–H bonds. Thus, it is noteworthy that, in 2011, the Chatani 
group reported nickel-catalyzed chelation-assisted functionalization of inert C–H bonds in 
benzamides 17. Thus, versatile approach to isoquinolone derivatives 18 was elaborated along 
                                                             
18 J. Canivet, J. Yamaguchi, I. Ban, K. Itami, Org. Lett. 2009, 11, 1733–1736. 
19 H. Hachiya, K. Hirano, T. Satoh, M. Miura, Org. Lett. 2009, 11, 1737–1740. 
20
 H. Hachiya, K. Hirano, T. Satoh, M. Miura, Angew. Chem. Int. Ed. 2010, 49, 2202–2205. 
21 a) K. Muto, J. Yamaguchi, K. Itami, J. Am. Chem. Soc. 2012, 134, 169–172; b) Also see: L. Ackermann, A. 
Althammer, S. Fenner, Angew. Chem. Int. Ed. 2009, 48, 201–204. 
22 O. Vechorkin, V. Proust, X. Hu, Angew. Chem. Int. Ed. 2010, 49, 3061–3064. 
23 L. Ackermann, B. Punji, W. Song, Adv. Synth. Catal. 2011, 353, 3325–3329. 




the route of C–H/N–H bond activations (Scheme 1.8a).25 
 
Scheme 1.7 Examples of nickel-catalyzed direct alkylation. 
More recently, the nickel-catalyzed direct alkylation of benzamides 17 with alkyl halides 12 
was also achieved through this chelation-assisted reaction manifold (Scheme 1.8b).26 
 
Scheme 1.8 Nickel-catalyzed chelation-assisted C–H bonds functionalization. 
1.2 Transition-Metal-Catalyzed Secondary Alkylation 
The discovery of the ruthenium-catalyzed ortho-alkylation of aromatic ketones 20 with 
olefins 15 by Murai and coworkers 27  in 1993 opened a new paradigm in directed 
alkylations.28 However, this strategy was limited to specific secondary alkylations, mainly 
because of the anti-Markovnikov selectivity of alkylations with terminal olefins, low 
                                                             
25
 H. Shiota, Y. Ano, Y. Aihara, Y. Fukumoto, N. Chatani, J. Am. Chem. Soc. 2011, 133, 14952–14955. 
26 Y. Aihara, N. Chatani, J. Am. Chem. Soc., 2013, 135, 5308–5311. 
27 S. Murai, F. Kakiuchi, S. Sekine, Y. Tanaka, A. Kamatani, M. Sonoda, N. Chatani, Nature 1993, 366, 529–531. 
28 Selected reviews: a) N. A. Foley, J. P. Lee, Z. Ke, T. B. Gunnoe, T. R. Cundari, Acc. Chem. Res. 2009, 42, 585–597; 
b) F. Kakiuchi, Top. Organomet. Chem. 2007, 24, 1–33; c) F. Kakiuchi, N. Chatani, Adv. Synth. Catal. 2003, 345, 




reactivity of internal olefins and isomerization of internal acyclic olefins (Scheme 1.9).  
 
Scheme 1.9 Ruthenium-catalyzed ortho-alkylation of ketones. 
More recently, alkyl halides have emerged as important alternative reagents for the direct 
alkylation.29 The alkylation of either reactive acidic C–H bonds in azoles or of inert ones in 
arenes with Lewis basic directing groups could be achieved through this strategy. 
Nevertheless, while successful for the primary alkylation, these electrophiles have been 
applied for only a handful of secondary alkylation (Scheme 1.10).30  
 
Scheme 1.10 Direct alkylations with secondary alkyl halides. 
Besides alkyl halides 22, other reagents were also utilized for secondary alkylations. In 2008, 
Li and coworkers reported the only example of ruthenium-catalyzed direct secondary 
alkylation through the cross dehydrogenative coupling (CDC) process (Scheme 1.11),31 in 
which the unreactive cycloalkanes 24 were directly attached to the ortho-position of 
substituted 2-phenylpyridines 3 through activation of two C–H bonds. 
                                                             
29
 For review, see: L. Ackermann, Chem. Commun. 2010, 46, 4866–4877. 
30 Examples of transition-metal-catalyzed alkylation with secondary halides: a) L. Ackermann, P. Novak, R. Vicente, 
N. Hofmann, Angew. Chem, Int. Ed. 2009, 48, 6045–6048; b) N. Hofmann, L. Ackermann, J. Am. Chem. Soc. 2013, 
135, 5877–5884; c) L. D. Tran, O. Daugulis, Org. Lett. 2010, 12, 4277–4279; d) P. Ren, Salihu, I.; Scopelliti, R., Hu, X. 
Org. Lett. 2012, 14, 1748–1751; e) B. Xiao, Z.-J. Liu, L. Liu, Y. Fu, J. Am. Chem. Soc. 2013, 135, 616–619. 





Scheme 1.11 Secondary alkylation through CDC process. 
Three years later, the Wang group reported the first copper-catalyzed synthesis of the 
secondary alkyl-substituted heterocycles 9 through alkylation with N-tosylhydrazones 26,32 
which was followed by Miura in 2012 with nickel and cobalt catalyst (Scheme 1.12a).33 The 
diazo compound generated in situ from N-tosylhydrazones under the basic reation condition 
was used as the alkylation reagent. Additionally, the phenol-directed alkylation with the 
corresponding secondary alcohols 28 was developed by Yi and coworkers in 2012 (Scheme 
1.12b).34  
 Scheme 1.12 Alkylations with other secondary electrophiles. 
1.3 Phenol Derivatives in Cross-Couplings and C–H Bonds 
Functionalizations 
Synthetic chemists are now able to provide a wide array of aryl, vinyl, allyl, and alkyl halides. 
However, such species are less available from natural sources and are not used as coupling 
partners in biosynthetic pathways. A key benefit of phenol- and ketone-based-electrophiles is 
                                                             
32 X. Zhao, G. Wu, Y. Zhang, J. Wang, J. Am. Chem. Soc. 2011, 133, 3296–3299. 
33 T. Yao, K. Hirano, T. Satoh, M. Miura, Angew. Chem. Int. Ed. 2012, 51, 775–779. 




their ready accessibility. In the case of phenols, such compounds are naturally abundant or 
can readily be prepared from other easily available aromatic species.35 
Additionally, oxygenation on the aromatic ring can facilitate the introduction of additional 
substituents via a number of pathways including, for example, electrophilic aromatic 
substitution. Depending on the nature of the phenol-derived substituent and the electrophile, it 
is often possible to control the predominant formation of para- or ortho-substituted products. 
The ortho-substitution of phenol derivatives 30 can also be achieved using directed 
ortho-metalation (DoM).36 Through this methodology, numerous functional groups, such as 
phenols, ethers, carbamates, and sulfamates, can undergo the directed ortho-lithiation. 
Subsequent transformation of the resulting organolithium species 32 with electrophilic species 
E+ 33 provides the ortho-substituted products 34 (Scheme 1.13).  
  
Scheme 1.13 Ortho-functionalization through the DoM process. 
Furthermore, phenol derivatives could also be ortho-functionalized directly through 
transition-metal-catalyzed C–H bond functionalization (Scheme 1.14a).37 Direct arylation 
and alkylation were both achieved with phenol esters, pivalates and carbamates as directing 
groups. Additionally, the ortho- and para-selective ruthenium-catalyzed oxygenation of the 
phenol derivatives 30 was recently developed by Ackermann and coworkers (Scheme 
1.14b).38  
                                                             
35 Z. Rappoport, The Chemistry of Phenols, John Wiley & Sons Ltd.: Chichester, U.K., 2003. 
36
 V. Snieckus, Chem. Rev. 1990, 90, 879–933. 
37 For examples of phenol-derived substituents as directing groups, see: a) B. Xiao, Y. Fu, J. Xu, T.-J. Gong, J.-J. Dai, 
J. Yi, L. Liu, J. Am. Chem. Soc. 2010, 132, 468–469; b) R. B. Bedford, R. L. Webster, J. C. Mitchell, Org. Biomol. Chem. 
2009, 7, 4853–4857; c) X. Zhao, C. S. Yeung, V. M. Dong, J. Am. Chem. Soc. 2010, 132, 5837–5844; d) J. Li, C. 
Kornhaaß, L. Ackermann, Chem. Commun. 2012, 48, 11343–11345.  





Scheme 1.14 Examples of hydroxyl-directed C–H activation. 
Based on the aforementioned advantages, the phenol-derived electrophiles have been widely 
studied and utilized in the cross-coupling chemistry39 and transition-metal-catalyzed C–N 
bond formations40 through the C–O bonds activation during the past decades. However, the 
direct C–H bond arylations with phenol-based electrophiles was still limited because of the 
high activation energy of the C–O bonds. Recently, the Ackermann group reported the direct 
C–H bonds functionalization of heteroarenes with phenol derivatives using palladium 
complexes,41 whereas nickel catalysts were utilized by Itami for the most recent direct 
arylations of C–H acidic azoles (Scheme 1.15a).21  
 
                                                             
39 Selected reviews: a) S. I. Kozhushkov, H. K. Potukuchi, L. Ackermann, Catal. Sci. Technol. 2013, 3, 562–571; b) B. 
M. Rosen, K. W. Quasdorf, D. A. Wilson, N. Zhang, A.-M. Resmerita, N. K. Garg, V. Percec, Chem. Rev. 2011, 111, 
1346–1416; c) B.-J. Li, D.-G. Yu, C.-L. Sun, Z.-J. Shi, Chem. Eur. J. 2011, 17, 1728–1759; d) D.-G. Yu, B.-J. Li, Z.-J. Shi, 
Acc. Chem. Res. 2010, 43, 1486–1495; e) A. Littke, in Modern Arylation Methods (Ed.: L. Ackermann), Wiley-VCH, 
Weinheim, 2009; pp 25–67, and references cited therein. 
40 For representative examples of C–N bond formation, see: a) T. Shimasaki, M. Tobisu, N. Chatani, Angew. Chem. 
Int. Ed. 2010, 49, 2929–2932; b) M. L. H. Mantel, A. T. Lindhardt, D. Lupp, T. Skrydstrup, Chem.;Eur. J. 2010, 16, 
5437–5442; c) R. J. Lundgren, M. Stradiotto, Angew. Chem. Int. Ed. 2010, 49, 8686–8690; d) C. M. So, Z. Zhou, C. P. 
Lau, F. Y. Kwong, Angew. Chem. Int. Ed. 2008, 47, 6402–6406; e) H. N. Nguyen, X. Huang, S. L. Buchwald, J. Am. 
Chem. Soc. 2003, 125, 11818–11819; f) A. H. Roy, J. F. Hartwig, J. Am. Chem. Soc. 2003, 125, 8704–8705; g) X. 
Huang, K. W. Anderson, D. Zim, L. Jiang, A. Klapars, S. L.Buchwald, J. Am. Chem. Soc. 2003, 125, 6653–6655; h) C. 
Bolm, J. P. Hildebrand, J. Rudolph, Synthesis 2000, 911–913; i) B. C. Hamann, J. F. Hartwig, J. Am. Chem. Soc. 1998, 
120, 7369–7370 
41 a) L. Ackermann, A. Althammer, S. Fenner, Angew. Chem. Int. Ed. 2009, 48, 201–204; b) L. Ackermann, S. 





 Scheme 1.15 Phenol-derived electrophiles for direct arylations. 
Nevertheless, the direct arylation of unactivated arenes with phenol derivatives is, to date, 
unfortunately largely restricted to relatively expensive complexes of the rare transition metals, 
such as ruthenium and palladium (Scheme 1.15b).42 
1.4 Transition-Metal-Catalyzed Indole Syntheses 
Indole derivatives likely represent one of the most important structural building blocks in 
bioorganic chemistry, drug discovery and medicinal chemistry.43 Representative examples of 
biologically active indoles include non-steroidal anti-inflammatory drugs indomethacin (39), 
and etodolac (40), neurotransmitter serotonin (41) and 5HT-3 antagonist ondansetron (42) 
(Scheme 1.16). Therefore, there is a continued strong demand for chemo- and site-selective 
syntheses of this heteroaromatic scaffold.44 
                                                             
42 Examples of late transition-metal-catalyzed direct arylations of arenes with phenol-derivatives, [Pd]: a) L. 
Ackermann, S. Fenner, Chem. Commun. 2011, 47, 430–432; [Ru]: b) L. Ackermann, J. Pospech, H. K. Potukuchi, Org. 
Lett. 2012, 14, 2146–2149; c) L. Ackermann, M. Mulzer, Org. Lett. 2008, 10, 5043–5045; d) L. Ackermann, R. 
Vicente, A. Althammer, Org. Lett. 2008, 10, 2299–2302; e) L. Ackermann, A. Althammer, R. Born, Angew. Chem. 
Int. Ed. 2006, 45, 2619–2622. 
43
 J. Alvarez-Builla, J. J. Vaquero, J. Barluenga, Modern Heterocyclic Chemistry, Wiley-VCH, Weinheim, 2011. 
44 Select reviews on the preparation of indoles: a) S. Cacchi, G. Fabrizi, A. Goggiamani, Org. React. 2012, 76, 281–
534; b) S. Cacchi, G. Fabrizi, A. Goggiamani, Org. Biomol. Chem. 2011, 9, 641–652; c) K. Krüger, A. Tillack, M. Beller, 
Adv. Synth. Catal. 2008, 350, 2153–2167; d) L. Ackermann, Synlett 2007, 507–526; e) G. R. Humphrey, J. T. Kuethe, 
Chem. Rev. 2006, 106, 2875–2911; f) D. A. Horton, G. T. Bourne, M. L. Smythe, Chem. Rev. 2003, 103, 893–930, 





Scheme 1.16 Selected biologically active indole derivatives. 
In addition to the classical Fischer indole synthesis,44e the Larock indole synthesis45 was 
widely studied during the last decade. Based on this methodology, significant progress has 
been accomplished with intramolecular addition reactions of ortho-alkynylanilines.46 The 
easily accessible ortho-alkynylhaloarenes 45 were converted into the corresponding indole 
derivatives via a reaction cascade comprising intermolecular aminations of aryl halides and 
subsequent intramolecular hydroaminations of alkynes. Thereby, variously decorated indole 
derivatives 47 featuring substituents at different positions were synthesized with high efficacy 
(Scheme 1.17).  
 
Scheme 1.17 Cascade reaction sequence for a modular synthesis of indoles. 
Although the transition-metal-catalyzed C–C and C–N bond forming reactions have proved 
particularly valuable for indoles syntheses, these transformations largely utilized 
pre-functionalized starting materials. Recently, significantly more step-economical strategies 
                                                             
45 a) For a review, see: R. C. J. Organomet. Chem. 1999, 576, 111–124; see also: b) C. Chen, D. R. Lieberman, R. D. 
Larsen, T. R. Verhoeven, P. J. Reider, J. Org. Chem. 1997, 62, 2676–2677. 
46 Selected examples: a) L. Ackermann, S. Barfüßer, H. K. Potukuchi, Adv. Synth. Catal. 2009, 351, 1064–1072; b) L. 
Ackermann, R. Sandmann, M. V. Kondrashov, Synlett 2009, 1219–1222; c) L. Ackermann, R. Sandmann, M. 
Schinkel, M. V. Kondrashov, Tetrahderon 2009, 65, 8930–8939; d) P.-Y. Yao, Y. Zhang, R. P. Hsung, K. Zhao, Org. Lett. 
2008, 10, 4275–4278; e) R. Sanz, M. P. Castroviejo, V. Guilarte, A. Perez, F. J. Fananas, J. Org. Chem. 2007, 72, 
5113–5118; f) Z.-Y. Tang, Q.-S. Hu, Adv. Synth. Catal. 2006, 348, 846–850; g) L. Ackermann, Org. Lett. 2005, 7, 




were devised by methods that capitalize upon unactivated C–H bonds as latent functional 
groups.47  
  
Scheme 1.18 Metal-catalyzed heterocycle syntheses through oxidative C–H activation. 
In 2008, Glorius reported a rhodium-catalyzed indole synthesis through oxidative coupling of 
acetanilides and alkynes.48 Since then, late transition metal catalysts, such as rhodium, 
palladium or ruthenium complexes have been widely utilized for the heterocycle syntheses by 
oxidative alkyne annulation through C–H/Het–H bond functionalizations (Scheme 1.18).49 
Remarkable, the use of copper (II) or silver (I) salts as the stoichiometric or cocatalytic 
oxidants proved to be crucial for the regeneration of the active species during the catalytic 
reactions. 
 
                                                             
47 For reviews, see: a) L. Ackermann, Acc. Chem. Res., 2013, 46, DOI:10.1021/ar3002798; b) G. Song, F. Wang, X. 
Li, Chem. Soc. Rev., 2012, 41, 3651–3678; c) T. Satoh, M. Miura, Chem. Eur. J., 2010, 16, 11212–11222.  
48 S. Würtz, S. Rakshit, J. J. Neumann, T. Droge, F. Glorius, Angew. Chem. Int. Ed., 2008, 47, 7230–7233 
49 Selected examples, a) S. Park, B. Seo, S. Shin, J.-Y. Son, P. H. Lee, Chem. Commun. 2013, 49, 8671–8673; b) J. Du, 
B. Zhou, Y. Yang, Y. Li, Chem. Asian J. 2013, 8, 1386–1390; c) N. Quiñones, A. Seoane, R. García-Fandiño, J. L. 
Mascareñas, M. Gulías, Chem. Sci. 2013, 4, 2874–2879; d). Z. Shi, C. Tang, N. Jiao, Adv. Synth. Cat. 2012, 354, 
2695–2700; e) M. V. Pham, B. Ye, N. Cramer, Angew. Chem. Int. Ed. 2012, 51, 10610–10614; f) H. Wang, C. 
Grohmann, C. Nimphius, F. Glorius, J. Am. Chem. Soc., 2012, 134, 19592–19595; g) M. P. Huestis, L. N. Chan, D. R. 
Stuart, K. Fagnou, Angew. Chem. Int. Ed., 2011, 50, 1338–1341; h) J. Chen, G. Song, C.-L. Pan, X. Li, Org. Lett., 2010, 
12, 5426–5429; i) D. R. Stuart, M. Bertrand-Laperle, K. M. N. Burgess, K. Fagnou, J. Am. Chem. Soc., 2008, 130, 
16474–16475; j) D. R. Stuart, P. Alsabeh, M. Kuhn, K. Fagnou, J. Am. Chem. Soc., 2010, 132, 18326–18339; 
Activated alkynes: k) R. Bernini, G. Fabrizi, A. Sferrazza, S. Cacchi, Angew. Chem. Int. Ed. 2009, 48, 8078–8081; l) T. 
Piou, L. Neuville, J. Zhu, Tetrahedron 2013, 69, 4415–4420; m) L. Ren, Z. Shi, N. Jiao, Tetrahedron 2013, 69, 4408–
4414; n) N. Zhang, B. Li, H. Zhong, J. Huang, Org. Biomol. Chem. 2012, 10, 9429–9439; o) Z. Shi, C. Zhang, S. Li, D. 
Pan, S. Ding, Y. Cui, N. Jiao, Angew. Chem. Int. Ed., 2009, 48, 4572–4576; [Ru]: p) W. Ma, K. Graczyk, L. Ackermann, 
Org. Lett. 2012, 14, 6318–6321; q) M. Deponti, S. I. Kozhushkov, D. S. Yufit, L. Ackermann, Org. Biomol. Chem. 
2013, 11, 142–148; r) C.-Z. Luo, P. Gandeepan, C.-H. Cheng, Chem. Commun. 2013, 49, 8528–8530; s) N. Kavitha, 
G. Sukumar, V. P. Kumar, P. S. Mainkar, S. Chandrasekhar, Tetrahedron Lett. 2013, 54, 4198–4201; t) P. Villuendas, E. 
P. Urriolabeitia, J. Org. Chem. 2013, 78, 5254–5263; u) B. Li, N. Wang, Ye Liang, S. Xu, B. Wang, Org. Lett. 2013, 15, 





Transition-metal-catalyzed arylation of amines with aryl halides are among the most 
important methods for the selective formation of C–N bonds. Particularly, the use of 
phenol-derived electrophiles in catalyzed arylations is highly attractive. However, the strategy 
was limited to the use of the expensive late transition metals. Consequently, nickel-catalyzed 
aminaitions would be a useful protocol for organic synthesis and constituted our first project 
(Scheme 2.1). 
 
Scheme 2.1 Nickel-catalyzed direct arylation of amines 46. 
As was mentioned above, the preparation of substituted indoles is of key importance in 
practical synthetic chemistry. Among other methods, the reaction cascade comprising 
intermolecular aminations of aryl halides and subsequent intramolecular hydroaminations of 
alkynes was widely studied in the past few years. Comparing to the application of the late 
transition metals like palladium and rhodium as the catalysts, the nickel-catalyzed indole 
synthesis from appropriate ortho-substituted aryl halides was the second research project 
(Scheme 2.2). 
 
Scheme 2.2 Nickel-catalyzed base-mediated indole synthesis. 
Alternatively, we became interested in the indole synthesis by oxidative alkyne annulation 




the use of late transition metals and stoichiometric amount of metal oxidant, which limited 
their application. To overcome these limitations, we set out to develop an unprecedented 
nickel-catalyzed alkyne annulation with electron-rich anilines 49 devoid of copper (II) or 
silver (I) salts as the sacrificial oxidants in the third project (Scheme 2.3). 
 
Scheme 2.3 Nickel-catalyzed indole synthesis through C–H/N–H activation. 
Transition-metal-catalyzed direct alkylations, especially of relatively unreactive arenes, with 
secondary alkylating reagents remain to be a challenging research topic. During recent years, 
chelation-assistance has offered a useful tool for C–H bond functionalizations. However, the 
application of bidentate directing groups towards alkylation with secondary alkylating 
reagents is still not available. It would be of high interest to explore a nickel-catalyzed 
secondary alkylation of the inert arenes, which is the goal of our forth project (Scheme 2.4). 
 
Scheme 2.4 Nickel-catalyzed chelation-assisted secondary alkylation. 
Efficient methods for the selective preparation of biaryls are of key importance, as these 
structural motifs are crucial building blocks for natural products, liquid crystals, and 
functional materials. Although the cobalt-catalyzed C–H bond functionalization was well 
studied during the past years, the direct arylation with aryl halides have proven elusive. 
Moreover, the direct arylation of unactivated arenes with phenol derivatives is, to date, 
restricted to the relatively expensive late transition metals, such as ruthenium and palladium. 




prime focus of the fifth project (Scheme 2.5). 
 
Scheme 2.5 Cobalt-catalyzed direct arylation by C–H/C–O cleavages. 
Cobalt-catalyzed direct alkylations of benzamides and imines have been established by the 
Nakamura and Yoshikai groups. However, the moderate yields and poor selectivities of the 
reported procedures prompted us to search for novel direct alkylations with unactivated alkyl 
chlorides 12a, and this task is the main purpose of the last project (Scheme 2.6). 
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Results and Discussion                                     
3. Nickel-Catalyzed Aminations of Aryl Sulfamates 
Transition-metal-catalyzed arylations of amines with aryl halides are among the most 
important methods for the selective formation of C–N bonds. Particularly, the use of 
phenol-derived electrophiles in catalyzed arylations is highly attractive, since they are readily 
accessible and can be easily implemented as directing groups in site-selective arene 
functionalization strategies. While these user-friendly electrophiles were recently employed 
for efficient C–C bond formations, their use in transition-metal-catalyzed aminations has 
unfortunately thus far proven elusive. Ackermann and coworkers previously reported on the 
development of efficient amination reactions for modular heteroarene syntheses.50 However, 
these protocols mainly used palladium, copper and titanium catalysts and were limited to the 
use of aryl halides. In 2010, Chatani developed an efficient nickel-catalyzed arylation of 
secondary amines with aryl pivalates.51 However, the protocol was limited to the application 
of activated phenol derivatives. The aminations performed with the less reactive aryl tosylates, 
mesylates and sulfamates were unknown. Continuing these investigations, we examined the 
ability of nickel complexes to catalyze aminations with aryl sulfamates, and these results are 
summarized in this chapter.52 
3.1 Optimization Studies of Nickel-Catalyzed Aminations  
At the outset of our studies, we tested various ligands and bases in the nickel-catalyzed 
amination of aryl sulfamate 30aa (Table 3.1). While representative monodentate phosphine 
ligands provided only unsatisfactory results (entries 2–7), nickel complexes derived from 
N-heterocyclic carbene (NHC) precursors (entries 8–9) or bidentate phosphine ligands 
                                                             
50 For representative examples, see: a) L. Ackermann, S. Barfüsser, H. K. Potukuchi, Adv. Synth. Catal. 2009, 351, 
1064–1072; b) L. Ackermann, R. Sandmann, L. T. Kaspar, Org. Lett. 2009, 11, 2031–2034; c) L. Ackermann, R. 
Sandmann, M. V. Kondrashov, Synlett 2009, 1219–1222; d) L. Ackermann, R. Sandmann, A. Villar, L. T. Kaspar, 
Tetrahedron 2008, 64, 769–777; e) L. Ackermann, J. H. Spatz, C. J. Gschrei, R. Born, A. Althammer, Angew. Chem. 
Int. Ed. 2006, 45, 7627–7630; f) L. Ackermann, R. Born, Angew. Chem. Int. Ed. 2005, 44, 2444–2447 and 
references cited therein. 
51 T. Shimasaki, M. Tobisu, N. Chatani, Angew. Chem. Int. Ed. 2010, 49, 2929–2932. 
52 L. Ackermann, R. Sandmann, W. Song, Org. Lett. 2011, 13, 1784–1786. 
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(entries 12–14) displayed improved catalytic activities. Notably, the best results were  
Table 3.1 Optimization of nickel-catalyzed amination with sulfamate 30aa.[a] 
 
Entry Ligand (mol %) Base Yield (%)[b] 
1 -- NaOt-Bu -- 
2 (1-Ad)2P(O)H (10) (54) NaOt-Bu -- 
3 HASPO (i-Pr) (10) (55) NaOt-Bu -- 
4 PPh3 (10) (56) NaOt-Bu -- 
5 PCy3 (10) (57) NaOt-Bu -- 
6 S-Phos (10) (58) NaOt-Bu -- 
7 X-Phos (10) (59) NaOt-Bu -- 
8 HIPrCl (10) (60) NaOt-Bu 85 
9 sHIPrCl (10) (61) NaOt-Bu 82 
10 phenathroline (5) (62) NaOt-Bu 8 
11 dppp (5) (63) NaOt-Bu -- 
12 dppe (5) (64) NaOt-Bu 52 
13 rac-BINAP (5) (65) NaOt-Bu 54 
14 dppf (5) (66) NaOt-Bu 95 
15 dppf (5) NaOt-Bu 65 
16 dppf (5) NaOt-Bu -- 
17 [c] dppf (5) NaOt-Bu -- 
[a] Reaction conditions: 30aa (0.50 mmol), 46a (0.75 mmol), Ni(cod)2 (5.0 mol %), L (5.0–10 
mol %), base (0.75 mmol), PhMe (2.0 mL), 105 °C , 16 h. [b] Yields of isolated products. [c] 
Co2(CO)8 (5.0 mol %). 
accomplished with dppf as the ligand, along with NaOt-Bu as the optimal choice of base. 
Interestingly, the cobalt complex which was efficient for the C–C bond formations did not 
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deliver the desired product here (entry 17). 
3.2 Scope of Nickel-Catalyzed Amination of Aryl Sulfamates 
3.2.1 Nickel-Catalyzed Direct Arylations of Primary Amines 
With the optimized catalytic system in hands, we explored its scope in the nickel-catalyzed 
amination of differently substituted sulfamates 30a (Table 3.2). Either electron-poor or less 
reactive electron-rich sulfamates delivered the desired products in excellent yields (entries 8–
10). Moreover, aniline derivatives 46 bearing electron-withdrawing as well as 
electron-donating substituents efficiently delivered the products 48, even when being 
sterically hindered. Importantly, challenging n-alkyl amines were converted with comparable 
catalytic efficacy (entries 13–14). 
Table 3.2 Nickel-catalyzed direct arylation with aryl sulfamates[a] 
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      30af 46i 48fi  
[a] Reaction conditions: 30a (0.50 mmol), 46 (0.75 mmol), Ni(cod)2 (5.0 mol %), dppf (5.0 
mol %), NaOt-Bu (1.0 mmol), PhMe (1.0 mL), 105 °C, 16 h; [b] Yield of isolated product. 
3.2.2 Nickel-Catalyzed Direct Arylations of Secondary Amines 
Compared to the arylations of primary amines the direct arylations of alkyl-substituted 
secondary amines 67 only gave moderate conversion with dppf as the ligand. However, a 
nickel catalyst generated in situ from an NHC precursor provided significant better results. 
The amination proceeded with high efficacy even at a lower reaction temperature (Scheme 
3.1). 
 Scheme 3.1 Nickel-catalyzed arylation of morpholine 68. 
Nickel-Catalyzed Aminations of Aryl Sulfamtes 
22 
 
3.3 Intermolecular Competition Reactions 
Intermolecular competition experiments were carried out to investigate the relative reaction 
rates. The reaction between electron-rich and electron-poor aryl sulfamates 30ad and 30ae 
revealed the latter to display a significantly higher inherent reactivity (Scheme 3.2).  
  
Scheme 3.2 Competition experiments with different sulfamates 30a. 
Additionally, the electron-rich aniline 46a gave much higher conversion than its 
electron-deficient analogue 46g (Scheme 3.3). 
 
Scheme 3.3 Competition experiments with different anilines 46. 
3.4 Conclusion 
In summary, we have elaborated the unprecedented general nickel-catalyzed arylations of 
primary 46 and secondary amines 67 through challenging C–O bond activations in sulfamates 
30a. Hence, nickel catalyst derived from ligand dppf allowed for arylations with aryl 
sulfamates as electrophiles, whereas the direct arylations of secondary amines worked more 
efficiently with N-heterocyclic carbene (NHC) precursor as the ligand.  
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4. Nickel-Catalyzed Amination/Hydroamination for Indole 
Synthesis 
In the previous research of the Ackermann group, palladium and copper complexes were 
found to enable the formation of indoles bearing inter alia aryl-, alkyl- or 
alkoxycarbonyl-substituents on nitrogen. In continuation of these studies, we became 
interested in exploring the unprecedented use of inexpensive nickel catalysts for a modular 
indole synthesis starting from ortho-alkynylhaloarenes through a reaction cascade comprising 
intermolecular aminations of aryl halides and subsequent intramolecular hydroaminations of 
alkynes, the results of which are disclosed in this chapter.53  
4.1 Optimization Studies of Nickel-Catalyzed Indole Synthesis 
At the outset of these studies, we probed representative ligands and nickel compounds for the 
envisioned amination/hydroamination sequential synthesis of indole (Table 4.1). Notably, no 
conversion of starting material 45aa to the desired product 47ac occurred in the absence of a 
stabilizing ligand, irrespective of the oxidation state of the nickel precursors (entries 1–2). 
While monodentate phosphine ligands provided only unsatisfactory catalysis, improved 
isolated yields were obtained with precursors of NHCs. However, nickel complexes derived 
from bidentate ligands proved to be superior, with dppf being optimal (entries 3–14). 
Generally, the use of additional base KOt-Bu proved beneficial to ensure quantitative 
cyclization of the intermediate to the desired indole. Importantly, decreased loading of 
KOt-Bu could even improve the isolated yields, which means a base-mediated intramolecular 




                                                             
53 L. Ackermann, W. Song, R. Sandmann, J. Organomet. Chem. 2011, 696, 195–201. 
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Table 4.1: Optimization study of nickel-catalyzed indole synthesis[a] 
 
Entry [Ni] Ligand (mol %) Yield (%) 
1 NiCl2 -- -- 
2 Ni(cod)2 -- -- 
3 Ni(cod)2 PPh3 (10) (56) -- 
4 Ni(cod)2 PCy3 (10) (57) -- 
5 Ni(cod)2 (1-Ad)2P(O)H (10) (54) 10 
6 Ni(cod)2 X-Phos (10) (59) -- 
7 Ni(cod)2 IMesHCl (10) (69) 12 
8 Ni(cod)2 IPrHCl (10) (60) 51 
9 Ni(cod)2 sHIPrCl (10) (61) 47 
10 Ni(cod)2 phenathroline  (62) 49 
11 Ni(cod)2 rac-BINAP (65) 31 
12 Ni(cod)2 dppp  (63) 46 
13 Ni(cod)2 dppe (64) 71 
14 Ni(cod)2 dppf  (66) 88 
15[b] Ni(cod)2 dppf  92 
[a] Reaction conditions: 45aa (1.0 equiv), 46c (1.5 equiv), [Ni] (5.0 mol %), ligand (5.0 
mol %), NaOt-Bu (1.5 equiv), PhMe (2.0 mL), 105 °C, 16 h; KOt-Bu (3.0 equiv), 120 °C, 6 h; 
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4.2 Scope of Nickel-Catalyzed Indole Synthesis 
4.2.1 Nickel-Catalyzed Indole Synthesis with Aniline Derivatives 
With an optimized catalytic system in hands, we probed its scope in the 
amination/hydroamination reaction sequence employing aniline derivatives 46 (Table 4.2). 
Notably, differently substituted aromatic amines could be employed, bearing either 
electron-donating or electron-withdrawing substituents (entries 1–4). Furthermore, the nickel 
catalyst was not restricted to the use of tolane derivatives. Indeed, substrates displaying 
alkyl-substituted alkynes were converted with an efficacy being comparable to the one 
observed when using the corresponding aryl-substituted analogues (entries 5–7). Moreover, 
sterically hindered aniline derivatives 46f and 46j provided the desired indoles in high yields, 
as did a nucleophile bearing a further Lewis-basic pyridyl moiety 46k (entries 8–10).  
Table 4.2 Nickel-catalyzed amination/hydroamination-based indole synthesis with aniline 
derivatives 46.[a] 
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 45aa 46k 47ak  
[a] Reaction conditions: 45a (0.5 mmol), 46 (0.75 mmol), [Ni(cod)2] (5.0 mol %), dppf (5.0 
mol %), NaOt-Bu (1.5 equiv), PhMe (2.0 mL), 105 °C, 16h; KOt-Bu (3.0 equiv), 120 °C, 6h. 
[b] Yield of isolated product. 
4.2.2 Nickel-Catalyzed Indole Synthesis with Benzyl and Alkyl Amines 
To our delight the nickel catalyst derived from dppf also enabled the preparation of indoles 
when using benzyl or even more challenging n-alkyl amines (Scheme 4.1). 
Nickel-Catalyzed Amination/Hydroamination for Indole Synthesis 
28 
 
Scheme 4.1 Nickel-catalyzed indole synthesis with benzyl and alkyl amines. 
4.2.3 Nickel-Catalyzed Indole Synthesis with Aryl Iodides as Electrophiles 
Notably, the catalytic system was further not limited to aryl bromides 45a as electrophiles, but 
also proved amenable to an efficient amination/hydroamination sequence with aryl iodides 
45b as starting material. As was observed for the corresponding bromoarenes, the 
intermolecular amination as well as the intramolecular hydroamination occurred readily with 
both aniline derivatives and alkyl amines, thereby yielding the corresponding indoles 47, 
respectively (Scheme 4.2). 
 
Scheme 4.2 Nickel-catalyzed indole synthesis from iodide 45ba. 
4.2.4 Nickel-Catalyzed Chloro-Substituted Indole Synthesis 
Finally, we exploited the excellent chemoselectivity of the dppf derived catalyst for the 
synthesis of indoles highlighting 6-chloro-substituents 45ad, a valuable asset for further 
catalyzed functionalizations (Scheme 4.3). 
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 Scheme 4.3 Nickel-catalyzed sequential synthesis of chloro-substituted indoles. 
4.3 Conclusion 
In summary, we have devised a versatile nickel catalyst for a sequential indole synthesis 
consisting of intermolecular aminations of aryl halides and subsequent intramolecular 
hydroaminations. Thus, an in situ generated complex derived from the ligand dppf (66) 
allowed for efficient transformations of ortho-alkynylhaloarenes with aryl as well as 
alkyl-substituted amines, and enabled the chemoselective synthesis of chloro-substituted 
indoles. 
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5. Nickel-Catalyzed Indole Synthesis via Oxidative Alkyne 
Annulation by Anilines 
While nickel-catalyzed C–C and C–N bond forming reactions have particularly proven to be 
valuable for the preparation of indoles, these transformations largely relied on 
prefunctionalized starting materials. Moreover, the previous indole synthesis based on the 
direct C–H bonds activation normally called for the use of expensive late transition metals 
and the addition of stoichiometric amounts of oxidants, which limited their further application. 
Recently, Chatani reported a nickel-catalyzed isoquinolone synthesis through an annulation 
process without the extra use of oxidant, which overcame the disadvantages of the traditional 
annulation chemistry. In consideration of the practical importance of modular indole 
syntheses, we hence became interested in developing unprecedented nickel-catalyzed alkyne 
annulations by electron-rich anilines, which are discussed in this chapter.54 
5.1 Optimization Studies of Nickel-Catalyzed Indole Synthesis via 
Oxidative Annulation by Anilines 
We commenced our studies by identifying the reaction conditions for the nickel-catalyzed 
indole synthesis with N-(pyridine-2-yl)aniline 49aa (Table 5.1). Comparing to other ligands, 
bidentate phosphine ligand dppf, in combination with Ni(cod)2, proved to be optimal (entries 
1–10). We were pleased to find that stoichiometric amounts of copper(II) or silver(I) salts 
were not required as sacrificial oxidants—a notable advantage over previously developed 
protocols. Interestingly, the formation of indole occurred most efficiently in the absence of 
solvents, thereby further improving the environmentally benign nature of our approach (entry 
14). Control experiments verified that the formation of indole was neither achieved in the 
absence of Ni(cod)2 nor without the dppf ligand (entries 15–16). Moreover, our studies 
revealed that representative palladium or cobalt complexes in lieu of the nickel(0) catalyst 
were ineffective (entries 17–18). 
                                                             
54 W. Song, L. Ackermann, Chem. Commun. 2013, 49, 6638–6640. 
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Table 5.1 Optimization study of nickel-catalyzed indole synthesis via alkyne annulation by 
anilines[a] 
 
Entry TM Ligand  Solvent Yield (%) 
1 Ni(cod)2 TMEDA (70) PhMe -- 
2 Ni(cod)2 terpyridine (71) PhMe -- 
3 Ni(cod)2 PPh3[b] (56) PhMe 40 
4 Ni(cod)2 dcype (72) PhMe -- 
5 Ni(cod)2 rac-BINAP (65) PhMe 21 
6 Ni(cod)2 dppp (63) PhMe 30 
7 Ni(cod)2 DPEphos (73) PhMe 30 
8 Ni(cod)2 Xantphos (74) PhMe 43 
9 Ni(cod)2 dppf (66) PhMe 48 
10[c] Ni(cod)2 dppf PhMe 63 
11[c] Ni(cod)2 dppf m-xylene 45 
12[c] Ni(cod)2 dppf o-xylene 35 
13[c] Ni(cod)2 PPh3[b] -- 65 
14[c] Ni(cod)2 dppf  -- 82 
15[c]  -- dppf  -- -- 
16[c] Ni(cod)2 -- PhMe -- 
17[c] Pd2(dba)3 dppf PhMe -- 
18[c] Co2(CO)8 dppf PhMe -- 
[a] Reaction conditions: 49aa (0. 50 mmol), 4a (1.50 mmol), [TM] (10 mol %), ligand (20 
mol %), 160 °C, 20 h, isolated yields. [b] PPh3 (40 mol %). [c] 4a (2.50 mmol). 
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5.2 Scope of Nickel-Catalyzed Oxidative Annulation with Anilines 
5.2.1 Nickel-Catalyzed Oxidative Annulation with Differently Functionalized 
Anlines 
With an optimized catalytic system in hand, we explored its versatility in the oxidative 
annulation of diphenylacetylene 4a (Scheme 5.1). Given that the N-2-pyrimidyl group is 
easily removed from the indole nucleus, we focused our studies on the use of 
N-pyrimidyl-substituted anilines 49b for enlarging the scope. We were delighted to find that  
 
Reaction conditions: 49b (0. 50 mmol), 4a (2.50 mmol), Ni(cod)2 (10 mol %), dppf (20 
mol %), 160 °C, 20 h; isolated yields. [a] Ni(cod)2 (5.0 mol %), dppf (10 mol %). [b] 4a (1.5 
mmol). 
Scheme 5.1 Scope of oxidative annulation with functionalized anlines 49b. 
the challenging pyrimidyl-substituted substrate was converted with a comparably high 
efficacy compared to reactions with the more electron-rich aniline. Additionally, half amount 
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of the catalyst also delivered the product in good yield. However, the decreased amount of 
diphenylacetylene caused a dramatic drop of the isolated yield. The optimized nickel(0) 
catalyst proved to be widely applicable, and allowed for the use of functionalized as well as 
sterically hindered ortho-substituted anilines, thereby furnishing the desired indoles 50. It is 
particularly notable that reactive electrophilic functional groups, such as the chloro, acetyl or 
cyano substituents, were well tolerated, which should prove instrumental for further 
derivatization of the thus obtained products.  
 
 
Scheme 5.2. Scope of nickel-catalyzed oxidative annulation with different alkynes 4. 
5.2.2 Nickel-Catalyzed Oxidative Annulation with Different Alkynes 
Subsequently, we tested the scope of the nickel catalyst with a representative set of substituted 
alkynes (Scheme 5.2). We observed that tolane derivatives featuring either electron-donating 
or electron-withdrawing groups were efficiently converted under the optimized reaction 
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conditions. Noteworthy, the catalytic system was not restricted to tolanes. Indeed, 
dialkylalkyne 4e provided the desired product as well. Importantly, the C–H/N–H bond 
functionalization with the unsymmetrical alkyne 4f yielded the corresponding indole 50af 
with excellent regioselectivity. 
5.2.3 Nickel-Catalyzed Oxidative Annulation with meta-Substituted Anlines 
Considering the remarkable reactivity of the nickel(0) catalyst, we became interested in 
rationalizing its mode of action. To this end, we conducted intramolecular competition 
experiments with meta-substituted anilines. The site-selectivity of the C–H bond 
functionalization was largely governed by steric interactions, while a less steric hindered 
fluoro-substituent 49bo led to significant amounts of products through C–H bond 
functionalization at the C-2 position as compared to the methyl- and 
trifluoromethyl-substituted substrates 49bm and 49bn (Scheme 5.3). 
Scheme 5.3 Nickel-catalyzed oxidative annulation with meta-substituted anilines. 
5.3 Removal of the Directing Group 
For future practical applications it is important to note that the 2-pyrimidyl group was easily 
removed from indole to deliver the corresponding NH-free indole 75. To our delight, after 
reacted with NaOEt in DMSO for 24 hours, the NH-free indole was obtained in an excellent 
yield (Scheme 5.4). 
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Scheme 5.4 Removal of the directing group in the indole derivative 50aa. 
 
Scheme 5.5 Intermolecular competition experiments. 
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5.4 Mechanistic Studies 
5.4.1 Intermolecular Competition Experiments 
A series of competition reactions was carried out to understand the reaction mechanism. The 
intermolecular competition experiments with differently substituted alkynes 4 highlighted aryl 
acetylenes to be preferentially converted, and the electron-donating group on the alkynes also 
enhanced the reactivity (Scheme 5.5a), while electron-deficient arenes were found to be 
slightly more reactive (Scheme 5.5b). These experimental findings can be rationalized in 
terms of a rate-determining migratory alkyne insertion. 
5.4.2 Experiments with Deuterium-Labeled Arenes 
Additionally, we performed oxidative annulations with isotopically labeled substrate 
[D]5-49ba (Scheme 5.6), revealing a considerable H/D exchange. Notably, the scrambling 
with the free N–H functionality exclusively occurred in the ortho-positions of the arene. 
These results, thus, provide strong support for an intrinsically reversible C–H bond metalation 
event to be operative.  
 
Scheme 5.6 Intermolecular competition experiments. 
Based on the mechanistic studies we consequently proposed the catalytic cycle to involve an 
initial reversible C–H bond metalation of aniline. Subsequent rate-determining migratory 
insertion and reductive elimination furnished the desired indole and regenerated the 
catalytically active nickel complex. 
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5.5 Conclusion 
In summary, we have reported on an unprecedented nickel-catalyzed oxidative alkyne 
annulation by electron-rich anilines with removable directing groups. The C–H/N–H bond 
functionalization proceeded with excellent chemo-, regio- and site-selectivities in the absence 
of metal salts as oxidants, thereby furnishing substituted indoles 50 with broad scope. 
Experimental mechanistic studies provided strong support for a reversible C–H bond 
activation, and are suggestive of a rate-limiting migratory alkyne insertion. 
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6. Nickel-Catalyzed Chelation-Assisted Secondary Alkylation 
Later, we get interested in the nickel-catalyzed C–C bond formations. In 2011, we published a 
nickel-catalyzed primary alkylation of the azoles with alkyl halides.23 However, the secondary 
alkylation was proved unsuccessful under the elaborated reaction condition. Until now, there 
is no example for the nickel-catalyzed secondary alkylation of inert arenes.  
Bidentate directing groups have attracted much attention during recent years due to their 
remarkable potential to activate the ortho C–H bonds in arenes. Since the pioneering direct 
arylation study by Daugulis,55 a variety of reactions utilizing an N,N-bidentate assisted 
transformation of C–H bonds have been developed. 56  Thus, we developed the first 
nickel-catalyzed secondary alkylation through C–H bond functionalizations of arenes.  
6.1 Optimization Studies of Nickel-Catalyzed Secondary Alkylation 
We initiated our studies by exploring the reaction conditions for the desired direct secondary 
alkylation of N-quinolin-8-yl benzamide 17a with bromocyclohexane 22aa as the electrophile 
(Table 6.1). At the outset, we tested a diverse array of commercially available nickel 
precursors. Among other nickel sources, (DME)NiCl2 was found to be most suitable, and 
showed an even better activity as compared to the commonly used Ni(cod)2 (entries 1–5).  
 
                                                             
55 V. Zaitsev, D. Shabashov, O. Daugulis, J. Am. Chem. Soc. 2005, 127, 13154–13155. 
56 [Pd]: a) B. V. S. Reddy, L. R. Reddy, E. Corey, J. Org. Lett. 2006, 8, 3391–3394; b) R. Giri, N. Maugel, B. M. 
Foxman, J.-Q. Yu, Organometallics 2008, 27, 1667–1670; c) F.-R. Gou, X.-C. Wang, P.-F. Huo, H.-P. Bi, Z.-H. Guan, 
Y.-M. Liang, Org. Lett. 2009, 11, 5726–5729; d) D. Shabashov, O. Daugulis, J. Am. Chem. Soc. 2010, 132, 3965–
3972; e) G. He, G. Chen, Angew. Chem. Int. Ed. 2011, 50, 5192–5196; f) Y. Zhao, G. Chen, Org. Lett. 2011, 13, 
4850–4853; g) B. V. S. Reddy, G. Revathi, A. S.  Reddy, J. S. Yadav, Tetrahedron Lett. 2011, 52, 5926–5929; h) Y. 
Ano, M. Tobisu, N. Chatani, J. Am. Chem. Soc. 2011, 133, 12984–12986; i) G. He, Y. Zhao, S. Zhang, C. Lu, G. Chen, J. 
Am. Chem. Soc. 2012, 134, 3–6; j) E. T. Nadres, O. Daugulis, J. Am. Chem. Soc. 2012, 134, 7–10; k) Y. Ano, M. 
Tobisu, N. Chatani, Org. Lett. 2012, 14, 354–357; l) Y. Xie, Y. Yang, L. Huang, X. Zhang, Y. Zhang, Org. Lett. 2012, 14, 
1238–1241; m) L. D. Tran, O. Daugulis, Angew. Chem. Int. Ed. 2012, 51, 5188–5191; n) S.-Y. Zhang, G. He, Y. Zhao, K. 
Wright, W. A. Nack, G. Chen, J. Am. Chem. Soc. 2012, 134, 7313–7316; o) N. Rodríguez, J. A. Romero-Revilla, M. Á. 
Fernández-Ibáñez, J. C. Carretero, Chem. Sci. 2013, 4, 175–179; p) S.-Y. Zhang, G. He, W. A. Nack, Y. Zhao, Q. Li, G. 
Chen, J. Am. Chem. Soc. 2013, 135, 2124–2127; [Cu]: q) L. D. Tran, I. Popov, O. Daugulis, J. Am. Chem. Soc. 2012, 
134, 18237–18240; r) M. Nishino, K. Hirano, T. Satoh, M. Miura, Angew. Chem. Int. Ed. 2013, 52, 4457–4461; [Ru]: 
s) S. Inoue, H. Shiota, Y. Fukumoto, N. Chatani, J. Am. Chem. Soc. 2009, 131, 6898–6899; t) N. Hasegawa, V. Charra, 
S. Inoue, Y. Fukumoto, N. Chatani, J. Am. Chem. Soc. 2011, 133, 8070–8073; u) K. Shibata, N. Hasegawa, Y. 
Fukumoto, N. Chatani, ChemCatChem 2012, 4, 1733–1736; v) N. Hasegawa, K. Shibata, V. Charra, S. Inoue, Y. 
Fukumoto, N. Chatani, Tetrahedron 2013, 69, 4466–4472; w) Y. Aihara, N. Chatani, Chem. Sci. 2013, 4, 664–670; 
[Ni]: x) H. Shiota, Y. Ano, Y. Ahihara, Y. Fukumoto, N. Chatani, J. Am. Chem. Soc. 2011, 133, 14952–14955; [Fe]: y) R. 
Shang, L. Ilies, A. Matsumoto, E. Nakamura, J. Am. Chem. Soc. 2013, 135, 6030–6032. 
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Table 6.1: Optimization of the nickel-catalyzed secondary alkylation.[a] 
 
Entry [Ni] Ligand Base Solvent Yield (%)[b] 
1 Ni(acac)2 -- LiOt-Bu o-xylene 10 
2 Ni(cod)2 -- LiOt-Bu o-xylene 52 
3 Ni(OTf)2 -- LiOt-Bu o-xylene 33 
4 NiCl2 -- LiOt-Bu o-xylene -- 
5 (DME)NiCl2 -- LiOt-Bu o-xylene 55 
6 (DME)NiCl2 PPh3 (56) LiOt-Bu o-xylene 30 
7 (DME)NiCl2 IPrHCl (60) LiOt-Bu o-xylene -- 
8 (DME)NiCl2 X-phos (59) LiOt-Bu o-xylene 20 
9 (DME)NiCl2 DME (76) LiOt-Bu o-xylene 60 
10 (DME)NiCl2 BDMAE (77) LiOt-Bu o-xylene 70 
11 (DME)NiCl2 phenanthroline (62) LiOt-Bu o-xylene -- 
12 (DME)NiCl2 L-proline (78) LiOt-Bu o-xylene 22 
13 (DME)NiCl2 TMEDA (70) LiOt-Bu o-xylene 45 
14 (DME)NiCl2 BDMAE Na2CO3 o-xylene -- 
15 (DME)NiCl2 BDMAE Cs2CO3 o-xylene -- 
16 (DME)NiCl2 BDMAE NaOAc o-xylene -- 
17 (DME)NiCl2 BDMAE LiOt-Bu Dioxane 71 
18 (DME)NiCl2 BDMAE LiOt-Bu PhMe 76 
19[c] (DME)NiCl2 BDMAE LiOt-Bu PhMe 86 
[a] Reaction conditions: 17a (0.50 mmol), 22aa (1.0 mmol), [Ni] (10 mol %), ligand (20 
mol %), base (2.0 equiv), solvent (1.0 mL), 160 °C, 20 h. [b] Yield of isolated product. [c] 
BDMAE (40 mol %). 
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Thereafter, we explored a set of representative ligands with the (DME)NiCl2 as the nickel 
source. Comparing to other ligands, the BDMAE (Bis (2-dimethylaminoethyl) ether) and 
DME (Dimethoxyethane) were found to provide higher conversion to the desired product, and 
the BDMAE was proved to be the optimal choice (entries 6–13). Subsequently, we probed a 
variety of bases and solvents for the secondary alkylation of the substrate. The most effective 
transformation was accomplished with LiOt-Bu as the base. On the contrary, the alkylation 
occurred with significantly reduced efficacy when other bases were employed (entries 14–16). 
Moreover, a higher efficacy was found when toluene was used as the solvent instead of 
o-xylene (entries 17–19). 
 
 
Scheme 6.1. Nickel-catalyzed alkyaltions with secondary alkyl bromides 22a.  
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6.2 Scope of Nickel-Catalyzed Secondary Alkylation 
6.2.1 Nickel-Catalyzed Alkylation with Secondary Alkyl Bromides 
With the optimized catalytic system in hands, we probed its scope in the C–H bonds 
functionalization of diversely substituted arenes 17 with secondary alkyl bromides 20a. To 
our delight, good selectivity was achieved even without substitution on the ortho-position. 
Thus, only mono-substituted product 51 was obtained in high efficacy. Generally, the 
electron-withdrawing groups tended to deliver the alkylation product in higher yields as 
compared to the electron-donating derivatives. Moreover, a variety of functional groups were 
tolerated in this reaction. The reaction with meta-substituted substrates resulted in the 
selective alkylation at the less hindered C–H bonds. Most probably, the regioselectivity was 
rather controlled by the steric nature of the substituent. Additionally, the ɑ,β-unsaturated 
amide 17k could also be applied for the secondary alkylation reaction. Consequently, a 
variety of alkyl bromides 22a were proved to be applicable to the alkylation reaction. To our 
delight, acyclic secondary alkyl bromides were also amendable to the reaction conditions, 
without formation of isomerizations by-products.  
  
Scheme 6.2. Nickel-catalyzed secondary alkylation with alkyl chlorides 22b. 
6.2.2 Nickel-Catalyzed Alkylations with Secondary Alkyl Chlorides 
We were pleased to observe that the less reactive secondary alkyl chlorides 22b turned out to 
be viable electrophiles as well, even without addition of NaI. However, somewhat lower 
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yields of the desired products 51 were obatained as compared to the analogous reactions with 
bromides 22a.  
6.2.3 Nickel-Catalyzed Alkylations of Indoles with Secondary Electrophiles 
Likewise, indoles 79 served as valuable substrates for the nickel-catalyzed secondary 
alkylation. Secondary alkylation with either cyclic or acyclic alkyl bromides delivered the 
desired products in high efficacy.  
 
 Scheme 6.3. Nickel-catalyzed secondary alkylation of indole 79. 
6.3 Mechanistic Studies 
6.3.1 Intermolecular Competition Reactions 
Continuing our investigations of these chelation-assisted reactions, we performed several 
intermolecular competition experiments on direct alkylations of variously substituted arenes 
17a, 17d and 17e as well as of indole 79 with the goal to elucidate the mode of action of this 
unique active nickel catalyst. These experiments revealed the substrate 17d with an 
electron-withdrawing group to react faster than its electron-enriched (17e, Scheme 6.4a) and 
electron-neutral (17a, Scheme 6.4b) analogues. On the other hand, arene 17a displayed 
comparable reactivity in its competition experiment with indole 79 with the slightly enhanced 
reactivity of the latter (Scheme 6.4c). Both results indicated the significance of the kinetic C–
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H bond acidity for the success of the nickel-catalyzed alkylations.  
Scheme 6.4 Intermolecular competition experiments with different (hetero)arenes. 
6.3.2 Reaction with Deuterium-labeled Substrate  
Additionally, we performed the secondary alkylation with isotopically labeled substrate 
[D]5-17b, revealing a considerable H/D exchange exclusively occurring in the ortho-positions 
of the arene. This result, thus, provided strong support for a reversible C–H bond metalation 
event to be operative and indicate that cleavage of the C−H bond likely is not the 
rate-determining step (Scheme 6.5). 
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Scheme 6.5. Reaction with deuterium-labeled substrate D5-17b. 
6.4 Conclusion 
A nickel-catalyzed direct secondary alkylation of unreactive arenes through chelation-assisted 
C−H bonds activation was developed. A series of substituted arenes was efficiently converted 
and good chemo- and site-selectivities were achieved. Different kinds of electrophiles were 
used to deliver the desired products in high efficacy, even with unreactive secondary alkyl 
chlorides.  
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7. Cobalt-Catalyzed Direct Arylations via C–O bond Cleavages 
Biaryl derivatives are important building blocks in organic synthesis, especially with 
applications to natural products synthesis, medicinal chemistry, and materials science.1a The 
most commonly used methods for aryl-aryl bond formations involve traditional 
transition-metal-catalyzed cross couplings of aryl halides with metal reagents. However, these 
methods are limited by the preparation of the prerequisite organometallic reagents and the 
formation of stoichiometric amount of by-products. The direct introduction of the aryl 
electrophiles through C–H bond cleavages57 has been widely studied during the past decades 
as an alternative strategy for biaryl bond formations. The reactivity of arylating electrophiles 
toward transition metals typically follows the trend ArI > ArBr ≈ ArOTf >> ArCl > ArOTs. 
However, their prices and accessibility follows almost the same trend. While aryl halides are 
still widely applied as electrophiles for direct arylations, recent focus has been shifted towards 
the use of phenol derivatives, which are inexpensive, readily accessible, and can easily be 
implemented as directing groups in versatile arene functionalization strategies. In recent years, 
cobalt-catalyzed C–H bond activation was well studied. However, cobalt-catalyzed direct 
arylation of inert arenes with phenol electrophiles are not available. In this chapter, we will 
focus on this area and describe the first cobalt-catalyzed direct arylation via the direct C–
H/C–O bond cleavages.58  
7.1 Optimization Studies of Cobalt-Catalyzed Direct Arylations  
We initiated our studies by exploring the reaction conditions for the direct arylation with 
electronically deactivated sulfamate 30ad employing Co(acac)2 as the pre-catalyst in DMPU 
as the solvent (Table 7.1). While unsatisfactory results were obtained in the absence of ligands 
(entry 1) as well as with the mono- or bidentate phosphine ligands or phenanthroline (entries 
2–4), the N-heterocyclic carbene (NHC) precursors showed higher efficacies for catalytic C– 
 
                                                             
57 L. Ackermann, R. Vicente, Metal-Catalyzed Direct Arylations, in Modern Arylation Methods (Ed.: L. Ackermann), 
Wiley-VCH, Weinheim, 2009, pp. 311–333. 
58 W. Song, L. Ackermann, Angew. Chem. Int. Ed. 2012, 51, 8251–8254. 
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Table 7.1 Optimization of the direct arylation reaction with sulfamate 30ad.[a] 
 
Entry Ligand Base Solvent Yield (%)[b] 
1 -- CyMgCl DMPU 15 
2 [c] dppe (64) CyMgCl DMPU -- 
3 PCy3 (57) CyMgCl DMPU 21 
4 [c] phenanthroline (62) CyMgCl DMPU 11 
5 sIPrHCl (61) CyMgCl DMPU 42 
6 sIMesHCl (81) CyMgCl DMPU 40 
7 IPrHCl (60) CyMgCl DMPU 47 
8 IMesHCl (69) CyMgCl DMPU 82 
9 IMesHCl KOt-Bu DMPU -- 
10 IMesHCl LiHMDS DMPU -- 
11 IMesHCl MeMgCl DMPU 59 
12 IMesHCl t-BuMgCl DMPU 40 
13 IMesHCl CyMgCl NMP -- 
14 IMesHCl CyMgCl toluene -- 
15[d] IMesHCl CyMgCl DMPU 38 
16[e] IMesHCl CyMgCl DMPU -- 
17[f] IMesHCl CyMgCl DMPU 80 
[a] Reaction conditions: 3a (0.75 mmol), 30ad (0.50 mmol), Co(acac)2 (10 mol %), ligand (20 
mol %), base (2.0 equiv), solvent (1.0 mL), 60 °C, 16 h. [b] Yield of isolated product. [c] 10 
mol % of ligand was used. [d] Reaction runs at 23 °C. [e] Without Co(acac)2. [f] Co(acac)3 
(10 mol %). 
H bond transformations (entries 5–7) with IMesHCl (69) delivering the optimal yield (entry 
8). Notably, LiHMDS or KOtBu as bases failed to affect the desired direct arylation with aryl 
sulfamates (entries 9, 10), while CyMgCl was found to be the base of choice. Among the 
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solvents tested, polar aprotic DMPU proved beneficial for the direct arylation. Notably, 
comparable catalytic efficacies were obtained using both cobalt(II) and cobalt(III) complexes 
(entries 8, 17). 
7.2 Scope of Cobalt-Catalyzed Direct Arylations 
7.2.1 Cobalt-Catalyzed Direct Arylations with Aryl Sulfamates  
With the optimized reaction condition in hands, we explored the scope of the cobalt-catalyzed 
C–H bond arylation with differently substituted aryl sulfamates 30a. Notably, 
electron-rich-and thus deactivated for an oxidative addition-aryl sulfamates were effectively 
converted, even when bearing sterically hindered ortho-substituents. Moreover, various 
pyridyl-substituted arenes 3 chemoselectively provided the desired monoarylated products 52. 
Besides, benzo[h]quinolones (3e) could also be arylated, furnishing the desired compounds in 
high efficiency (Scheme 7.1).  
Scheme 7.1 Cobalt-catalyzed direct arylations with aryl sulfamates 30a. 
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7.2.2 Cobalt-Catalyzed Direct Arylations with Aryl Carbamates  
The cobalt catalyst was not restricted to the use of sulfamates 30a as the electrophiles, but 
also allowed for the first C–H bond arylations of arenes with widely accessible aryl 
carbamates 30b. Both electron-rich and functionalized, electron-deficient aryl carbamates 
were converted with remarkably high catalytic efficacy. Furthermore, both electron-rich and 
electron-poor arenes 3 could deliver the desired products 52 in high yield. Considering the 
reaction mechanism, an intramolecular competition experiment with meta-fluoro-substituted 
arene 3g site-selectively furnished biaryl through functionalization of the kinetically more 
acidic C–H bond. Most probably, this selectivity resulted from the concerted action of the 
chelating effect of 2-pyridyl moiety and the well-documented ortho-orienting influence of the 
fluorine substituents.59 Moreover, aryl carbamates 30bi/30bj which are functionalized with 
sterically hindered substituents in the ortho-position, delivered the desired products, thereby 
illustrating the power of aryl carbamates for strategies that merge directed ortho metalation 
(DoM) and C–H bond functionalization. Additionally, differently substituted pyridyl-directing 
groups could be employed to give the desired products 52dd/52hd with high site-selectivity, 
as could a less electron-donating 2-pyrimidyl-substituent 52id (Scheme 7.2).  
7.2.3 Direct Arylation at Ambient Temperature 
Interestingly, the direct arylation with carbamate 30b worked efficiently even at ambient 
temperature. While, the direct arylation with other phenol-derived electrophiles at room 
temperature afforded product 52ad only in lower yields (Scheme 7.3). 
7.2.4 Cobalt-Catalyzed Direct Arylation of Heteroarenes  
Likewise, heteroarenes could also serve as valuable substrates for the cobalt-catalyzed direct 
arylation with aryl sulfamates 30a and carbamates 30b. Indeed, N-substituted indoles 82 were 
selectively arylated at the C-2 position, which allowed for the synthesis of, among other 
products, sterically encumbered heterobiaryl (Scheme 7.4), a feature that should prove 
instrumental for future applications to asymmetric C–H bond arylations. 
                                                             
59 For reviews, see: a) E. Clot, O. Eisenstein, N. Jasim, S. A. Macgregor, J. E. McGrady, R. N. Perutz, Acc. Chem. Res. 
2011, 44, 333–348; b) M. E. Evans, C. L. Burke, S Yaibuathes, E. Clot, O. Eisenstein, W. D. Jones, J. Am. Chem. Soc. 
2009, 131, 13464–13473; c) E. Clot, C. Mégret, O. Eisenstei, R. N. Perutz, J. Am. Chem. Soc. 2009, 131, 7817–7827. 




 Scheme 7.2 Cobalt-catalyzed direct arylations with aryl carbamates 30b. 
  
Scheme 7.3 Cobalt-catalyzed direct arylations with aryl electrophiles 30ad-30dd.  





Scheme 7.4 Cobalt-catalyzed direct arylation of indoles 82. 
7.3 Cobalt-Catalyzed Direct Benzylation with Phosphate  
Intriguingly, the inexpensive cobalt catalyst also enabled direct benzylation reactions on 
indoles. The C(sp2)–C(sp3) bond formation was realized with benzyl phosphate 84 under 
remarkably mild reaction conditions. On the contrary, lower yield was observed when the 
temperature was increased. Additionaly, only trace amounts of product could be detected 
when 2-phenyl pyridine 3 was used as substrate (Scheme 7.5). 
 
Scheme 7.5 Cobalt-catalyzed direct benzylation of indole 82a with phosphate 84. 
Cobalt-Catalyzed Direct Arylations via C–O bond Cleavages 
51 
 
Scheme 7.6 Competition experiments with different electrophiles. 
7.4 Mechanistic Studies 
7.4.1 Intermolecular Competition Reactions 
Considering the unique reactivity of the cobalt catalyst, we became interested in probing its 
mode of action. To this end, intermolecular competition experiments between aryl sulfamates 
30a and carbamates 30b revealed the latter to display a significantly higher inherent reactivity 
and electron-deficient carbamates were preferentially converted (Scheme 7.6). Moreover, 
intermolecular competition experiments with differently substituted arenes 3 and heteroarenes 
82 provided strong support for a non-SEAr-type reaction manifold. Instead, the reactivity of 
the arene is likely governed by the kinetic C–H bond acidity, as is indicated by the selective 
conversion of indole 82a, as compared to arene 3a (Scheme 7.7). 
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 Scheme 7.7 Competition experiments with different (hetero)arenes. 
7.4.2 Reaction in the Presence of Radical Scavenger 
The direct arylation with aryl sulfamate 30ad in the presence of one equivalent of 
2,2,6,6-tetramethyl-1-piperidinyloxyl (TEMPO) led to the formation of the desired product 
52ad in 68% yield. The result is comparable to that obtained in the absence of the radical 
scavenger (82%). This finding suggests that a radical reaction mechanism in the direct C–
H/C–O arylation is unlikely (Scheme 7.8). 
 
Scheme 7.8 Cobalt-catalyzed direct arylation in presence of TEMPO. 
7.5 Conclusion 
In summary, we have reported on the first use of inexpensive cobalt catalysts for direct C–H 
bond arylation and benzylation with phenol-derived organic electrophiles through challenging 
C–H/C–O bond cleavage. The high catalytic efficacy of the versatile cobalt catalyst set the 
stage for unprecedented transition-metal-catalyzed direct arylations and benzylations of 
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arenes with easily accessible fluorine-free aryl sulfamates, carbamates, and phosphates, which 
even proved to be viable at ambient temperature. Importantly, mechanistic studies provided 
strong evidence for a non-radical reaction manifold. 
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8. Cobalt-Catalyzed Direct Primary and Secondary Alkylation 
with Unreactive Alkyl Chlorides 
Having identified a highly effective cobalt catalyst for direct arylations with aryl sulfamates 
30a and carbamates 30b, we were subsequently interested in exploring challenging C–H bond 
alkylations with β-hydrogen-containing alkyl chlorides under non-acidic reaction conditions. 
In contrast to the widely utilized C(sp2)−C(sp2) bond forming processes, the corresponding 
transformations of unactivated alkyl halides are less developed, most probably because of the 
difficult oxidatative addition and due to the strong tendency of the intermediate metalated 
alkyls to undergo β-hydride elimination reactions, overall leading to undesired β-eliminations 
of the organic electrophiles. Particularly, secondary alkyl halides have proven to be extremely 
challenging substrates, as these alkyl halides are more sterically demanding and electron-rich, 
thereby rendering the elementary step of oxidative addition rather difficult. Yet, remarkable 
advances are constituted by ortho-selective palladium-, nickel-, copper-, and 
ruthenium-catalyzed direct alkylations. On the contrary, studies on cobalt-catalyzed direct 
alkyaltions are scarce. To overcome these limitations, in this chapter, we devised reaction 
conditions for versatile high effective and site-selective cobalt-catalyzed direct alkylations of 
arenes with primary and secondary alky chlorides.60  
8.1 Optimization Studies of Cobalt-Catalyzed Direct Alkylations 
Based on our previous studies on cobalt-catalyzed direct arylations of arenes 3, we initiated 
the optimization studies by using cobalt(II) complexes together with Grignard reagents as the 
base. However, only unsatisfactorily low conversions of 2-phenylpyridine (3b) were observed 
in the absence of an additional ligand (Table 8.1, entries 1–3). A set of representative ligands 
was therefore subsequently probed, and improved results were accomplished by using 
NHC-coordinated cobalt catalysts, with IPrHCl (60) delivering optimal yields (entries 4–9). 
Moreover, an appropriate amount of the base was essential for increasing both the yields and 
the site-selectivity (entries 9–11). Notably, a nickel(II) complex did not give the desired 
                                                             
60 B. Punji, W. Song, G. A. Shevchenko, L. Ackermann, Chem. Eur. J. 2013, 19, 10605–10610. 
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product 53ba under otherwise identical reaction conditions (entry 12), thus highlighting the 
power of cobalt-catalyzed C−H bond functionalizations. 
Table 8.1 Optimization of cobalt-catalyzed direct alkylations.[a] 
 
Entry Ligand RMgCl Yield (%)[b] 
1 -- t-BuMgCl (3.0) 5 
2  -- MeMgCl (3.0) 15 
3 -- CyMgCl (3.0) 27 
4  dppe (64) MeMgCl (3.0) 6 
5 PCy3 (57) MeMgCl (3.0) 10 
6[c] Phenanthroline (62) MeMgCl (3.0) 27 
7 IMesHCl (69) MeMgCl (3.0) 30 
8 IPrHCl (60) MeMgCl (3.0) 34 
9 IPrHCl CyMgCl (3.0) 67 
10 IPrHCl CyMgCl (1.6) 78 
11 IPrHCl CyMgCl (2.0) 90 
12[d] IPrHCl CyMgCl (2.0) -- 
[a] Reaction conditions: 3b (0.50 mmol), 12aa (0.75 mmol), Co(acac)2 (10 mol %), ligand (20 
mol %), RMgCl, DMPU (1.0 mL), 23 °C, 16 h. [b] Yield of isolated product. [c] 
phenanthroline (10 mol %). [d] Ni(acac)2 (10 mol %) was used.  
8.2 Scope of Cobalt-Catalyzed Direct Alkylations 
8.2.1 Cobalt-Catalyzed Alkylations of Arenes with Primary Alkyl Chlorides 
The scope of the optimized catalytic system was, thereafter, explored for the direct alkylation 
of arenes 3 with unactivated, β-hydrogen-containing primary alkyl chlorides 12a (Scheme 
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8.1). Differently decorated arenes thereby delivered the desired products 53 with excellent 
chemo- and site-selectivities using a variety of primary alkyl chlorides. 
 
 
Scheme 8.1 Scope of cobalt-catalyzed direct alkylations with alkyl chlorides 12a. 
8.2.2 Cobalt-Catalyzed Primary Alkylations of Indoles 
Consequently, we became attracted by applying the optimized cobalt catalysts in the direct 
functionalization of N-heteroaryl indoles 82 (Scheme 8.2). Notably, both N-pyridyl- as well as 
N-pyrimidyl-substituted heteroarenes were efficiently converted, the latter of which being 
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particularly attractive because of their removable directing group. The catalytic system 
displayed a notably wide substrate scope, as was among others illustrated by the successful 
use of various n-alkyl chlorides 12a. Furthermore, substituted indoles 82a–82e proved to be 
viable substrates, even when being sterically congested through substituents in the position 
C-3 or C-7 of the indole nucleus. 
 
  
Scheme 8.2 Scope of cobalt-catalyzed direct alkylations of indoles 82. 
8.2.3 Cobalt-Catalyzed Secondary Alkylations with Alkyl Chlorides 
Finally, we were particularly pleased to observe that the optimized cobalt catalytic system 
even allowed for direct alkylations with challenging secondary alkyl halides 22b. Notably, 
these C−H bond functionalizations occurred with excellent ortho-selectivity through chelation 
assistance and proved amenable to direct arene as well as heteroarene functionalizations 
(Scheme 8.3). Notably, in contrast to alkylations of arenes 3 (Scheme 8.1) and to benzylation 
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of indoles 82 (Scheme 7.5), the alkylation of the indole 82a with cyclohexyl chloride 22ba 
proceeded more efficiently at slightly elevated reaction temperature (Scheme 8.3b). 
 
Scheme 8.3 Cobalt-catalyzed direct secondary alkylations. 
8.3 Mechanistic Studies 
8.3.1 Intermolecular Competition Reactions 
Given the high catalytic activity and selectivity of the cobalt catalysts under mild reaction 
conditions, we became intrigued in gaining insight into its mode of action. To this end, we 
performed a series of competition experiments, which revealed that electron-deficient arene 
3k reacted preferentially in the cobalt-catalyzed direct alkylations (Scheme 8.4a), thus 
rendering a simple electrophilic C−H bond activation manifold less likely to be operative. 
Moreover, the analogous functionalization of the electron-rich heteroaromatic indole 82c 
occurred preferentially (Scheme 8.4b), which can be rationalized in terms of its increased 
kinetic C−H bond acidity due to the inductive effect exerted by the heteroatom. 
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Scheme 8.4 Intermolecular competition experiments: C−H bond alkylation. 
8.3.2 Reaction in Presence of Radical Scavenger  
Furthermore, we performed cobalt-catalyzed direct alkylations in the presence of 
stoichiometric amounts of the radical scavenger TEMPO (Scheme 8.5). A somewhat reduced 
yield was obtained after the reaction, which can be explained with SET-type elementary steps.  
 
Scheme 8.5 Cobalt-catalyzed direct alkylation in presence of radical scavenger. 
8.4 Conclusion 
In summary, we have reported on the development of cobalt catalysts for direct C−H bond 
alkylations of heteroaryl-substituted arenes and heteroarenes with cost-effective chlorides as 
the electrophiles. Particularly, catalytic complexes derived from inexpensive Co(acac)2 and 
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N-heterocyclic carbene (NHC) precursors proved to be highly effective at ambient reaction 
temperature. The C−H bond functionalizations proceeded with excellent chemo- and 
site-selectivities as well as ample scope. Notably, this cobalt-NHC catalyst allowed for 
difficult direct alkylations with various β-hydrogen-containing pimary alkyl chlorides. 
Moreover, challenging secondary alkyl chlorides proved to be for the first time suitable 






This thesis focused on development of first row transition-metal-catalyzed C–C/C–N bond 
formations. The inexpensive nickel and cobalt complexes were introduced to facilitate 
different kinds of novel chemical transformations.  
In the first project, the nickel complexes catalyzed C–N bond formations through challenging 
C–O bond cleavages. Direct arylations of primary and secondary amines were achieved using 
Ni(cod)2 combined with dppf 66 or IPrHCl 60 as the (pre)ligands (Scheme 9.1).  
 
 Scheme 9.1 Nickel-catalyzed direct arylation of amines. 
Consequently, the nickel catalyst in situ derived from the complex Ni(cod)2 and dppf ligand 
was applied for amination/hydroamination sequential synthesis of indole. Differently 
substituted indoles 47 were synthesized from the ortho-alkynylhaloarenes 45 with aryl- as 






Scheme 9.2 Nickel-catalyzed base-mediated synthesis of indole 47. 
Later, the indole synthesis through an unprecedented nickel-catalyzed oxidative alkyne 
annulation by electron-rich anilines 49 was reported. The C–H/N–H bond functionalization 
proceeded with excellent chemo-, regio- and site-selectivities in the absence of metal salts as 




Scheme 9.3 Nickel-catalyzed indole synthesis through C–H/N–H bond activations. 
Besides the nickel-catalyzed C–N bond formations, nickel-catalyzed chelation-assisted 
secondary alkylation was subsequently developed. A series of secondary alkylation products 
51/80 were obtained by using the complexes derived from (DME)NiCl2 and the user-friendly 





Scheme 9.4 Nickel-catalyzed chelation-assisted secondary alkylation. 
In the fifth project, cobalt-catalyzed direct C–H bond functionalization was developed. The 
cobalt complexes derived from N-heterocyclic carbene (NHC) precursors enabled the direct 
arylation and benzylation with phenol-derived organic electrophiles through challenging C–
H/C–O bond cleavage (Scheme 9.5). 
 
Scheme 9.5 Cobalt-catalyzed direct arylation/benzylation by C–H/C–O cleavages. 
Finally, the cobalt complexes also facilitated the challenging direct primary and secondary 
















10.1 General Remarks 
All reactions involving moisture- or air-sensitive reagents or products were performed under a 
N2 atmosphere using pre-dried glassware and standard Schlenk techniques. Syringes for 
handling of dry solvents were flushed with dry nitrogen threefold prior to use.  
Solvents  
All solvents for reactions involving moisture-sensitive reagents were dried, distilled and 
stored under inert atmosphere (argon or nitrogen) according to the following standard 
procedures. 
solvent  drying method  
Dichloromethan  Purified using an solvent purification system (SPS) from 
MBRAUN.  
N,N-Dimethylformamide  Dried over CaH2 for 8 h, degassed and distilled under 
reduced pressure.  
N-Methyl-2-pyrrolidone  Stirred for 4 h at 150 °C over CaH2 and subsequently 
distilled under reduced pressure.  
Tetrahydrofuran  Purified using an SPS solvent purification system from 
MBRAUN.  
Toluene  Either predried over KH followed by distillation from 
sodium benzophenone ketyl or purified using a solvent 
purification system from MBRAUN.  
1,4-Dioxane  Dried by distillation from sodium benzophenone ketyl.  
o-Xylene Either predried over KH followed by distillation from 
sodium benzophenone ketyl or purified using a solvent  
1,3-Dimethyl-tetrahydro-pyrimi
dinone 
Dried over CaH2 for 8 h, degassed and distilled under 
reduced pressure. 
Vacuum  
The following pressures were measured on the used vacuum pump and were not corrected: 




Melting Points  
Melting points were measured using a Stuart® Melting Point Apparatus SMP3 from 
BARLOWORLD SCIENTIFIC. Reported values are uncorrected and are given as a range 
(M.r.), if the melting occurred not at a specific melting point (M.p.). 
Chromatography  
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-plates 
(MACHEREY-NAGEL) with 254 nm fluorescent indicator from MERCK. Plates were 
visualized under UV-light and developed by treatment with a KMnO4 solution followed by 
careful applying a heat gun. Chromatographic purification of products was accomplished by 
flash column chromatography on MERCK silica gel, grade 60 (0.040–0.063 mm and 0.063–
0.200 mm, 70–230 mesh astimated).  
High Performance Liquid Chromatography  
Preparative and analytical separations were performed on an HPLC-System from KNAUER 
(Smartline Pump 100, Dynamic Mixing Chamber, Injection- and Control-Valve, Smartline 
UV Detector 2500). Separation column ChiralPak IC (250 20 mm or 4.6 250 mm) from 
DAICEL CHEM. IND. (LTD) was used. Organic solvents of HPLC grade were employed. 
All samples were filtered through Polytetrafluorethylen Filter from ROTH (Ø 25 mm, 0.2 μm) 
or VWR (Ø 13 mm, 0.2 μm) prior to separation.  
Gas Chromatograpgy  
The conversion of the reactions was monitored applying coupled gas chromatography/mass 
spectrometry using G1800C GCDplus with mass detector HP 5971, 5890 Series II with mass 
detector HP 5972 from HEWLETT-PACKARD and 7890A GC-System with mass detector 
5975C (Triplex-Axis-Detector) from AGILENT TECHNOLOGIES equipped with HP-5MS 





Nuclear Magnetic Resonance Spectroscopy  
Nuclear magnetic resonance (NMR) spectroscopy was performed at 300 or 600 MHz 
(1H-NMR), 75.5 or 125 MHz (13C-NMR, APT) and 282 MHz (19F-NMR) on BRUKER AM 
250, VARIAN Unity-300 and Inova 500 instruments. Chemical shifts are reported as δ-values 
in ppm relative to the residual proton peak of the deuterated solvent or its carbon atom, 
respectively, or the standard trimethylsilyl (TMS) peak. 
1H-NMR  13C-NMR  
CDCl3 :  7.26 ppm  77.0 ppm  
DMSO-D6 :  2.49 ppm  49.5 ppm  
For characterization of the observed resonance multiplicities the following abbrevations were 
applied: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), 
dt (doublet of triplet), or analogue representations. The coupling constants J are reported in 
Hertz (Hz).  
Infrared Spectroscopy  
Infrared spectra were recorded on a BRUKER Alpha-P ATR-spectrometer. Liquid probes 
have been measured as film and solid probes neat. Analysis of the spectral data has been done 
by using the OPUS 3.1 software from BRUKER, respectively OPUS 6. Absorption (ṽ) is 
given in wave numbers (cm–1). Spectra were recorded in the range of 4000 to 400 cm–1  
Mass Spectrometry  
EI- and EI-HR-MS spectra were measured on a Time-of-Flight mass spectrometer AccuTOF 
from JOEL. ESI-mass spectra were recorded on an Ion-Trap mass spectrometer LCQ from 
FINNIGAN or on a Time-of-Flight mass spectrometer microTOF from BRUKER. 
ESI-HR-MS spectra were recorded on a BRUKER APEX IV or a BRUKER DALTONIC (7T, 
Transform Ion Cyclotron Resonance (FTICR)) mass spectrometer. The ratios of mass to 




10.2 Starting Materials 
The following starting materials were prepared according to modified literature procedures: 
Aryl sulfamates 30a, 61 ortho-alkynylbromoarenes 45, 62  N-phenylpyridine 49a, 63  
N-arylpyrimidines 49b, 64  N-(pentadeuteriophenyl)-pyrimidin-2-amine [D]5-49ba, 65 
diarylalkynes 4,66 N-quinolin-8-yl benzamides 17,67 phenylpyridines 3,68 aryl carbamates 
30b,69 N-pyridylindoles 82,70 benzyl phosphate 84.71 Other chemicals were obtained from 
commercial sources and were used without further purification. 
10.3 Representative Procedure 
Representative Procedure A: Nickel-catalyzed amination of sulfamates 30a.  
To a solution of [Ni(cod)2] (6.9 mg, 0.025 mmol, 5.0 mol %), dppf (66) (13.9 mg, 0.025 mmol, 
5.0 mol %) and NaOt-Bu (96 mg, 0.75 mmol) in PhMe (1.0 mL) were added sulfamate 30aa 
(108 mg, 0.50 mmol) and aniline 46a (92 mg, 0.75 mmol) at ambient temperature. The 
resulting mixture was stirred for 16h at 105 °C . Sat. aq. NaHCO3 (60 mL) was added at ambient 
temperature, and the reaction mixture was extracted with EtOAc (3 x 50 mL). The combined 
organic layers were dried over Na2SO4 and concentrated in vacuo. The remaining residue was 
purified by column chromatography on silica (n-hexane/ EtOAc 50/1) to yield 48aa (101 mg, 
95%) as a white solid. 
Representative Procedure B: Nickel-catalyzed indole synthesis with aryl bromides 45. 
To a solution of [Ni(cod)2] (6.9 mg, 0.025 mmol, 5.0 mol %), dppf (66) (13.9 mg, 0.025 mmol, 
5.0 mol %) and NaOt-Bu (96 mg, 0.750 mmol) in PhMe (2 mL) were added alkynyl bromide 
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45aa (129 mg, 0.500 mmol) and aniline 46c (80 mg, 0.75 mmol) at ambient temperature. The 
resulting mixture was stirred for 16h at 105 °C . At ambient temperature, KOt-Bu (168 mg, 1.50 
mmol) was added under N2 and the resulting mixture was stirred for 6h at 120 °C . EtOAc (5 mL) 
and H2O (5 mL) were added to the cooled suspension. The separated aqueous layer was 
extracted with EtOAc (3 x 10 mL) and combined organic layers were washed with H2O (10 mL) 
and brine (10 mL). Drying with Na2SO4 and purification by column chromatography 
(n-hexane/ EtOAc 500/1) yielded 47ac (125 mg, 88%) as a white solid 
Representative Procedure C: Nickel-catalyzed Alkyne Annulation by Anilines 49. 
Aniline 49aa (85.5 mg, 0.50 mmol), tolane (4a) (446 mg, 2.50 mmol), Ni(cod)2 (13.8 mg, 10.0 
mol %), and dppf (66) (55.4 mg, 20.0 mol %) were stirred at 160 °C  for 20 h in a sealed tube. 
After cooling the reaction mixture to ambient temperature, the crude product was purified by 
column chromatography on silica gel (n-hexane/EtOAc: 10:1→5:1) to yield 50aa’ as a white 
solid (142 mg, 82%).  
Representative Procedure D: Nickel-catalyzed secondary alkylation with alkyl bromides 
22a.  
To a mixture of benzamide 17a (131 mg, 0.50 mmol), bromocyclohexane (22aa) (163 mg, 1.00 
mmol), (DME)NiCl2 (11 mg, 10.0 mol %), BDMAE (77) (32 mg, 40.0 mol %) and LiOt-Bu 
(80 mg, 1.00 mmol) was added PhMe (1.0 mL). Thereafter, the resulted mixture was stirred 
under N2 at 160 °C  for 20 h. After cooling the reaction mixture to ambient temperature, the 
crude product was purified by column chromatography on silica gel (n-hexane/EtOAc 20:1) to 
yield 51aa as a white solid (148 mg, 86%).  
Representative Procedure E: Cobalt-catalyzed direct arylation with aryl sulfamate 30a.  
To a mixture of arene 3a (127 mg, 0.75 mmol), sulfamate 30ad (116 mg, 0.50 mmol), 
Co(acac)2 (12.8 mg, 10.0 mol %), and IMesHCl (69) (34.0 mg, 20.0 mol %) in DMPU (1.0 mL) 
was added CyMgCl (0.50 mL, 1.00 mmol) slowly. Thereafter, the reaction mixture was stirred 
under N2 at 60 °C  for 16 h. At ambient temperature, aq NH4Cl (2.0 mL) and H2O (2.0 mL) were 




organic phase was washed with brine (50 mL) and dried over Na2SO4. After filtration and 
evaporation of the solvents in vacuo, the crude product was purified by column 
chromatography on silica gel (n-hexane/EtOAc 10:1→5:1) to yield 52ad as a white solid (112 
mg, 82%). 
Representative Procedure F: Cobalt-catalyzed direct alkylation with alkyl chlorides 12a.  
To a mixture of arene 3b (78 mg, 0.50 mmol), 1-chlorohexane (12aa) (90 mg, 0.75 mmol), 
Co(acac)2 (12.8 mg, 10.0 mol %) and IPrHCl (60) (42.5 mg, 20.0 mol %) in DMPU (1.0 mL) 
was slowly added CyMgCl (0.50 mL, 1.00 mmol). Thereafter, the reaction mixture was stirred 
under N2 at 23 °C  for 16 h. At ambient temperature, aq. sat. NH4Cl (2.0 mL) and H2O (2.0 mL) 
were added, and the reaction mixture was extracted with MTBE (3   30 mL). The combined 
organic phase was washed with brine (50 mL) and dried over Na2SO4. After filtration and 
evaporation of the solvents in vacuo, the crude product was purified by column 
chromatography on silica gel (n-hexane/EtOAc 20:1) to yield 53ba as colorless oil (106 mg, 
90%). 
 
10.4 Analytical Data 
4-Methoxy-N-o-tolylbenzenamine (48aa)  
 
The general procedure A was followed using 30aa (108 mg, 0.50 mmol) and 46a (92 mg, 
0.75 mmol). After purification by column chromatography 48aa (101 mg, 95%) was obtained 
as a white solid. (m.p. 84°C).  
1H-NMR (300 MHz, CDCl3): δ = 7.14 (d, J = 7.5 Hz, 1H), 7.11-6.75 (m, 4H), 6.93-6.73 (m, 
3H), 5.18 (s, 1H), 3.79 (s, 3H), 2.25 (s, 3H).  
13C-NMR (125 MHz, CDCl3): δ = 155.1 (Cq), 143.3 (Cq), 136.3 (Cq), 130.7 (CH), 126.8 (CH), 
125.3 (Cq), 122.1 (CH), 119.9 (CH), 115.2 (CH), 114.7 (CH), 55.6 (CH3), 17.8 (CH3).  




MS (EI) m/z (relative intensity): 213 (84) [M+], 198 (100), 180 (10), 154 (8), 91 (6), 77 (3). 
HR-MS (ESI) m/z calcd for C14H15NO 213.1154, found 213.1156.  
The spectral data were in accordance with those reported in the literature.72 
 
Diphenylamine (48bb)  
 
The general procedure A was followed using 30ab (101 mg, 0.50 mmol) and 46b (70 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48bb (80 
mg, 94%) was obtained as a white solid (m.p. 53°C ).  
1H NMR (300 MHz, CDCl3): δ= 7.31-7.23 (m, 4H), 7.05 (d, J = 7.5 Hz, 4H), 6.92 (t, J = 
7.2 Hz, 4H), 5.68 (s, 1H).  
13C NMR (75 MHz, CDCl3): δ = 143.1 (Cq), 129.3 (CH), 121.0 (CH), 117.8 (CH).  
IR (KBr): 3395, 3043, 2338, 1716, 1592, 1418, 1311, 1172, 746, 691 cm-1.  
MS (EI) m/z (relative intensity) 169 (100) [M+], 141 (4), 115 (4), 77 (10), 51 (14).  
HR-MS (EI) m/z calcd for [C12H11N] 169.0891, found 169.0890.  
The spectral data were in accordance with those reported in the literature.73 
 
4-Methyl-N-phenylbenzenamine (48bc)  
 
The general procedure A was followed using 30ab (101 mg, 0.50 mmol) and 46c (80 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48bc (87 
mg, 95%) was obtained as a white solid (m.p. 90°C ).  
1H NMR (300 MHz, CDCl3): δ= 7.25 (t, J = 7.2 Hz, 2H), 7.18-6.95 (m, 6H), 6.95-6.80 (m, 
1H), 5.61 (s, 1H), 2.32 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 143.9 (Cq), 140.3 (Cq), 130.9 (Cq), 129.8 (CH), 129.3 (CH), 
120.3 (CH), 118.9 (CH), 116.8 (CH), 20.7 (CH3).  
                                                             
72 Chen, L.; Yu, G.; Li, F.; Zhu, X.; Zhang, B.; Guo, R.; Li, X.; Yang, Q.; Jin, S.; Liu, C.; Liu, S. J. Organomet. Chem. 2010, 
695, 1768–1775. 




IR (KBr): 3393, 3018, 2362, 1595, 1395, 1110, 877, 745, 693 cm-1.  
MS (EI) m/z (relative intensity) 183 (100) [M+], 167 (18), 154 (2), 77 (11), 51 (6).  
HR-MS (EI) m/z calcd for [C13H13N] 183.1084, found 183.1050.  
 
N-Phenyl-3-(triflouromethyl)aniline (48bd)  
 
The general procedure A was followed using 30ab (101 mg, 0.50 mmol) and 46d (121 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48bd (98 
mg, 83%) was obtained as colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 7.37-7.27 (m, 4H), 7.21-7.02 (m, 5H), 5.81 (s, 1H). 
13C-NMR (125 MHz, CDCl3): δ = 143.9 (Cq), 141.7 (Cq), 131.6 (Cq, 2JC-F = 33 Hz), 
129.7 (CH), 129.5 (CH), 124.0 (Cq, 1JC-F = 271 Hz), 122.2 (CH), 119.6 (CH, 4JC-F = 1 Hz), 
118.9 (CH), 116.8 (CH, 3JC-F = 4 Hz), 113.1 (CH, 3JC-F = 4 Hz).  
19F-NMR (282 MHz, CDCl3): δ = -62.8 (s).  
IR (film): 3401, 3039, 2539, 1940, 1594, 1497, 1337, 1217, 997, 923, 874, 746, 658 cm-1.  
MS (EI) m/z (relative intensity): 237 (100) [M+], 216 (10), 167 (50), 139 (10), 114 (20), 
84 (70), 65 (40).  
HR-MS (EI) m/z calcd for [C13H10F3N] 237.0765, found 237.0766.  
The spectral data were in accordance with those reported in the literature.74 
 
3,5-Dimethyl-N-phenylbenzenamine (48be)  
 
The general procedure A was followed using 30ab (101 mg, 0.50 mmol) and 46e (91 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48be (95 
mg, 96%) was obtained as a pale yellow solid (m.p. 52 °C ).  
1H NMR (300 MHz, CDCl3): δ= 7.32-7.22 (m, 2H), 7.11-7.04 (m, 2H), 6.96-6.89 (m, 1H), 
6.72 (s, 2H), 6.60 (s, 1H), 5.62 (s, 1H), 2.28 (s, 6H).  
                                                             




13C NMR (75 MHz, CDCl3): δ = 143.2 (Cq), 142.9 (Cq), 138.9 (Cq), 129.2 (CH), 122.8 (CH), 
120.73 (CH), 117.8 (CH), 115.5 (CH), 21.5 (CH3).  
IR (KBr): 3393, 3026, 2917, 2856, 1591, 1376, 1376, 1331, 1033, 750, 690 cm-1.  
MS (EI) m/z (relative intensity) 197 (100) [M+], 181 (24), 167 (10), 77 (10), 51 (5).  
HR-MS (EI) m/z calcd for [C14H15N] 197.1204, found 197.1206.  
The spectral data were in accordance with those reported in the literature.75 
 
2,4,6-Trimethyl-N-phenylbenzenamine (48bf)  
 
The general procedure A was followed using 30ab (101 mg, 0.50 mmol) and 46f (101 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48bf (101 
mg, 96%) was obtained as a pale yellow solid (m.p. 57 °C ).  
1H NMR (300 MHz, CDCl3): δ= 7.14 (t, J = 7.6 Hz, 2H), 6.94 (s, 2H), 6.80-6.65 (m, 1H), 
6.49 (d, J = 7.3 Hz, 2H), 5.09 (s, 1H), 2.30 (s, 3H), 2.17 (s, 6H).  
13C NMR (75 MHz, CDCl3): δ = 146.5 (Cq), 135.8 (Cq), 135.4 (Cq), 135.3 (Cq), 129.1 (CH), 
129.1 (CH), 117.8 (CH), 113.2 (CH), 21.0 (CH3), 18.3 (CH3).  
IR (KBr): 3390, 3014, s2917, 2856, 1600, 1375, 1312, 1027, 746, 693, 625 cm-1.  
MS (EI) m/z (relative intensity) 211 (100) [M+], 196 (34), 181 (15), 134 (12), 77 (12), 51 (7). 
HR-MS (EI) m/z calcd for [C15H17N] 211.1361, found 211.1367.  
 
4-Methoxy-N-p-tolylbenzenamine (48ca) (48dc)  
 
The general procedure A was followed using 30ac (108 mg, 0.50 mmol) and 46a (92 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48ca (89 
mg, 84%) was obtained as a white solid (m.p. 82 °C ).  
The general procedure A was followed using 30ad (116 mg, 0.50 mmol) and 46c (80 mg, 
                                                             




0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48dc (85 
mg, 80%) was obtained as a white solid (m.p. 82 °C ).  
1H NMR (300 MHz, CDCl3): δ= 7.11-6.93 (m, 4H), 6.92-6.76 (m, 4H), 5.39 (s, 1H), 3.78 (s, 
3H), 2.27 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 154.8 (Cq), 142.4 (Cq), 136.6 (Cq), 129.8 (CH), 129.3 (Cq), 
121.1 (CH), 116.6 (CH), 114.7 (CH), 55.6 (CH3), 20.5 (CH3).  
IR (KBr): 3415, 2951, 2835, 1613, 1516, 1316, 1179, 1106, 739, 703 cm-1.  
MS (EI) m/z (relative intensity) 213 (68) [M+], 198 (100), 154 (11), 77 (3), 43 (16).  
HR-MS (EI) m/z calcd for [C14H15NO] 213.1154, found 213.1146.  
The spectral data were in accordance with those reported in the literature.76  
 
4-Methoxy-N-p-tolylbenzenamine (48cg) (48ec)  
 
The general procedure A was followed using 30ac (108 mg, 0.50 mmol) and 46g (83 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48cg (81 
mg, 82%) was obtained as a colorless oil.  
The general procedure A was followed using 30ae (110 mg, 0.50 mmol) and 46c (80 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48ec (88 mg, 
87%) was obtained as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ= 7.42-7.45 (d, J = 8.2 Hz, 2H), 7.15-7.13 (d, J = 8.2 Hz, 2H), 
7.04-7.07 (d, J = 8.5 Hz, 2H), 6.95-6.97 (d, J = 8.5 Hz, 2H), 5.82 (s, 1H), 2.33 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 146.2 (Cq), 138.3 (Cq), 133.0 (Cq), 130.0 (CH), 129.8 (CH), 
121.2 (Cq), 120.9 (CH), 114.8 (CH), 21.0 (CH3)..  
IR (KBr): 3415, 2951, 2835, 1612, 1515, 1316, 1179, 1106, 729, 704 cm-1.  
MS (EI) m/z (relative intensity) 201 (68) [M+], 188 (100), 152 (11), 77 (3), 43 (16).  
HR-MS (ESI) m/z calcd for [C13H13FNO+H]+ 202.1032. Found: 202.1040 
 
                                                             




4-Methoxy-N-p-tolylbenzenamine (48ea)  
 
The general procedure A was followed using 30ae (110 mg, 0.50 mmol) and 46a (82 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48ea (96 mg, 
88%) was obtained as a white solid.  
1H NMR (300 MHz, CDCl3): δ= 7.02–6.98 (m, 2H), 6.94–6.83 (m, 6H), 5.37 (s, 1H), 3.79 (s, 
3H). 
13C NMR (75 MHz, CDCl3): δ = 157.2 (Cq), 155.0 (Cq), 141.1 (Cq), 136.5 (CH), 121.2 (Cq), 
117.7 (CH), 115.7 (CH), 114.7 (CH), 55.6 (CH3).  
IR (KBr): 3414, 2952, 2839, 1612, 1515, 1316, 1179, 1100, 729, 702 cm-1.  
MS (EI) m/z (relative intensity) 217 (61) [M+], 195 (100), 145 (11), 78 (15), 43 (20).  
HR-MS (ESI) m/z calcd for [C13H13FNO]+ 217.0903. Found: 217.0905 
 
N-(3-(Trifluoromethyl)phenyl)naphthalen-2-amine (48fd)  
 
The general procedure A was followed using 30af (126 mg, 0.50 mmol) and 46d (121 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48fd (146 
mg, 98%) was obtained as a pale pink solid (m.p. 70 °C ).  
1H-NMR (300 MHz, CDCl3): δ = 7.84-7.74 (m, 2H), 7.69 (d, J = 7.0 Hz, 1H), 7.537-7.40 (m, 
2H), 7.40-7.29 (m, 3H), 7.29-7.22 (m, 2H), 7.18 (d, J = 6.9 Hz, 1H), 5.99 (s, 1H).  
13C-NMR (125 MHz, CDCl3): δ = 143.8 (Cq), 139.3 (Cq), 134.3(Cq), 131.8 (Cq, 2JC-F = 33 Hz), 
129.8 (CH), 129.7 (CH), 129.4 (CH), 127.6 (CH), 126.6 (CH), 126.5 (CH), 124.1 (CH), 124.0 
(Cq, 1JC-F = 272 Hz), 120.4 (CH), 120.1 (CH), 117.3 (CH, 4JC-F = 3.7 Hz), 116.8 (CH, 3JC-F = 4 
Hz), 113.1 (CH, 3JC-F = 4 Hz).  
19F-NMR (282 MHz, CDCl3): δ = -62.8 (s). IR (film): 3398, 3058, 2362, 1596, 1336, 1171, 
1069, 851, 753, 696 cm-1.  




HR-MS (EI) m/z calcd for [C17H12F3N] 287.0922, found 287.0915.  
The spectral data were in accordance with those reported in the literature.77 
 
N-Mesitylnaphthalen-2-amine (48ff)  
 
The general procedure A was followed using 30af (126 mg, 0.50 mmol) and 46f (101 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48ff (111 
mg, 85%) was obtained as a pale brown solid (m.p. 82°C ).  
1H NMR (300 MHz, CDCl3): δ= 7.66 (dd, J = 4.8, 4.6 Hz, 2H), 7.49 (d, J = 8.6 Hz, 2H),  
7.36-7.28 (m, 1H), 7.23-7.13 (m, 1H), 6.99 (s, 2H), 6.95 (dd, J = 2.2, 2.7 Hz, 1H), 6.54 (d, 
J = 2.7 Hz, 1H), 5.27 (s, 1H), 2.34 (s, 3H), 2.20 (s, 6H).  
13C NMR (75 MHz, CDCl3): δ = 144.3 (Cq), 136.0 (Cq), 135.6 (Cq), 135.3 (Cq), 135.0 (Cq), 
129.3 (CH), 129.1 (CH), 127.8 (CH), 127.6 (CH), 126.2 (CH), 125.9 (CH), 122.1 (CH), 117.4 
(CH), 105.7 (CH), 21.0 (CH3), 18.2 (CH3).  
IR (KBr): 3391, 2915, 1632, 1601, 1516, 1310, 1249, 1181, 808, 745 cm-1.  
MS (EI) m/z (relative intensity) 261 (100) [M+], 245 (25), 231 (20), 115 (15), 77 (6), 43 (16). 
HR-MS (EI) m/z calcd for [C19H19N] 261.1517, found 261.1517.  
The spectral data were in accordance with those reported in the literature.78 
 
N-Hexylnaphthalen-2-amine (48fh)  
 
The general procedure A was followed using 30af (126 mg, 0.50 mmol) and 46h (76 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48fh (85 mg, 
75%) was obtained as colorless oil.  
1H NMR (300 MHz, CDCl3): δ= 7.68 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 8.0 Hz, 2H), 7.41-7.32 
(m, 1H), 7.25-7.15 (m, 1H), 6.87 (dd, J = 2.2, 2.2 Hz, 1H), 6.80 (d, J = 2.1 Hz, 1H), 3.76 (s, 
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1H), 3.21 (t, J = 7.2 Hz, 2H), 1.76-1.58 (m, 2H), 1.55-1.25 (m, 6H), 1.01-0.87 (m, 3H).  
13C NMR (75 MHz, CDCl3): δ= 146.1 (Cq), 135.3 (Cq), 128.8 (CH), 127.6 (CH), 127.4 (Cq), 
126.2 (CH), 125.8 (CH), 121.7 (CH), 117.9 (CH), 105.1 (CH), 44.0 (CH2), 31.6 (CH2), 29.4 
(CH2), 26.9 (CH2), 22.6 (CH2), 14.0 (CH3).  
IR (KBr): 3409, 3050, 2954, 2927, 2856, 1604, 1516, 1358, 1145, 745 cm-1.  
MS (EI) m/z (relative intensity) 227 (28) [M+], 156 (100), 127 (14), 115 (9), 77 (2), 43 (15). 
HR-MS (EI) m/z calcd for [C16H21N] 227.1674, found 227.1670.  
The spectral data were in accordance with those reported in the literature.79 
 
N-Octylnaphthalen-2-amine (48fi)  
 
The general procedure A was followed using 30af (126 mg, 0.50 mmol) and 46i (97 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 50:1) 48fi (93 mg, 
73%) was obtained as colorless oil.  
1H NMR (300 MHz, CDCl3): δ= 7.72-7.55 (m, 3H), 7.40-7.29 (m, 1H), 7.24-7.12 (m, 1H), 
6.87 (dd, J = 2.6, 2.5 Hz, 1H), 6.80 (d, J = 2.3 Hz, 1H), 3.81 (s, 1H), 3.20 (t, J = 7.2 Hz, 2H), 
1.77-1.61 (m, 2H), 1.52-1.16 (m, 10H), 0.98-0.76 (m, 3H).  
13C NMR (75 MHz, CDCl3): δ= 146.0 (Cq), 135.3 (Cq), 128.8 (CH), 127.6 (CH), 127.4 (Cq), 
126.3 (CH), 125.9 (CH), 121.8 (CH), 118.0 (CH), 104.3 (CH), 44.1 (CH2), 31.8 (CH2), 29.4 
(CH2), 29.4 (CH2), 29.3 (CH2), 27.2 (CH2), 22.7 (CH2), 14.1 (CH3).  
IR (KBr): 3412, 3050, 2926, 2854, 1604, 1517, 1359, 1249, 1145, 746 cm-1.  
MS (EI) m/z (relative intensity) 255 (62) [M+], 156 (100), 127 (20), 115 (11), 77 (2), 43 (5). 
HR-MS (EI) m/z calcd for [C18H25N] 255.1987, found 255.1982.  
The spectral data were in accordance with those reported in the literature.80  
 
4-Phenylmorpholine (68ba)  
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The general procedure A was followed using 30ab (101 mg, 0.50 mmol) and 67 (65 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 68ba (80 mg, 
99%) was obtained as a white solid (m.p. 55°C ).  
1H NMR (300 MHz, CDCl3): δ= 7.33-7.21 (m, 2H), 6.95-6.83 (m, 2H), 3.85 (t, 
J = 4.8 Hz, 4H), 3.14 (t, J = 5.0 Hz, 4H).  
13C NMR (75 MHz, CDCl3): δ= 151.3 (Cq), 129.2 (CH), 120.0 (CH), 115.7 (CH), 66.9 (CH2), 
49.4 (CH2).  
IR (KBr): 3406, 3059, 3024, 1597, 1498, 1375, 1298, 1175, 1119, 732, 697 cm-1.  
MS (EI) m/z (relative intensity) 163 (48) [M+], 105 (100), 77 (35), 55 (30), 43 (70).  
HR-MS (EI) m/z calcd for [C10H13NO] 163.0997, found 163.0994.  
 
4-p-Tolylmorpholine (68ca)  
 
The general procedure A was followed using 30ac (108 mg, 0.50 mmol) and 67 (65 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 68ca (81 mg, 
92%) was obtained as a pale yellow solid (m.p. 47 °C ). 
1H NMR (300 MHz, CDCl3): δ= 7.08 (d, J = 8.2 Hz, 2H), 6.86-6.79 (m, 2H), 3.84 (t, 
J = 4.8 Hz, 4H), 3.09 (t, J = 4.6 Hz, 4H), 2.26 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ= 149.2 (Cq), 129.7 (CH), 129.6 (Cq), 116.3 (CH), 66.9 (CH2), 
49.9 (CH2), 20.4 (CH3).  
IR (KBr): 3398, 2958, 2852, 1699, 1558, 1513, 1259, 1117, 745, 695 cm-1.  
MS (EI) m/z (relative intensity) 177 (28) [M+], 119 (50), 91 (11), 58 (18), 43 (100).  
HR-MS (EI) m/z calcd for [C11H15NO] 177.1154, found 177.1154.  
 
4-(4-Fluorophenyl)morpholine (68ea)  
 
The general procedure A was followed using 30ae (110 mg, 0.50 mmol) and 67 (65 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 68ea (81 mg, 




1H NMR (300 MHz, CDCl3): δ = 7.02-6.91 (m, 2H), 6.90-6.79 (m, 2H), 3.84 (t, 
J = 4.8 Hz, 4H), 3.06 (t, J = 4.5 Hz, 4H).  
13C NMR (75 MHz, CDCl3): δ= 157.3 (Cq, 1JC-F = 240 Hz), 147.9 (Cq, 4JC-F = 4 Hz), 117.4.0 
(CH, 3JC-F = 7 Hz), 124.0 (CH, 2JC-F = 22 Hz), 66.9 (CH2), 50.3 (CH2).  
IR (KBr): 3395, 3056, 2285, 2824, 1726, 1511, 1375, 1239, 1120, 711 cm-1.  
MS (EI) m/z (relative intensity) 181 (52) [M+], 123 (100), 95 (25), 75 (12), 57 (5).  
HR-MS (EI) m/z calcd for [C10H12FNO] 181.0903, found 181.0907.  




The general procedure B was followed using 45aa (129 mg, 0.50 mmol) and 46c (80 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 47ac 
(125 mg, 88%) as a white solid (m.p. 97-98 °C ).  
1H NMR (300 MHz, CDCl3): δ 7.70 (dd, J = 5.7, 3.3Hz, 1H), 7.44-7.03 (m, 12H), 6.81 (s, 
1H), 2.41 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ 140.8, 139.1, 137.0, 135.9, 132.6, 129.9, 128.9, 128.2, 128.1, 
127.8, 127.2, 122.2, 120.5, 120.4, 110.7, 103.4, 21.1.  
IR (KBr): 3054, 3033, 2920, 1514, 1451, 1356, 1322, 1208, 1108, 1022, 741, 696 cm-1.  
MS (EI) m/z (relative intensity) 283 (100) [M+], 267 (14), 165 (13), 133 (9).  
HR-MS (EI) m/z calcd for C21H17N 283.1361, found 283.1359.  
 
1,2-Diphenyl-1H-indole (47ab)  
                                                             





The general procedure B was followed using 45aa (129 mg, 0.50 mmol) and 46b (70 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 
47ab (115 mg, 86%) was obtained as a white solid (m.p. 83-84 °C ).  
1H NMR (300 MHz, CDCl3): δ 7.73 (m, 1H), 7.48-7.14 (m, 13H), 6.85 (d, J = 0.8 Hz, 1H). 
13C NMR (75 MHz, CDCl3): δ 140.7, 139.0, 138.5, 132.5, 129.2, 129.0, 128.3, 128.1, 128.0, 
127.3, 127.2, 122.3, 120.7, 120.5, 110.6, 103.7.  
IR (KBr): 3056, 1597, 1495, 1451, 1377, 1352, 1321, 795, 755, 697 cm-1. MS (EI) m/z 
(relative intensity) 269 (100) [M+], 268 (35), 165 (26), 133 (27), 127 (12).  




The general procedure B was followed using 45aa (129 mg, 0.50 mmol) and 46a (92 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 
47aa (146 mg, 98%) was obtained as a white solid (m.p. 143-144 °C ).  
1H NMR (300 MHz, CDCl3): δ 7.74 (m, 1H), 7.42-7.12 (m, 10H), 6.97 (d, J = 8.9 Hz, 2H), 
6.85 (s, 1H), 3.86 (s, 3H).   
13C NMR (75 MHz, CDCl3): δ 158.5, 140.8, 139.3, 132.6, 131.3, 129.1, 128.8, 128.1, 128.1, 
127.2, 122.1, 120.5, 120.4, 114.4, 110.6, 103.1, 55.4.  
IR (KBr): 3054, 2956, 2835, 1612, 1512, 1460, 1294, 1175, 1031, 842, 754, 694 cm-1.  
MS (EI) m/z (relative intensity) 299 (100) [M+], 284 (26), 256 (10), 254 (16).  





1,2-Di-p-anisyl-1H-indole (47ba).  
 
The general procedure B was followed using 45ab (144 mg, 0.50 mmol) and 46a (92 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc, 100/1) indole 
47ba (147 mg, 89%) was obtained as a yellow solid (m.p. 136-137 °C).  
1H NMR (300 MHz, CDCl3): δ 7.68 (m, 1H), 7.23-7.13 (m, 7H), 6.93 (dt, J = 9.8, 3.4 Hz, 
2H), 6.80 (dt, J = 9.8, 3.1 Hz, 2H), 6.73 (d, J = 0.7 Hz, 1H), 3.86 (s, 3H), 3.79 (s, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 158.9, 158.5, 140.8, 139.2, 131.4, 130.1, 129.2, 128.2, 
125.1, 121.8, 120.4, 120.2, 114.4, 113.6, 110.5, 102.2, 55.4, 55.2.  
IR (KBr): 3000, 2933, 2838, 1608, 1541, 1513, 1456, 1361, 1249, 1116, 1031, 834, 740, 646 
cm-1.  
MS (EI) m/z (relative intensity) 329 (100) [M+], 314 (36), 298 (2), 283 (5), 271 (5), 254 (15), 
242 (16), 215 (3), 190 (2).  
HR-MS (ESI) m/z calcd for [C22H19NO2+H]+  330.1489, found 330.1489. 
 
2-Phenyl-1-{m(-trifluoromethyl)phenyl}-1H-indole (47ad).  
 
The general procedure B was followed using 45aa (129 mg, 0.50 mmol) and 46d (121 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 
47ad (115 mg, 72%) was obtained as a white solid (m.p. 91-92°C ).  
1H NMR (300 MHz, CDCl3): δ 7.71 (m, 1H), 7.67-7.47 (m, 3H), 7.39 (d, J = 7.9 Hz, 1H), 




13C NMR (75 MHz, CDCl3): δ 140.6, 139.1, 138.6, 132.0, 131.8 (2JC,F = 34 Hz), 131.2, 129.8, 
129.0, 128.5, 128.3, 127.6, 124.7 (3JC,F = 4 Hz), 123.7 (3JC,F = 4 Hz), 122.8, 121.5 (1JC,F = 251 
Hz),  121.2, 120.8, 110.2, 104.6.  
IR (KBr): 3059, 1597, 1496, 1456, 1375, 1326, 1129, 799, 752, 698 cm-1.  
MS (EI) m/z (relative intensity) 337 (100) [M+], 336 (19), 267 (14), 165 (26), 133 (23). 
HR-MS (ESI) m/z calcd for [C21H14NF3+H]+ 338.1151, found 338.1152.  
 
2-n-Hexyl-1-phenyl-1H-indole (47cb).  
 
The general procedure B was followed using 45ac (133 mg, 0.50 mmol) and 46b (70 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 
47cb (108 mg, 78%) was obtained as a yellow oil.  
1H NMR (300 MHz, CDCl3): δ 7.71-7.47 (m, 4H), 7.42 (t, J = 4.2 Hz, 2H), 7.23-7.11 (m, 3H), 
6.50 (s, 1H), 2.76-2.58 (t, J = 7.6 Hz, 2H), 1.71-1.58 (m, 2H), 1.40-1.20 (m, 6H), 0.93 (t, J = 
6.8 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ 142.0, 138.3, 138.1, 129.4, 128.3, 128.1, 127.8, 121.0, 119.9, 
119.6, 109.9, 100.1, 31.5, 28.9, 28.6, 27.1, 22.5, 14.0.  
IR (KBr): 3056, 2927, 2857, 1596, 1498, 1459, 1392, 1211, 1016, 778, 762, 699 cm-1.  
MS (EI) m/z (relative intensity) 277 (44) [M+], 220 (46), 207 (100), 191 (6), 178 (7), 165 (3), 
152 (2), 128 (6).  
HR-MS (EI) m/z calcd for C20H23N 277.1830, found 277.1831.  
 





The general procedure B was followed using 45ac (133 mg, 0.50 mmol) and 46c (80 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 47cc 
(117 mg, 81%) was obtained as a yellow oil.  
1H NMR (300 MHz, CDCl3): δ 7.66 (m, 1H), 7.38 (d, J = 8.5 Hz, 2H), 7.29 (m, 2H), 
7.20-7.10 (m, 3H), 6.48 (s, 1H), 2.70 (t, J = 7.8 Hz, 2H), 2.52 (s, 3H), 1.71-1.60 (m, 2H), 1.32 
(m, 6H), 0.94 (t, J = 6.8 Hz, 3H).   
13C NMR (75 MHz, CDCl3): δ 142.1, 138.4, 137.6, 135.4, 130.0, 128.1, 128.0, 120.8, 119.8, 
119.5, 110.0, 99.8, 31.5, 28.9, 28.6, 27.0, 22.5, 21.2, 14.0.  
IR (KBr): 3054, 2954, 2926, 2858, 1608, 1514, 1459, 1394, 1211, 1017, 817, 741 cm-1.  
MS (EI) m/z (relative intensity) 291 (46) [M+],  221 (100), 220 (66), 205 (34), 204 (44).  
HR-MS (EI) m/z calcd for C21H25N 291.1987, found 291.1978.  
 
1-(p-Anisyl)-2-n-hexyl-1H-indole (47ca).  
 
The general procedure B was followed using 45ac (133 mg, 0.50 mmol) and 46a (92 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 47ca 
(113 mg, 75%) was obtained as a yellow oil.  
1H NMR (300 MHz, CDCl3): δ 7.61 (m, 1H), 7.33-7.23 (m, 2H), 7.19-6.99 (m, 5H), 6.43 (s, 
1H), 3.91 (s, 3H), 2.62 (t, J = 7.4 Hz, 2H), 1.69-1.55 (m, 2H), 1.28 (s, 6H), 0.90 (t, J = 5.9 Hz, 
3H).  
13C NMR (75 MHz, CDCl3): δ 159.0, 142.3, 138.6, 130.7, 129.4, 128.0, 120.8, 119.7, 119.5, 
114.5, 109.9, 99.6, 55.5, 31.5, 28.9, 28.6, 27.0, 22.5, 14.1.  
IR (KBr): 3050, 2928, 2857, 1580, 1547, 1460, 1294, 1211, 1036, 831, 778, 742 cm-1.  
MS (EI) m/z (relative intensity) 307 (51) [M+],  237 (100), 205 (29), 192 (11), 43 (15).  








The general procedure B was followed using 45aa (129 mg, 0.50 mmol) and 46j (107 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 
47aj (124 mg, 78%) was obtained as a yellow solid (m.p. 73-74 °C ). 
1H NMR (300 MHz, CDCl3): δ 7.93 (t, J = 7.4 Hz, 2H), 7.75 (m, 1H), 7.55-7.42 (m, 3H), 
7.42-7.30 (m, 2H), 7.26-7.04 (m, 7H), 6.94 (d, J = 0.8 Hz, 1H), 6.82 (dd, J = 8.2, 0.9 Hz , 1H). 
13C NMR (75 MHz, CDCl3): δ 142.1, 140.2, 135.3, 134.3, 132.5, 131.3, 128.6, 128.3, 128.2, 
128.2, 128.1, 127.3, 127.2, 127.1, 126.5, 125.5, 123.6, 122.2, 120.6, 120.5, 111.2, 103.2.  
IR (KBr): 3053, 1599, 1509, 1460, 1403, 1317, 1215, 1017, 796, 747, 695 cm-1.  
MS (EI) m/z (relative intensity) 319 (100) [M+], 302 (4), 289 (3), 241 (8), 215 (5), 190 (2). 
HR-MS (EI) m/z calcd for C24H17N 319.1361, found 319.1364.  
 
1-Mesityl-2-phenyl-1H-indole (47af).  
 
The general procedure B was followed using 45aa (129 mg, 0.50 mmol) and 46f (101 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 
47af (124 mg, 81%) was obtained as a yellow oil.  
1H NMR (300 MHz, CDCl3): δ 7.80 (dd, J = 6.2, 2.8 Hz, 1H), 7.43-7.18 (m, 7H), 7.03 (s, 2H), 
7.00-6.90 (m, 2H), 2.42 (s, 3H), 1.93 (s, 6H).  
                                                             




13C NMR (75 MHz, CDCl3): δ 140.5, 138.0, 137.9, 136.9, 133.9, 132.8, 129.2, 128.2, 128.2, 
127.4, 127.2, 122.1, 120.4, 120.2, 110.5, 102.0, 21.1, 17.7.  
IR (KBr): 3054, 3027, 2919, 1604, 1486, 1371, 1209, 1030, 854, 793, 741, 696 cm-1.  
MS (EI) m/z (relative intensity) 311 (100) [M+], 310 (17), 296 (20), 237 (13).  
HR-MS (ESI) m/z calcd for [C23H21N+H]+ 312.1747, found 312.1741.  
 
2-Phenyl-1-(3-pyridyl)-1H-indole (47ak).  
 
The general procedure B was followed using 45aa (129 mg, 0.50 mmol) and 46k (71 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 
47ak (98 mg, 74%) was obtained as a white oil.  
1H NMR (300 MHz, CDCl3): δ 8.70-8.55 (m, 2H), 7.74 (m, 1H), 7.55 (m, 1H), 7.41-7.18 (m, 
9H), 6.87 (s, 1H).  
13C NMR (75 MHz, CDCl3): δ 148.9, 148.0, 140.6, 138.7, 135.2, 135.1, 131.8, 129.0, 128.5, 
128.4, 127.6, 123.7, 122.8, 121.2, 120.7, 110.0, 104.7.  
IR (KBr): 3053, 1482, 1426, 1326, 1208, 1024, 798, 749, 703 cm-1.  
MS (EI) m/z (relative intensity) 270 (100) [M+], 241 (8), 216 (3), 190 (4), 165 (12), 134 (11). 
HR-MS (EI) m/z calcd for C19H14N2 270.1157, found 270.1161.  
 
1-Benzyl-2-phenyl-1H-indole (47al).  
 
The general procedure B was followed using 45aa (129 mg, 0.50 mmol) and 46l (80 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 47al 
(120 mg, 85%) was obtained as a white solid (m.p. 95-96 °C ).  
1H NMR (300 MHz, CDCl3): δ 7.68 (dd, J = 5.9, 0.8 Hz, 1H), 7.36-7.14 (m, 11H), 7.07-7.02 




13C NMR (75 MHz, CDCl3): δ 141.8, 138.2, 138.0, 132.7, 129.2, 128.7, 128.5, 128.3, 128.0, 
127.1, 126.0, 121.9, 120.5, 120.1, 110.5, 102.3, 47.7.  
IR (KBr): 3056, 3029, 2917, 1603, 1488, 1454, 1348, 1312, 1163, 730, 698, 670 cm-1.  
MS (EI) m/z (relative intensity) 283 (50) [M+],  165 (12), 91 (100), 65 (9).  
HR-MS (ESI) m/z calcd for [C21H17N+H]+ 284.1434, found 284.1434.  
 
 
1-Benzyl-2-n-hexyl-1H-indole (47cl).  
 
The general procedure B was followed using 45ac (133 mg, 0.50 mmol) and 46l (80 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 47cl 
(95 mg, 67%) was obtained as a white solid (m.p. 68-69 °C ).  
1H NMR (300 MHz, CDCl3): δ 7.60 (m, 1H), 7.36-7.06 (m, 6H), 6.98 (d, J = 8.1 Hz, 2H), 
6.38 (s, 1H), 5.34 (s, 2H), 2.69 (t, J = 7.8 Hz, 2H), 1.82-1.61 (m, 2H), 1.48-1.19 (m, 6H), 0.90 
(dd, J = 5.76, 6.11 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ 141.4, 138.0, 137.1, 128.7, 128.2, 127.2, 125.9, 120.7, 120.0, 
119.4, 109.3, 99.3, 46.3, 31.6, 29.0, 28.4, 26.7, 22.5, 14.1.  
IR (KBr): 3031, 2953, 2921, 2851, 1650, 1541, 1453, 1352, 1309, 1250, 773, 733, 697 cm-1. 
MS (EI) m/z (relative intensity) 291 (70) [M+], 234 (32), 221 (94), 130 (23), 91 (100), 65 (14). 
HR-MS (EI) m/z calcd for C21H25N 291.1987, found 291.1978.  
The spectral data are in accordance with those reported in literature.83 
 
1-n-Hexyl-2-phenyl-1H-indole (47ah).  
 
                                                             




The general procedure B was followed using 45aa (129 mg, 0.50 mmol) and 46h (76 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 
47ah (102 mg, 74%) was obtained as a yellow oil.  
1H NMR (300 MHz, CDCl3): δ 7.73 (d, J = 7.6 Hz, 1H), 7.62-7.43 (m, 6H), 7.32 (m, 1H), 
7.23 (m, 1H), 6.62 (s, 1H), 4.22 (t, J = 7.6 Hz, 2H), 1.86-1.70 (m, 2H), 1.40-1.10 (m, 6H), 
0.91 (t, J = 6.8 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ 141.3, 137.3, 133.3, 129.4, 128.4, 128.2, 127.8, 121.4, 120.5, 
119.7, 110.0, 102.0, 43.9, 31.2, 29.9, 26.4, 22.4, 13.9.  
IR (KBr): 3056, 2954, 2859, 1646, 1462, 1350, 1313, 1166, 744, 699 cm-1.  
MS (EI) m/z (relative intensity) 277 (44) [M+], 221 (11), 206 (100), 204 (15), 178 (12), 165 
(19).  
HR-MS (ESI) m/z calcd for [C20H23N+H]+ 278.1903, found 278.1900.  
 
1-n-Octyl-2-phenyl-1H-indole (47ai).  
 
The general procedure B was followed using 45aa (129 mg, 0.50 mmol) and 46i (97 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 47ai 
(120 mg, 80%) was obtained as a yellow oil.  
1H NMR (300 MHz, CDCl3): δ  7.67 (d, J = 7.8 Hz, 1H), 7.59-7.36 (m, 6H), 7.26 (m, 1H), 
7.15 (m, 1H), 6.55 (s, 1H), 4.16 (t, J = 7.7 Hz, 2H), 1.77-1.65 (m, 2H), 1.34-1.09 (m, 10H), 
0.89 (t, J = 6.9 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ 141.3, 137.3, 133.3, 129.4, 128.4, 128.2, 127.9, 121.4, 120.5, 
119.7, 110.0, 102.0, 43.9, 31.7, 29.9, 29.1, 29.0, 26.7, 22.6, 14.1.  
IR (KBr): 3030, 2926, 2855, 1606, 1462, 1350, 1163, 1016, 786, 743, 700 cm-1.  
MS (EI) m/z (relative intensity) 305 (43) [M+], 207 (16), 206 (100), 193 (13), 165 (9).  
HR-MS (ESI) m/z calcd for [C22H27N+H]+ 306.2216, found 306.2218.  
 





The general procedure B was followed using 45ad (145 mg, 0.50 mmol) and 46c (80 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 
47dc (113 mg, 72%) was obtained as a white solid (m.p. 112-113°C ).  
1H NMR (300 MHz, CDCl3): δ 7.57 (d, J = 8.4 Hz, 1H), 7.30-7.19 (m, 8H), 7.16-7.05 (m, 
3H), 6.75 (s, 1H), 2.41 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ 141.5, 139.5, 137.5, 135.3, 132.1, 130.1, 128.8, 128.2, 128.0, 
127.6, 127.5, 126.7, 121.2, 121.2, 110.7, 103.2, 21.2.  
IR (KBr): 3057, 3034, 1604, 1514, 1457, 1378, 1071, 927, 759, 732, 695 cm-1.  
MS (EI) m/z (relative intensity) 317 (100) [M+], 281 (23), 267 (14), 239 (3), 179 (6), 165 (8). 
HR-MS (EI) m/z calcd for C21H16ClN 317.0971, found 317.0968.  
 
1-Benzyl-6-chloro-2-phenyl-1H-indole (47dl).  
 
The general procedure B was followed using 45ad (145 mg, 0.50 mmol) and 46l (80 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 47dl 
(115 mg, 73%) was obtained as a white solid (m.p. 130-131°C ).  
1H NMR (300 MHz, CDCl3): δ 7.56 (d, J = 8.4 Hz, 1H), 7.47-7.06 (m, 10H), 6.99 (d, J = 6.3 
Hz, 2H) 6.61 (s, 1H), 5.31 (s, 2H).  
13C NMR (75 MHz, CDCl3): δ 142.6, 138.4, 137.6, 132.2, 129.2, 128.9, 128.6, 128.3, 127.7, 
127.3, 126.9, 125.9, 121.4, 120.9, 110.5, 102.4, 47.8.  
IR (KBr): 3060, 3030, 1605, 1460, 1384, 1073, 916, 760, 732, 698 cm-1.  
MS (EI) m/z (relative intensity) 317 (80) [M+], 226 (8), 199 (12), 91 (100), 65 (15), 43 (13). 
HR-MS (EI) m/z calcd for C21H16ClN 317.0971, found 317.0971.  
 





The general procedure B was followed using 45ad (145 mg, 0.50 mmol) and 46i (97 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 500:1) indole 47di 
(91 mg, 53%) was obtained as a yellow oil.  
1H NMR (300 MHz, CDCl3): δ 7.60-7.34 (m, 7H), 7.10 (d, J = 8.4 Hz, 1H), 6.48 (s, 1H), 4.09 
(t, J = 7.5 Hz, 2H), 1.75-1.55 (m, 2H), 1.32-1.10 (m, 10H), 0.87 (t, J = 6.9 Hz, 3H).   
13C NMR (75 MHz, CDCl3): δ 142.1, 137.8, 132.8, 129.4, 128.5, 128.1, 127.3, 126.7, 121.3, 
120.3, 110.0, 102.1, 44.1, 31.7, 29.8, 29.0, 28.9, 26.6, 22.6, 14.1.  
IR (KBr): 3062, 2926, 2856, 1607, 1463, 1341, 1302, 1068, 919, 810, 759, 699 cm-1.  
MS (EI) m/z (relative intensity) 339 (81) [M+],  242 (38), 240 (100), 227 (23), 205 (88).  




The general procedure C was followed using 49aa (85.5 mg, 0.50 mmol) and 4a (446 mg, 
2.50 mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50aa’ 
(142 mg, 82%) was obtained as a white solid (m.p. 159–160 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.61 (ddd, J = 4.8, 2.0, 0.9 Hz, 1H), 7.78–7.65 (m, 2H), 
7.59–7.52 (m, 1H), 7.42–7.06 (m, 13H), 6.82 (dt, J = 8.0, 0.9 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 151.8 (Cq), 149.1 (CH), 137.6 (CH), 137.4 (Cq), 135.9 (Cq), 
134.6 (Cq), 131.7 (Cq), 130.9 (CH), 130.3 (CH), 128.3 (Cq), 128.2 (CH), 128.1 (CH), 127.4 
(CH), 126.1 (CH), 123.4 (CH), 122.2 (CH), 121.6 (CH), 121.5 (CH), 119.6 (CH), 118.2 (Cq), 
111.5 (CH).  
IR (neat): 3050, 1582, 1464, 1388, 1028, 696 cm-1.  
MS (EI) m/z (relative intensity) 346 (100) [M+], 267 (25), 165 (11), 78 (15), 51 (11).  







The general procedure C was followed using 49ba (86 mg, 0.50 mmol) and 4a (446 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50aa (141 
mg, 81%) was obtained as a white solid (m.p. 148–149 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.62 (d, J = 4.9 Hz, 2H), 8.28–8.20 (m, 1H), 7.83–7.76 (m, 
1H), 7.47–7.29 (m, 7H), 7.24 (m, 5H), 7.01 (t, J = 4.9 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 157.9 (CH), 157.8 (Cq), 136.9 (Cq), 136.0 (Cq), 134.1 (Cq), 
132.7 (Cq), 130.2 (CH), 130.1 (CH), 129.1 (Cq), 128.1 (CH), 127.7 (CH), 126.9 (CH), 126.3 
(CH), 123.8 (CH), 122.1 (CH), 120.1 (Cq), 119.6 (CH), 117.4 (CH), 112.6 (CH).  
IR (neat): 3054, 1556, 1416, 1257, 1027, 847 cm-1.  
MS (EI) m/z (relative intensity) 347 (100) [M+], 267 (16), 165 (5), 77 (3), 53 (3).  
HR-MS (EI) m/z calcd for [C24H17N3] + 347.1422, found 347.1417.  




The general procedure C was followed using 49bb (124 mg, 0.50 mmol) and 4a (446 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50ba (144 
mg, 68%) was obtained as a white solid (m.p. 207–208 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.64 (d, J = 4.9 Hz, 2H), 8.27 (dd, J = 8.6, 0.6 Hz, 1H), 
7.94 (dd, J = 1.9, 0.6 Hz, 1H), 7.74–7.67 (m, 2H), 7.64 (dd, J = 8.6, 1.9 Hz, 1H), 7.51–7.31 
(m, 8H), 7.27–7.16 (m, 5H), 7.06 (t, J = 4.9 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 158.0 (CH), 157.9 (Cq), 142.0 (Cq), 136.7 (Cq), 136.4 (Cq), 
                                                             




135.7 (Cq), 134.0 (Cq), 132.7 (Cq), 130.4 (CH), 130.2 (CH), 129.7 (Cq), 128.6 (CH), 128.3 
(CH), 127.8 (CH), 127.3 (CH), 127.1 (CH), 126.6 (CH), 126.5 (CH), 123.5 (CH), 120.5 (Cq), 
118.1 (CH), 117.6 (CH), 112.9 (CH). 
IR (neat): 3041, 1560, 1417, 1228, 915, 722 cm-1.  
MS (EI) m/z (relative intensity) 423 (100) [M+], 346 (10), 264 (3), 77 (3), 43 (2).  




The general procedure C was followed using 49bc (101 mg, 0.50 mmol) and 4a (446 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→3:1) 50ca (127 
mg, 67%) was obtained as a white solid (m.p. 186–187 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.59 (d, J = 4.9 Hz, 2H), 8.10 (dd, J = 9.0, 0.6 Hz, 1H), 
7.36–7.23 (m, 5H), 7.21–7.11 (m, 6H), 7.03 (t, J = 4.9 Hz, 1H), 6.98 (dd, J = 9.0, 2.6 Hz, 1H), 
3.83 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 157.9 (CH), 155.8 (Cq), 136.7 (Cq), 134.3 (Cq), 134.3 (Cq), 
132.9 (Cq), 131.9 (Cq), 130.3 (CH), 130.2 (CH), 129.9 (Cq), 128.2 (CH), 127.7 (CH), 126.9 
(CH), 126.4 (CH), 120.3 (Cq), 117.3 (CH), 113.7 (CH), 113.2 (CH), 101.6 (CH), 55.8 (CH3). 
IR (neat): 3052, 2988, 1572, 1420, 1161, 730 cm-1.  
MS (EI) m/z (relative intensity) 377 (100) [M+], 334 (35), 254 (10), 79 (4), 53 (3).  




The general procedure C was followed using 49bd (95 mg, 0.50 mmol) and 4a (446 mg, 2.50 




mg, 82%) was obtained as a white solid (m.p. 176–177 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.60 (d, J = 4.9 Hz, 2H), 8.12 (dd, J = 9.0, 4.6 Hz, 1H), 
7.40–7.09 (m, 11H), 7.09–7.02 (m, 2H).  
13C NMR (75 MHz, CDCl3): δ = 159.2 (Cq, 1JC-F = 237.8 Hz), 158.0 (CH), 157.8 (Cq), 137.6 
(Cq), 133.7 (Cq), 133.3 (Cq), 132.5 (Cq), 130.2 (CH), 130.1 (CH), 129.9 (Cq, 3JC-F = 10.0 Hz), 
128.3 (CH), 127.8 (CH), 127.2 (CH), 126.6 (CH), 120.0 (Cq, 4JC-F = 4.6 Hz), 117.7 (CH), 
113.8 (CH, 3JC-F = 9.4 Hz), 111.7 (CH, 2JC-F = 25.8 Hz), 104.8 (CH, 2JC-F = 24.4 Hz). 
19F-NMR (283 MHz, CDCl3): δ = -(121.4–121.6) (m).  
IR (neat): 3051, 1561, 1418, 1178, 913, 731 cm-1.  
MS (EI) m/z (relative intensity) 365 (100) [M+], 285 (14), 181 (4), 79 (2), 53 (3).  




The general procedure C was followed using 49be (103 mg, 0.50 mmol) and 4a (446 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50ea (104 
mg, 55%) was obtained as a white solid (m.p. 169–170 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.61 (d, J = 4.9 Hz, 2H), 8.07 (d, J = 8.9 Hz, 1H), 7.64 (d, J 
= 2.0 Hz, 1H), 7.40–7.10 (m, 11H), 7.08 (t, J = 4.9 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 158.1 (CH), 157.7 (Cq), 137.3 (Cq), 135.3 (Cq), 133.5 (Cq), 
132.4 (Cq), 130.4 (Cq), 130.2 (CH), 130.2 (CH), 128.3 (CH), 127.8 (CH), 127.7 (Cq), 127.3 
(CH), 126.8 (CH), 123.9 (CH), 119.7 (Cq), 119.1 (CH), 117.8 (CH), 113.9 (CH).  
IR (neat): 3051, 1603, 1415, 1069, 956 cm-1.  
MS (EI) m/z (relative intensity) 381 (100) [M+], 345 (25), 172 (15), 79 (2), 53 (3).  
HR-MS (EI) m/z calcd for [C24H16ClN3] + 381.1033, found 381.1035. 
 





The general procedure C was followed using 49bf (107 mg, 0.50 mmol) and 4a (446 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50fa (132 
mg, 68%) was obtained as a white solid (m.p. 171–172 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.63 (d, J = 4.9 Hz, 2H), 8.31 (d, J = 1.2 Hz, 1H), 8.11 (d, J 
= 8.8 Hz, 1H), 7.98 (dd, J = 8.9, 1.6 Hz, 1H), 7.45–7.02 (m, 11H), 2.64 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 198.0 (Cq), 158.2 (CH), 157.4 (Cq), 139.4 (Cq), 137.5 (Cq), 
133.3 (Cq), 132.0 (Cq), 131.8 (Cq), 130.2 (CH), 130.1 (CH), 128.7 (Cq), 128.4 (CH), 127.8 
(CH), 127.3 (CH), 126.7 (CH), 123.9 (CH), 121.2 (CH), 120.7 (Cq), 118.2 (CH), 112.4 (CH), 
26.7 (CH3).  
IR (neat): 3053, 1672, 1467, 1180, 948 cm-1.  
MS (EI) m/z (relative intensity) 389 (100) [M+], 346 (36), 172 (5), 79 (4), 43 (12).  




The general procedure C was followed using 49bg (98 mg, 0.50 mmol) and 4a (446 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→3:1) 50ga (130 
mg, 70%) was obtained as a white solid (m.p. 193–194 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.65 (d, J = 4.9 Hz, 2H), 8.13 (dd, J = 8.6, 0.8 Hz, 1H), 
8.02 (dd, J = 1.7, 0.7 Hz, 1H), 7.54 (dd, J = 8.6, 1.6 Hz, 1H), 7.40–7.06 (m, 11H).  
13C NMR (75 MHz, CDCl3): δ = 158.3 (CH), 157.2 (Cq), 138.4 (Cq), 138.2 (Cq), 132.7 (Cq), 
131.5 (Cq), 130.1 (CH), 130.0 (CH), 128.9 (Cq), 128.4 (CH), 127.9 (CH), 127.7 (CH), 127.0 
(CH), 126.5 (CH), 124.9 (CH), 120.2 (Cq), 119.7 (Cq), 118.5 (CH), 113.5 (CH), 105.1 (Cq).  




MS (EI) m/z (relative intensity) 372 (100) [M+], 292 (12), 186 (7), 79 (2), 53 (3).  




The general procedure C was followed using 49bh (95 mg, 0.50 mmol) and 4a (446 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50ha (131 
mg, 72%) was obtained as a white solid (m.p. 201–202 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.69 (d, J = 4.9 Hz, 2H), 7.50 (dd, J = 8.0, 0.8 Hz, 1H), 
7.38–7.06 (m, 12H), 6.96 (ddd, J = 12.1, 8.0, 0.8 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 158.3 (Cq), 158.2 (CH), 149.7 (Cq, 1JC-F = 245.6 Hz), 137.9 
(Cq), 134.0 (Cq), 132.0 (Cq, 3JC-F = 4.3 Hz), 131.2 (Cq), 130.8 (CH), 130.2 (CH), 128.3 (CH), 
127.9 (CH), 127.7 (CH), 126.4 (CH), 124.9 (Cq, 2JC-F = 9.8 Hz), 121.6 (CH, 3JC-F = 7.0 Hz), 
119.4 (CH), 118.7 (Cq, 4JC-F = 2.3 Hz), 115.6 (CH, 4JC-F = 3.3 Hz), 109.3 (CH, 2JC-F = 18.1 Hz). 
19F-NMR (283 MHz, CDCl3): δ = -127.9 (dd, J = 12.2, 4.7 Hz).  
IR (neat): 3033, 1559, 1432, 1224, 979, 727 cm-1.  
MS (EI) m/z (relative intensity) 365 (100) [M+], 288 (20), 181 (4), 79 (5), 43 (18).  




The general procedure C was followed using 49bi (101 mg, 0.50 mmol) and 4a (446 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→3:1) 50ia (125 
mg, 66%) was obtained as a white solid (m.p. 190–191 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.68 (d, J = 4.9 Hz, 2H), 7.39–7.25 (m, 5H), 7.23–7.06 (m, 
8H), 6.71 (d, J = 7.9 Hz, 1H), 3.62 (s, 3H).  




131.5 (Cq), 131.0 (CH), 130.2 (CH), 130.0 (Cq), 128.2 (CH), 127.8 (CH), 127.6 (Cq), 127.4 
(CH), 126.0 (CH), 121.7 (CH), 119.3 (CH), 117.9 (Cq), 112.8 (CH), 105.0 (CH), 55.9 (CH3). 
IR (neat): 3046, 1561, 1433, 1242, 924, 702 cm-1.  
MS (EI) m/z (relative intensity) 377 (100) [M+], 334 (32), 256 (25), 79 (6), 53 (6).  




The general procedure C was followed using 49bj (93 mg, 0.50 mmol) and 4a (446 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50ja (117 
mg, 65%) was obtained as a white solid (m.p. 151–152 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.70 (d, J = 4.9 Hz, 2H), 7.63 (dt, J = 7.9, 0.6 Hz, 1H), 
7.40–7.09 (m, 12H), 7.03 (d, J = 7.2 Hz, 1H), 1.96 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.7 (Cq), 157.9 (CH), 137.8 (Cq), 136.6 (Cq), 134.6 (Cq), 
131.7 (Cq), 131.0 (CH), 130.3 (CH), 128.7 (Cq), 128.1 (CH), 127.7 (CH), 127.4 (CH), 126.1 
(CH), 125.9 (CH), 121.5 (Cq), 121.4 (CH), 119.7 (CH), 118.0 (Cq), 117.9 (CH), 19.4 (CH3). 
IR (neat): 3024, 1560, 1442, 1231, 920, 786 cm-1.  
MS (EI) m/z (relative intensity) 361 (100) [M+], 284 (20), 178 (3), 77 (2), 53 (4).  
HR-MS (EI) m/z calcd for [C25H19N3] + 361.1579, found 361.1566.  
 
5, 7-Dimethyl-2, 3-diphenyl-1-(pyrimidin-2-yl)-1H-indole (50ka) 
 
The general procedure C was followed using 49bk (100 mg, 0.50 mmol) and 4a (446 mg, 
2.50 mmol). After purification by column chromatography (n-hexane/EtOAc 10:1–5:1) 50ka 
(93 mg, 49%) was obtained as a white solid (m.p. 182–183 °C).  




2.40 (s, 3H), 1.92 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.8 (Cq), 158.0 (CH), 138.0 (Cq), 135.1 (Cq), 134.8 (Cq), 
131.8 (Cq), 131.0 (CH), 130.8 (Cq), 130.3 (CH), 129.1 (Cq), 128.1 (CH), 127.7 (CH), 127.6 
(CH), 127.3 (CH), 126.0 (CH), 121.2 (Cq), 119.5 (CH), 117.9 (Cq), 117.4 (CH), 21.3 (CH3), 
19.3 (CH3).  
IR (neat): 3050, 1557, 1462, 1230, 919, 728 cm-1.  
MS (EI) m/z (relative intensity) 375 (100) [M+], 298 (23), 179 (3), 79 (2), 43 (5).  




The general procedure C was followed using 49bl (110 mg, 0.50 mmol) and 4a (446 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50la (178 
mg, 90%) was obtained as a white solid (m.p. 180–181 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.76 (d, J = 4.9 Hz, 2H), 7.99 (d, J = 8.0 Hz, 1H), 7.95 (d, J 
= 8.7 Hz, 1H), 7.71 (d, J = 8.7 Hz, 1H), 7.56–7.47 (m, 2H), 7.46–7.35 (m, 3H), 7.35–7.15 (m, 
8H), 6.92 (d, J = 8.7 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 159.9 (Cq), 158.8 (CH), 137.0 (Cq), 134.3 (Cq), 131.9 (Cq), 
131.4 (Cq), 131.3 (Cq), 131.1 (CH), 130.3 (CH), 129.1 (CH), 128.2 (CH), 127.7 (CH), 127.3 
(CH), 126.1 (CH), 125.1 (CH), 124.8 (Cq), 123.6 (CH), 122.8 (CH), 122.0 (Cq), 120.6 (CH), 
120.3 (CH), 119.3 (CH), 118.9 (Cq).  
IR (neat): 3047, 2948, 1560, 1267, 911, 736 cm-1.  
MS (EI) m/z (relative intensity) 397 (100) [M+], 317 (10), 213 (4), 98 (6), 43 (8).  







The general procedure C was followed using 49ba (86 mg, 0.50 mmol) and 4b (515 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50ab (129 
mg, 69%) was obtained as a white solid (m.p. 161–162 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.63 (d, J = 4.9 Hz, 2H), 8.20–8.12 (m, 1H), 7.80–7.67 (m, 
1H), 7.41–7.25 (m, 4H), 7.23–6.99 (m, 7H), 2.41 (s, 3H), 2.33 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 158.0 (Cq), 157.9 (CH), 136.9 (Cq), 136.5 (Cq), 135.9 (Cq), 
135.8 (Cq), 131.2 (Cq), 130.1 (CH), 130.0 (CH), 129.8 (Cq), 129.3 (Cq), 128.9 (CH), 128.5 
(CH), 123.6 (CH), 122.0 (CH), 119.7 (Cq), 119.6 (CH), 117.4 (CH), 112.4 (CH), 21.2 (CH3), 
21.2 (CH3).  
IR (neat): 3017, 2196, 1519, 1318, 980, 760 cm-1.  
MS (EI) m/z (relative intensity) 375 (100) [M+], 286 (10), 172 (3), 79 (2), 43 (3).  




The general procedure C was followed using 49bd (90 mg, 0.50 mmol) and 4b (515 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50db 
(132 mg, 67%) was obtained as a white solid (m.p. 141–142 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.62 (d, J = 4.9 Hz, 2H), 8.04 (q, J = 4.5 Hz, 1H), 7.30 (dd, 
J = 9.4, 2.6 Hz, 1H), 7.22–6.95 (m, 10H), 2.36 (s, 3H), 2.29 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.2 (Cq, 1JC-F = 236.3 Hz), 158.1 (CH), 157.9 (Cq), 137.5 




129.9 (CH), 129.6 (Cq), 129.1 (CH), 128.6 (CH), 119.7 (Cq, 4JC-F = 4.8 Hz), 117.6 (CH), 113.5 
(CH, 3JC-F = 9.9 Hz), 111.4 (CH, 2JC-F = 25.8 Hz), 104.8 (CH, 2JC-F = 24.9 Hz), 21.3 (CH3), 
21.2 (CH3).  
19F-NMR (283 MHz, CDCl3): δ = -(121.8–122.2) (m).  
IR (neat): 2921, 1614, 1520, 1419, 1153, 976 cm-1.  
MS (EI) m/z (relative intensity) 393 (100) [M+], 302 (8), 181 (3), 79 (3), 43 (7).  




The general procedure C was followed using 49ba (86 mg, 0.50 mmol) and 4c (595 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→3:1) 50ac (136 
mg, 67%) was obtained as a white solid (m.p. 166–167 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.63 (d, J = 4.9 Hz, 2H), 8.14–8.04 (m, 1H), 7.71–7.60 (m, 
1H), 7.36–7.18 (m, 4H), 7.12–7.00 (m, 3H), 6.94–6.83 (m, 2H), 6.80–6.66 (m, 2H), 3.81 (s, 
3H), 3.76 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 158.5 (Cq), 158.1 (Cq), 158.1 (Cq), 158.0 (CH), 136.8 (Cq), 
135.6 (Cq), 131.4 (CH), 131.3 (CH), 129.4 (Cq), 126.6 (Cq), 125.2 (Cq), 123.5 (CH), 122.0 
(CH), 119.5 (CH), 119.3 (Cq), 117.4 (CH), 113.7 (CH), 113.3 (CH), 112.4 (CH), 55.1 (CH3), 
55.0 (CH3).  
IR (neat): 2930, 1558, 1416, 1241, 1029, 727 cm-1.  
MS (EI) m/z (relative intensity) 407 (100) [M+], 392 (20), 241 (9), 79 (2), 43 (5).  







The general procedure C was followed using 49bd (90 mg, 0.50 mmol) and 4c (595 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→3:1) 50dc (127 
mg, 60%) was obtained as a white solid (m.p. 159–160 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.62 (d, J = 4.9 Hz, 2H), 8.02 (ddd, J = 9.0, 4.6, 0.4 Hz, 
1H), 7.27 (ddd, J = 9.4, 2.6, 0.4 Hz, 1H), 7.24–7.17 (m, 2H), 7.08 (t, J = 4.9 Hz, 1H), 7.05–
6.96 (m, 3H), 6.91–6.83 (m, 2H), 6.75–6.68 (m, 2H), 3.81 (s, 3H), 3.76 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.3 (Cq, 1JC-F = 237.2 Hz), 158.7 (Cq), 158.3 (Cq), 158.1 
(CH), 158.0 (Cq), 137.2 (Cq), 133.2 (Cq), 131.4 (CH), 131.2 (CH), 130.2 (Cq, 3JC-F = 9.8 Hz), 
126.2 (Cq), 125.0 (Cq), 119.2 (Cq, 4JC-F = 4.8 Hz), 117.6 (CH), 113.9 (CH), 113.5 (CH, 3JC-F = 
8.9 Hz), 113.4 (CH), 111.4 (CH, 2JC-F = 25.1 Hz), 104.7 (CH, 2JC-F = 25.1 Hz), 55.2 (CH3), 
55.1 (CH3).  
19F-NMR (283 MHz, CDCl3): δ = -(121.7–122.2) (m).  
IR (neat): 2931, 1609, 1560, 1134, 975, 759 cm-1.  
MS (EI) m/z (relative intensity) 425 (100) [M+], 350 (8), 259 (9), 79 (2), 43 (5).  




The general procedure C was followed using 49ba (86 mg, 0.50 mmol) and 4d (536 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50ad (109 
mg, 57%) was obtained as a white solid (m.p. 199–200 °C ).  




(ddd, J = 7.9, 1.3, 0.7 Hz, 1H), 7.38–7.31 (m, 1H), 7.30–7.23 (m, 3H), 7.15–6.98 (m, 5H), 
6.94-6.84 (m, 2H).  
13C NMR (75 MHz, CDCl3): δ = 162.0 (Cq, 1JC-F = 247.7 Hz), 161.6 (Cq, 1JC-F = 245.8 Hz), 
158.1 (CH), 157.8 (Cq), 136.8 (Cq), 135.1 (Cq), 131.9 (CH, 3JC-F = 8.2 Hz), 131.8 (CH, 3JC-F = 
8.2 Hz), 129.9 (Cq, 4JC-F = 3.6 Hz), 129.0 (Cq), 128.8 (Cq, 4JC-F = 4.2 Hz), 124.1 (CH), 122.4 
(CH), 129.5 (Cq), 119.4 (CH), 117.6 (CH), 115.3 (CH, 2JC-F = 21.2 Hz), 115.0 (CH, 2JC-F = 
21.2 Hz), 112.8 (CH).  
19F-NMR (283 MHz, CDCl3): δ = -(113.8–114.8) (m), -(115.3–116.3) (m).  
IR (neat): 3052, 1561, 1419, 1221, 946, 746 cm-1.  
MS (EI) m/z (relative intensity) 383 (100) [M+], 303 (14), 181 (8), 79 (3), 43 (5).  




The general procedure C was followed using 49bl (110 mg, 0.50 mmol) and 4e (345 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1→10:1) 50le 
(112 mg, 63%) was obtained as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 8.90 (d, J = 4.9 Hz, 2H), 7.89 (d, J = 8.5 Hz, 1H), 7.71 (d, J 
= 8.5 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.37–7.22 (m, 2H), 7.20–7.10 (m, 1H), 6.78 (d, J = 
8.5 Hz, 1H), 2.91–2.72 (m, 4H), 1.80–1.61 (m, 2H), 1.58–1.40 (m, 2H), 1.40–1.17 (m, 4H), 
0.99 (t, J = 7.3 Hz, 3H), 0.81 (t, J = 7.3 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 160.2 (Cq), 159.1 (CH), 137.4 (Cq), 131.3 (Cq), 130.5 (Cq), 
129.1 (CH), 126.4 (Cq), 124.5 (CH), 122.8 (CH), 122.0 (Cq), 121.9 (CH), 120.9 (CH), 119.8 
(CH), 118.6 (CH), 116.2 (Cq), 33.3 (CH2), 32.4 (CH2), 24.6 (CH2), 24.1 (CH2), 22.8 (CH2), 
22.4 (CH2), 14.1 (CH3), 13.7 (CH3).  
IR (neat): 2954, 1558, 1417, 1274, 926, 740 cm-1.  








The general procedure C was followed using 49ba (86 mg, 0.50 mmol) and 4f (565 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50af (108 
mg, 55%) was obtained as a white solid (m.p. 178–179 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.47 (dd, J = 4.9, 0.9 Hz, 2H), 8.02–7.87 (m, 2H), 7.78 (s, 
4H), 7.37–7.16 (m, 2H), 6.95 (td, J = 4.9, 0.9 Hz, 1H), 1.34 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 157.8 (CH), 157.3 (Cq), 139.7 (Cq), 136.9 (Cq), 132.8 (CH), 
132.8 (Cq), 129.6 (Cq, 2JC-F = 32.6 Hz), 128.1 (Cq), 126.6 (Cq), 126.0 (Cq, 1JC-F = 271.3 Hz), 
123.4 (CH, 3JC-F = 3.8 Hz), 123.2 (CH), 122.5 (CH), 121.0 (CH), 117.5 (CH), 112.4 (CH), 
33.5 (Cq), 32.3 (CH3).  
19F-NMR (283 MHz, CDCl3): δ = -62.8 (s).  
IR (neat): 2955, 1619, 1421, 1106, 955 cm-1.  
MS (EI) m/z (relative intensity) 395 (43) [M+], 380 (100), 286 (14), 183 (20), 79 (3).  




The general procedure C was followed using 49bm (93 mg, 0.50 mmol) and 4a (446 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50ma 
(110 mg, 61%) was obtained as a white solid (m.p. 154–155 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.65 (d, J = 4.9 Hz, 2H), 7.99 (s, 1H), 7.61 (d, J = 8.1 Hz, 
1H), 7.39–7.11 (m, 11H), 7.06 (t, J = 4.9 Hz, 1H), 2.55 (s, 3H).  




133.8 (Cq), 132.9 (Cq), 130.3 (CH), 130.2 (CH), 128.1 (CH), 127.7 (CH), 127.0 (Cq), 126.8 
(CH), 126.3 (CH), 123.7 (CH), 120.1 (Cq), 119.3 (CH), 117.4 (CH), 112.4 (CH), 21.9 (CH3). 
IR (neat): 3025, 2916, 1556, 1418, 1196, 920 cm-1.  
MS (EI) m/z (relative intensity) 361 (100) [M+], 284 (9), 172 (6), 79 (5), 53 (5).  




The general procedure C was followed using 49bn (120 mg, 0.50 mmol) and 4a (446 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50na (175 
mg, 84%) was obtained as a white solid (m.p. 175–176 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.66 (dd, J = 4.9, 0.6 Hz, 2H), 8.44 (s, 1H), 7.76 (dd, J = 
8.3, 0.6 Hz, 1H), 7.50 (ddd, J = 8.3, 1.0, 0.6 Hz, 1H), 7.39–7.03 (m, 11H).  
13C NMR (75 MHz, CDCl3): δ = 158.3 (CH), 157.5 (Cq), 138.7 (Cq), 135.9 (Cq), 133.4 (Cq), 
132.1 (Cq), 131.5 (Cq), 130.2 (CH), 130.2 (CH), 128.4 (CH), 127.9 (CH), 127.5 (CH), 126.9 
(Cq, 1JC-F = 272.0 Hz), 126.8 (CH), 125.6 (Cq, 2JC-F = 32.1 Hz), 120.1 (CH), 120.0 (Cq), 118.8 
(CH, 3JC-F = 3.6 Hz), 118.1 (CH), 110.4 (CH, 3JC-F = 4.3 Hz).  
19F-NMR (283 MHz, CDCl3): δ = -60.6 (s).  
IR (neat): 3064, 2920, 1564, 1420, 1157, 917 cm-1.  
MS (EI) m/z (relative intensity) 415 (100) [M+], 338 (11), 239 (4), 79 (7), 53 (8).  
HR-MS (EI) m/z calcd for [C25H16F3N3] + 415.1296, found 415.1284. 
 
6-Fluoro-2,3-diphenyl-1-(pyrimidin-2-yl)-1H-indole (50oa) and 
4-Fluoro-2,3-diphenyl-1-(pyrimidin-2-yl)-1H-indole (50oa’) 
The general procedure C was followed using 49bo (95 mg, 0.50 mmol) and 4a (446 mg, 2.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 50oa (78 
mg, 43%) was obtained as a white solid (m.p. 160–161 °C ) and 50oa’ (52 mg, 29%) was 





6-Fluoro-2,3-diphenyl-1-(pyrimidin-2-yl)-1H-indole (50oa):  
1H NMR (300 MHz, CDCl3): δ = 8.61 (d, J = 4.9 Hz, 2H), 7.91 (dd, J = 10.4, 2.3 Hz, 1H), 
7.59 (dd, J = 8.7, 5.7 Hz, 1H), 7.38–7.10 (m, 10H), 7.07 (t, J = 4.9 Hz, 1H), 7.01 (td, J = 9.0, 
2.3 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 160.7 (Cq, 1JC-F = 237.2 Hz), 158.1 (CH), 157.8 (Cq), 137.0 
(Cq, 3JC-F = 12.5 Hz), 136.3 (Cq, 4JC-F = 4.2 Hz), 133.8 (Cq), 132.6 (Cq), 130.2 (CH), 130.1 
(CH), 128.3 (CH), 127.8 (CH), 127.1 (CH), 126.6 (CH), 125.7 (Cq), 120.4 (CH, 3JC-F = 10.4 
Hz), 120.1 (Cq), 117.7 (CH), 110.5 (CH, 2JC-F = 24.4 Hz), 99.8 (CH, 2JC-F = 28.2 Hz). 
19F-NMR (283 MHz, CDCl3): δ = -(118.1–118.4) (m).  
IR (neat): 3056, 1979, 1562, 1416, 1122, 974 cm-1.  
MS (EI) m/z (relative intensity) 365 (100) [M+], 285 (14), 172 (3), 79 (2), 53 (3).  
HR-MS (EI) m/z calcd for [C24H16FN3] + 365.1328, found 365.1327. 
 
 
4-Fluoro-2,3-diphenyl-1-(pyrimidin-2-yl)-1H-indole (50oa’):  
1H NMR (300 MHz, CDCl3): δ = 8.63 (d, J = 4.9 Hz, 2H), 7.86 (dd, J = 8.3, 0.7 Hz, 1H), 
7.37–7.05 (m, 12H), 6.90 (ddd, J = 11.0, 7.9, 0.7 Hz, 1H).  
13C NMR (75 MHz, CDCl3): δ = 158.2 (CH), 157.8 (Cq), 156.7 (Cq, 1JC-F = 246.7 Hz), 139.0 
(Cq, 3JC-F = 9.6 Hz), 136.6 (Cq, 4JC-F = 1.4 Hz ), 134.1 (Cq, 4JC-F = 1.4 Hz), 132.1 (Cq), 131.0 
(CH, JC-F = 2.1 Hz), 130.3 (CH), 127.7 (CH), 127.5 (CH), 127.2 (CH), 126.5 (CH), 124.0 (CH, 
3JC-F = 8.1 Hz), 118.1 (CH), 117.9 (Cq, 3JC-F = 3.1 Hz), 117.5 (Cq, 2JC-F = 17.8 Hz), 108.4 (CH, 
4JC-F = 3.9 Hz), 107.7 (CH, 2JC-F = 19.5 Hz).  
19F-NMR (283 MHz, CDCl3): δ = -(118.5–119.5) (m).  




MS (EI) m/z (relative intensity) 365 (100) [M+], 285 (15), 182 (2), 79 (3), 53 (4).  




A mixture of 50aa (174 mg, 0.50 mmol), NaOEt (102 mg, 1.50 mmol) and DMSO (2.0 mL) 
was stirred at 120 °C under a nitrogen atmosphere for 24 h. After cooling to ambient 
temperature, the reaction mixture was diluted with EtOAc (75 mL) and washed with brine (30 
mL). The aqueous phase was extracted with EtOAc (2×30 mL), and the combined organic 
phase was dried over Na2SO4. After filtration and evaporation of the solvents in vacuum, the 
crude product was purified by column chromatography on silica gel (n-hexane/EtOAc 10:1) 
to yield 75 (124 mg, 92%) as a white solid (m.p. 120–121 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.19 (sbr, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.50–7.22 (m, 12H), 
7.21–7.12 (m, 1H).  
13C NMR (75 MHz, CDCl3): δ = 135.9 (Cq), 135.0 (Cq), 134.1 (Cq), 132.7 (Cq), 130.1 (CH), 
128.8 (Cq), 128.7 (CH), 128.5 (CH), 128.2 (CH), 127.7 (CH), 126.2 (CH), 122.7 (CH), 120.4 
(CH), 119.7 (CH), 115.1 (Cq), 110.9 (CH).  
IR (neat): 3055, 1504, 1250, 1147, 956, 737 cm-1.  
MS (EI) m/z (relative intensity) 269 (100) [M+], 165 (18), 105 (19), 77 (14), 51 (4).  
HR-MS (EI) m/z calcd for [C20H15N] + 269.1204, found 269.1199.  
The spectral data were in accordance with those reported in the literature.85 
 
2-Cyclohexyl-4-methyl-N-(quinolin-8-yl)benzamide (51aa) 
                                                             





The general procedure D was followed using 17a (131 mg, 0.50 mmol) and 22aa (163 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 51aa (148 
mg, 86%) was obtained as a white solid (m.p. 177–178 °C ).  
1H NMR (300 MHz, CDCl3): δ = 10.12 (s, 1H), 8.94 (dd, J = 7.3, 1.1 Hz, 1H), 8.73 (dd, J = 
4.3, 1.7 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.63–7.47 (m, 3H), 7.42 (dd, J = 8.3, 4.3 Hz, 
1H), 7.23 (s, 1H), 7.09 (dd, J = 7.8, 1.1 Hz, 1H), 3.14 (tt, J = 11.7, 3.3 Hz, 1H), 2.40 (s, 3H), 
1.99 (d, J = 12.8 Hz, 2H), 1.83–1.70 (m, 2H), 1.67–1.15 (m, 6H).  
13C NMR (75 MHz, CDCl3): δ = 168.8 (Cq), 148.1 (CH), 146.1 (Cq), 140.2 (Cq), 138.5 (Cq), 
136.3 (CH), 134.9 (Cq), 133.7 (Cq), 128.0 (Cq), 127.7 (CH), 127.4 (CH), 127.3 (CH), 126.5 
(CH), 121.6 (CH), 121.6 (CH), 116.4 (CH), 40.3 (CH), 34.7 (CH2), 26.7 (CH2), 26.1 (CH2), 
21.6 (CH3).  
IR (ATR): 3339, 2935, 2849, 1665, 1609, 1264, 828, 691 cm-1.  
MS (EI) m/z (relative intensity) 344 (43) [M+], 200 (100), 144 (79), 105 (35), 43 (20).  




The general procedure D was followed using 17b (124 mg, 0.50 mmol) and 22aa (163 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 51ba (132 
mg, 80%) was obtained as a white solid (m.p. 140–141 °C ).  
1H NMR (300 MHz, CDCl3): δ = 10.14 (s, 1H), 8.98 (dd, J = 7.3, 1.4 Hz, 1H), 8.73 (dd, J = 
4.3, 1.7 Hz, 1H), 8.14 (dd, J = 8.3, 1.7 Hz, 1H), 7.63–7.56 (m, 2H), 7.53 (dd, J = 8.3, 1.6 Hz, 
1H), 7.46–7.38 (m, 3H), 7.32–7.25 (m, 1H), 3.15 (tt, J = 11.7, 3.3 Hz, 1H), 2.02 (d, J = 12.8 




13C NMR (75 MHz, CDCl3): δ = 168.6 (Cq), 148.1 (CH), 145.9 (Cq), 138.5 (Cq), 136.5 (Cq), 
136.2 (CH), 134.7 (Cq), 130.2 (CH), 127.9 (Cq), 127.3 (CH), 127.2 (CH), 127.0 (CH), 125.8 
(CH), 121.7 (CH), 121.6 (CH), 116.5 (CH), 40.3 (CH), 34.6 (CH2), 26.7 (CH2), 26.0 (CH2). 
IR (ATR): 3335, 2924, 2852, 1667, 1424, 1263, 996, 797 cm-1.  
MS (EI) m/z (relative intensity) 330 (48) [M+], 186 (70), 144 (100), 91 (42), 41 (17).  




The general procedure D was followed using 17c (133 mg, 0.50 mmol) and 22aa (163 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 51ca (145 
mg, 83%) was obtained as a white solid (m.p. 123–124 °C ).  
1H NMR (300 MHz, CDCl3): δ = 10.11 (s, 1H), 8.93 (dd, J = 7.3, 1.4 Hz, 1H), 8.73 (dd, J = 
4.3, 1.7 Hz, 1H), 8.13 (dd, J = 8.3, 1.7 Hz, 1H), 7.60 (dd, J = 6.0, 2.6 Hz, 1H), 7.56 (t, J = 3.6 
Hz, 1H), 7.52 (dd, J = 8.3, 1.6 Hz, 1H), 7.41 (dd, J = 8.3, 4.3 Hz, 1H), 7.10 (dd, J = 10.7, 2.6 
Hz, 1H), 6.95 (td, J = 8.3, 2.6 Hz, 1H), 3.18 (tt, J = 11.7, 3.3 Hz, 1H), 2.01 (d, J = 12.2 Hz, 
2H), 1.83–1.61 (m, 3H), 1.51–1.18 (m, 5H).  
13C NMR (75 MHz, CDCl3): δ = 167.5 (Cq), 163.7 (Cq, 1JC-F = 248.8 Hz), 149.3 (Cq, 1JC-F = 
7.4 Hz), 148.1 (CH), 138.3 (Cq), 136.2 (CH), 134.5 (Cq), 132.4 (Cq, 4JC-F = 3.0 Hz), 129.2 
(CH, 3JC-F = 8.9 Hz), 127.8 (Cq), 127.2 (CH), 121.7 (CH), 121.5 (CH), 116.4 (CH), 113.9 (CH, 
2JC-F = 21.7 Hz), 112.6 (CH, 2JC-F = 21.9 Hz), 40.4 (CH, 4JC-F = 1.2 Hz), 34.5 (CH2), 26.6 
(CH2), 26.0 (CH2).  
IR (ATR): 3327, 2936, 2853, 1663, 1480, 1262, 954, 794 cm-1.  
MS (EI) m/z (relative intensity) 348 (41) [M+], 204 (68), 144 (100), 130 (40), 109 (34). 







The general procedure D was followed using 17d (158 mg, 0.50 mmol) and 22aa (163 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 51da (146 
mg, 73%) was obtained as a white solid (m.p. 136–137 °C ).  
1H NMR (300 MHz, CDCl3): δ = 10.14 (s, 1H), 8.94 (dd, J = 7.0, 2.1 Hz, 1H), 8.74 (dd, J = 
4.3, 1.7 Hz, 1H), 8.16 (dd, J = 8.3, 1.7 Hz, 1H), 7.72–7.66 (m, 2H), 7.64–7.52 (m, 2H), 7.43 
(dd, J = 8.3, 4.3 Hz, 1H), 3.16 (tt, J = 11.7, 3.3 Hz, 1H), 2.08–1.93 (m, 2H), 1.89–1.62 (m, 
3H), 1.60–1.15 (m, 5H).  
13C NMR (75 MHz, CDCl3): δ = 167.1 (Cq), 148.2 (CH), 146.8 (Cq), 139.6 (Cq, 4JC-F = 1.4 
Hz), 138.3 (Cq), 136.2 (CH), 134.2 (Cq), 132.0 (Cq, 2JC-F = 32.2 Hz), 127.9 (Cq), 127.6 (CH), 
127.2 (CH), 124.9 (Cq, 1JC-F = 271.2 Hz), 123.9 (CH, 3JC-F = 3.7 Hz), 122.7 (CH, 3JC-F = 3.7 
Hz), 122.1 (CH), 121.7 (CH), 116.7 (CH), 40.6 (CH), 34.5 (CH2), 26.6 (CH2), 25.9 (CH2). 
19F-NMR (282 MHz, CDCl3): δ = -62.7 (s).  
IR (ATR): 3338, 2926, 2854, 1672, 1427, 1228, 788 cm-1.  
MS (EI) m/z (relative intensity) 398 (23) [M+], 236 (47), 144 (100), 129 (14), 43 (14). 




The general procedure D was followed using 17e (139 mg, 0.50 mmol) and 22aa (163 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 10:1) 51ea (94 
mg, 52%) was obtained as a white solid (m.p. 109–110 °C ).  
1H NMR (300 MHz, CDCl3): δ = 10.12 (s, 1H), 8.93 (dd, J = 7.3, 1.1 Hz, 1H), 8.73 (dd, J = 




1H), 7.41 (dd, J = 8.3, 4.3 Hz, 1H), 6.95 (d, J = 2.6 Hz, 1H), 6.80 (dd, J = 8.3, 2.6 Hz, 1H), 
3.85 (s, 3H), 3.22 (tt, J = 11.7, 3.3 Hz, 1H), 2.01 (d, J = 12.8 Hz, 2H), 1.81–1.63 (m, 3H), 
1.54–1.18 (m, 5H).  
13C NMR (75 MHz, CDCl3): δ = 168.3 (Cq), 161.1 (Cq), 148.7 (Cq), 148.1 (CH), 138.5 (Cq), 
136.2 (CH), 134.9 (Cq), 129.1 (CH), 129.0 (Cq), 127.9 (Cq), 127.4 (CH), 121.6 (CH), 121.5 
(CH), 116.3 (CH), 113.1 (CH), 110.4 (CH), 55.2 (CH3), 40.3 (CH), 34.6 (CH2), 26.7 (CH2), 
26.1 (CH2).  
IR (ATR): 3337, 2921, 2850, 1664, 1446, 1262, 984, 794 cm-1.  
MS (EI) m/z (relative intensity) 360 (25) [M+], 217 (100), 199 (54), 144 (38), 43 (15). 
HR-MS (EI) m/z calcd for [C23H24N2O2] + 360.1838, found 360.1830. 
 
3-Cyclohexyl-N-(quinolin-8-yl)-[1, 1'-biphenyl]-4-carboxamide (51fa) 
 
The general procedure D was followed using 17f (162 mg, 0.50 mmol) and 22aa (163 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 51fa (175 
mg, 86%) was obtained as a white solid (m.p. 154–155 °C ).  
1H NMR (300 MHz, CDCl3): δ = 10.18 (s, 1H), 8.97 (dd, J = 7.3, 1.4 Hz, 1H), 8.75 (dd, J = 
4.2, 1.7 Hz, 1H), 8.17 (dd, J = 8.3, 1.7 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.66–7.58 (m, 4H), 
7.55 (dd, J = 8.3, 1.6 Hz, 1H), 7.53–7.42 (m, 4H), 7.38 (tt, J = 7.3, 1.3 Hz, 1H), 3.21 (tt, J = 
11.7, 3.3 Hz, 1H), 2.06 (d, J = 12.4 Hz, 2H), 1.88–1.61 (m, 3H), 1.59–1.21 (m, 5H).  
13C NMR (75 MHz, CDCl3): δ = 168.5 (Cq), 148.2 (CH), 146.7 (Cq), 143.1 (Cq), 140.1 (Cq), 
138.6 (Cq), 136.3 (CH), 135.4 (Cq), 134.8 (Cq), 128.8 (CH), 128.0 (Cq), 127.9 (CH), 127.7 
(CH), 127.5 (CH), 127.3 (CH), 126.0 (CH), 124.7 (CH), 121.8 (CH), 121.7 (CH), 116.6 (CH), 
40.6 (CH), 34.8 (CH2), 26.8 (CH2), 26.1 (CH2).  
IR (ATR): 3329, 2920, 2849, 1672, 1424, 1257, 912, 791 cm-1.  
MS (EI) m/z (relative intensity) 406 (35) [M+], 262 (100), 221 (40), 144 (53), 43 (22). 







The general procedure D was followed using 17g (141 mg, 0.50 mmol) and 22aa (163 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 51ga (116 
mg, 64%) was obtained as a white solid (m.p. 156–157 °C ).  
1H NMR (300 MHz, CDCl3): δ = 10.10 (s, 1H), 8.92 (dd, J = 7.1, 1.7 Hz, 1H), 8.73 (dd, J = 
4.3, 1.7 Hz, 1H), 8.14 (dd, J = 8.3, 1.7 Hz, 1H), 7.62–7.55 (m, 1H), 7.55–7.50 (m, 2H), 7.43 (t, 
J = 4.1 Hz, 1H), 7.40 (d, J = 1.7 Hz, 1H), 7.24 (dd, J = 8.3, 2.1 Hz, 1H), 3.13 (tt, J = 11.7, 3.3 
Hz, 1H), 1.99 (d, J = 12.6 Hz, 2H), 1.84–1.60 (m, 3H), 1.53–1.17 (m, 5H).  
13C NMR (75 MHz, CDCl3): δ = 167.5 (Cq), 148.2 (CH), 148.1 (Cq), 138.4 (Cq), 136.3 (CH), 
136.3 (Cq), 134.8 (Cq), 134.5 (Cq), 128.6 (CH), 127.9 (Cq), 127.4 (CH), 127.3 (CH), 126.0 
(CH), 121.9 (CH), 121.6 (CH), 116.5 (CH), 40.4 (CH), 34.4 (CH2), 26.5 (CH2), 25.9 (CH2). 
IR (ATR): 3325, 2936, 2852, 1664, 1424, 1225, 986, 792 cm-1.  
MS (EI) m/z (relative intensity) 364 (28) [M+], 220 (38), 144 (100), 115 (26), 41 (16). 




The general procedure D was followed using 17h (131 mg, 0.50 mmol) and 22aa (163 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 51ha (92 
mg, 54%) was obtained as a sticky oil.  
1H NMR (300 MHz, CDCl3): δ = 10.10 (s, 1H), 8.96 (dd, J = 7.3, 1.4 Hz, 1H), 8.74 (dd, J = 
4.3, 1.7 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.63–7.56 (m, 1H), 7.53 (dd, J = 8.3, 1.6 Hz, 
1H), 7.45–7.37 (m, 2H), 7.32 (d, J = 8.0 Hz, 1H), 7.29–7.22 (m, 1H), 3.07 (tt, J = 11.8, 3.3 Hz, 




(m, 3H).  
13C NMR (75 MHz, CDCl3): δ = 168.8 (Cq), 148.1 (CH), 142.9 (Cq), 138.5 (Cq), 136.5 (Cq), 
136.2 (CH), 135.4 (Cq), 134.8 (Cq), 130.9 (CH), 128.0 (Cq), 127.7 (CH), 127.4 (CH), 126.9 
(CH), 121.7 (CH), 121.6 (CH), 116.5 (CH), 40.2 (CH), 34.7 (CH2), 26.7 (CH2), 26.1 (CH2), 
20.8 (CH3).  
IR (ATR): 3335, 2923, 2851, 1663, 1424, 1262, 936, 794 cm-1.  
MS (EI) m/z (relative intensity) 344 (52) [M+], 200 (100), 144 (98), 91 (38), 41 (20). 
HR-MS (EI) m/z calcd for [C23H24N2O] + 344.1889, found 344.1887. 
 
2-Cyclohexyl- 5-(trifluoromethyl)-N-(quinolin-8-yl)-benzamide (51ia) 
 
The general procedure D was followed using 17i (158 mg, 0.50 mmol) and 22aa (163 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 51ia (128 
mg, 64%) was obtained as a white solid (m.p. 110–111 °C ).  
1H NMR (300 MHz, CDCl3): δ = 10.13 (s, 1H), 8.93 (dd, J = 7.0, 2.1 Hz, 1H), 8.75 (dd, J = 
4.3, 1.7 Hz, 1H), 8.17 (dd, J = 8.3, 1.7 Hz, 1H), 7.84 (s, 1H), 7.69 (dd, J = 8.3, 1.7 Hz, 1H), 
7.64–7.52 (m, 3H), 7.44 (dd, J = 8.3, 4.3 Hz, 1H), 3.14 (tt, J = 11.7, 3.3 Hz, 1H), 2.01 (d, J = 
12.3 Hz, 2H), 1.87–1.62 (m, 3H), 1.59–1.14 (m, 5H).  
13C NMR (75 MHz, CDCl3): δ = 167.1 (Cq), 149.8 (Cq, 4JC-F = 1.1 Hz), 148.3 (CH), 138.5 
(Cq), 137.1 (Cq), 136.3 (CH), 134.3 (Cq), 128.2 (Cq, 2JC-F = 32.2 Hz), 127.9 (Cq), 127.7 (CH), 
127.3 (CH), 126.8 (CH, 3JC-F = 3.7 Hz), 125.7 (Cq, 1JC-F = 271.2 Hz), 124.2 (CH, 3JC-F = 3.7 
Hz), 122.2 (CH), 121.7 (CH), 116.8 (CH), 40.7 (CH), 34.4 (CH2), 26.5 (CH2), 25.9 (CH2). 
19F-NMR (282 MHz, CDCl3): δ = -62.4 (s).  
IR (ATR): 3347, 2927, 2853, 1669, 1422, 1250, 997, 780 cm-1.  
MS (EI) m/z (relative intensity) 398 (30) [M+], 236 (43), 144 (100), 130 (25), 41 (13). 







The general procedure D was followed using 17j (149 mg, 0.50 mmol) and 22aa (163 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 51ja (115 
mg, 61%) was obtained as a white solid (m.p. 193–194 °C ).  
1H NMR (300 MHz, CDCl3): δ = 10.11 (s, 1H), 9.11 (dd, J = 7.4, 1.4 Hz, 1H), 8.64 (dd, J = 
4.2, 1.7 Hz, 1H), 8.17 (dd, J = 8.3, 1.7 Hz, 1H), 8.02–7.93 (m, 1H), 7.90 (d, J = 8.7 Hz, 1H), 
7.86–7.81 (m, 1H), 7.70–7.62 (m, 1H), 7.59 (dd, J = 8.3, 1.4 Hz, 1H), 7.54 (d, J = 8.7 Hz, 1H), 
7.48–7.37 (m, 3H), 2.96 (tt, J = 11.7, 3.3 Hz, 1H), 2.00 (m, 2H), 1.84–1.50 (m, 5H), 1.43–
1.08 (m, 3H).  
13C NMR (75 MHz, CDCl3): δ = 168.5 (Cq), 148.3 (CH), 141.8 (Cq), 138.5 (Cq), 136.2 (CH), 
134.5 (Cq), 133.2 (Cq), 131.9 (Cq), 130.2 (Cq), 129.4 (CH), 128.0 (Cq), 127.9 (CH), 127.4 
(CH), 126.9 (CH), 125.6 (CH), 125.1 (CH), 124.5 (CH), 122.0 (CH), 121.6 (CH), 116.9 (CH), 
42.1 (CH), 34.2 (CH2, split by atropisomeric effect), 26.6 (CH2), 26.0 (CH2).  
IR (ATR): 3336, 2922, 2848, 1670, 1446, 1214, 997, 796 cm-1.  
MS (EI) m/z (relative intensity) 380 (31) [M+], 237 (100), 195 (40), 144 (42), 55 (4).  
HR-MS (EI) m/z calcd for [C26H24N2O] + 380.1889, found 380.1895. 
 
N-(quinolin-8-yl)-[1, 1'-bi(cyclohexan)]-1-ene-2-carboxamide (51ka) 
 
The general procedure D was followed using 17k (126 mg, 0.50 mmol) and 20aa (163 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 51ka (97 
mg, 58%) was obtained as a white solid (m.p. 146–147 °C ).  
1H NMR (300 MHz, CDCl3): δ = 9.80 (s, 1H), 8.84 (dd, J = 7.3, 1.4 Hz, 1H), 8.75 (dd, J = 




1H), 2.59 (tt, J = 11.7, 3.3 Hz, 1H), 2.47–2.33 (m, 2H), 2.14–2.00 (m, 2H), 1.77–1.57 (m, 8H), 
1.55–1.28 (m, 3H), 1.27–0.97 (m, 3H).  
13C NMR (75 MHz, CDCl3): δ = 170.8 (Cq), 148.0 (CH), 143.0 (Cq), 138.5 (Cq), 136.2 (CH), 
134.7 (Cq), 129.3 (Cq), 127.9 (Cq), 127.4 (CH), 121.5 (CH), 121.3 (CH), 116.4 (CH), 43.1 
(CH), 31.2 (CH2), 27.3 (CH2), 26.2 (CH2), 26.0 (CH2), 24.1 (CH2), 22.4 (CH2), 22.4 (CH2).  
IR (ATR): 3340, 2921, 2834, 1662, 1423, 1231, 997, 769 cm-1.  
MS (EI) m/z (relative intensity) 334 (28) [M+], 190 (100), 144 (56), 91 (18), 41 (21).  




The general procedure D was followed using 17a (131 mg, 0.50 mmol) and 22ab (137 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 51ab (85 
mg, 52%) was obtained as colorless oil.  
The general procedure D was followed using 17a (131 mg, 0.50 mmol) and 22bb (92 mg, 1.00 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 51ab (83 mg, 
50%) was obtained as colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 10.10 (s, 1H), 8.94 (dd, J = 7.3, 1.4 Hz, 1H), 8.73 (dd, J = 
4.3, 1.7 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.61–7.51 (m, 2H), 7.49 (d, J = 7.9 Hz, 1H), 
7.42 (dd, J = 8.3, 4.3 Hz, 1H), 7.19 (s, 1H), 7.10 (ddd, J = 7.9, 1.7, 0.7 Hz, 1H), 3.24 (dt, J = 
7.0, 7.0 Hz, 1H), 2.40 (s, 3H), 1.77–1.55 (m, 2H), 1.29 (d, J = 6.7 Hz, 3H), 0.83 (t, J = 7.0 Hz, 
3H).  
13C NMR (75 MHz, CDCl3): δ = 168.9 (Cq), 148.2 (CH), 146.0 (Cq), 140.2 (Cq), 138.5 (Cq), 
136.3 (CH), 134.9 (Cq), 134.4 (Cq), 127.9 (Cq), 127.4 (CH), 127.2 (CH), 127.0 (CH), 126.5 
(CH), 121.6 (CH), 121.5 (CH), 116.4 (CH), 36.8 (CH), 31.1 (CH2), 22.3 (CH3), 21.6 (CH3), 
12.3 (CH3).  
IR (ATR): 3350, 2960, 2871, 1671, 1422, 1260, 919, 789 cm-1.  








The general procedure D was followed using 17a (131 mg, 0.50 mmol) and 22ac (151 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 51ac (125 
mg, 75%) was obtained as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 10.12 (s, 1H), 8.96 (dd, J = 7.3, 1.1 Hz, 1H), 8.73 (dd, J = 
4.3, 1.7 Hz, 1H), 8.13 (dd, J = 8.3, 1.7 Hz, 1H), 7.62–7.54 (m, 1H), 7.54–7.47 (m, 2H), 7.40 
(dd, J = 8.3, 4.3 Hz, 1H), 7.22 (s, 1H), 7.09 (ddd, J = 7.8, 1.7, 0.7 Hz, 1H), 3.36 (dt, J = 6.9, 
6.9 Hz, 1H), 2.41 (s, 3H), 1.77–1.47 (m, 2H), 1.31 (d, J = 6.9 Hz, 3H), 1.40–1.12 (m, 2H), 
0.82 (t, J = 7.3 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 168.8 (Cq), 148.1 (CH), 146.2 (Cq), 140.2 (Cq), 138.5 (Cq), 
136.2 (CH), 134.8 (Cq), 134.3 (Cq), 127.9 (Cq), 127.3 (CH), 127.2 (CH), 126.9 (CH), 126.5 
(CH), 121.6 (CH), 121.5 (CH), 116.4 (CH), 40.6 (CH2), 34.9 (CH), 22.7 (CH3), 21.5 (CH3), 
20.9 (CH2), 14.1 (CH3).  
IR (ATR): 3350, 2956, 2869, 1672, 1422, 1258, 789 cm-1.  
MS (EI) m/z (relative intensity) 332 (18) [M+], 159 (100), 145 (29), 91 (15), 41 (6).  




The general procedure D was followed using 79 (150.5 mg, 0.50 mmol) and 22aa (163 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 80aa (167 
mg, 87%) was obtained as a white solid (m.p. 159–160 °C ).  




4.2, 1.7 Hz, 1H), 8.18–8.10 (m, 2H) 7.65–7.55 (m, 1H), 7.49 (dd, J = 8.3, 1.2 Hz, 1H), 7.41 
(dd, J = 8.3, 4.2 Hz, 1H), 7.38–7.32 (m, 1H), 7.32–7.22 (m, 2H), 3.87 (s, 3H), 3.74 (tt, J = 
12.4, 3.1 Hz, 1H), 2.21–2.03 (m, 2H), 2.01–1.74 (m, 5H), 1.59–1.26 (m, 3H).  
13C NMR (75 MHz, CDCl3): δ = 164.7 (Cq), 148.8 (Cq), 148.0 (CH), 138.7 (Cq), 136.6 (Cq), 
136.2 (CH), 135.5 (Cq), 128.0 (Cq), 127.5 (CH), 125.7 (Cq), 121.8 (CH), 121.4 (CH), 121.1 
(CH), 120.8 (CH), 119.4 (CH), 116.0 (CH), 109.3 (CH), 109.0 (Cq), 36.7 (CH), 31.3 (CH3), 
30.6 (CH2), 26.9 (CH2), 25.9 (CH2).  
IR (ATR): 3354, 2925, 2851, 1651, 1421, 1236, 988, 790 cm-1.  
MS (EI) m/z (relative intensity) 383 (10) [M+], 240 (100), 171 (8), 144 (14), 43 (5).  




The general procedure D was followed using 79 (150.5 mg, 0.50 mmol) and 22ac (151 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 80ac (135 
mg, 73%) was obtained as a white solid (m.p. 159–160 °C ).  
1H NMR (300 MHz, CDCl3): δ = 10.53 (s, 1H), 9.00 (dd, J = 7.7, 1.4 Hz, 1H), 8.79 (dd, J = 
4.2, 1.7 Hz, 1H), 8.22–8.17 (m, 1H) 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.59 (t, J = 8.0 Hz, 1H), 
7.49 (dd, J = 8.3, 1.4 Hz, 1H), 7.42 (dd, J = 8.3, 4.2 Hz, 1H), 7.39–7.33 (m, 1H), 7.32–7.26 
(m, 2H), 4.16 (dt, J = 7.6, 7.6 Hz, 1H), 3.85 (s, 3H), 2.08–1.73 (m, 2H), 1.53 (d, J = 7.1 Hz, 
3H), 1.48–1.22 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H).  
13C NMR (75 MHz, CDCl3): δ = 164.6 (Cq), 149.5 (Cq), 148.1 (CH), 138.8 (Cq), 136.8 (Cq), 
136.2 (CH), 135.6 (Cq), 128.0 (Cq), 127.5 (CH), 125.5 (Cq), 121.8 (CH), 121.4 (CH), 121.3 
(CH), 120.7 (CH), 119.5 (CH), 116.1 (CH), 109.3 (CH), 109.2 (Cq), 37.5 (CH2), 31.4 (CH3), 
30.8 (CH), 21.4 (CH2), 19.2 (CH3), 14.1 (CH3).  
IR (ATR): 3350, 2952, 2868, 1651, 1420, 1238, 937, 793 cm-1.  








With aryl sulfamate: The general procedure E was followed using 3a (127 mg, 0.75 mmol) 
and 30ad (116 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 10:1→5:1) 52ad (112 mg, 82%) was obtained as a white solid (m.p. 
89-90 °C ).  
With aryl carbamate: The general procedure E was followed using 3a (127 mg, 0.75 mmol) 
and 30bd (98 mg, 0.50 mmol). After purification by column chromatography (n-hexane/EtOA
c 10:1→5:1) 52ad (123mg, 90%) was obtained as a white solid.  
1H NMR (300 MHz, CDCl3): δ = 8.60 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.51-7.46 (m, 1H), 
7.34 (td, J = 7.7, 1.8 Hz, 1H), 7.31-7.21 (m, 2H), 7.11-7.00 (m, 3H), 6.85 (td, J = 8.9, 1.0 Hz, 
1H), 6.79-6.72 (m, 2H), 3.76 (s, 3H), 2.42 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 159.6 (Cq), 158.4 (Cq), 149.4 (CH), 139.1 (Cq), 137.4 (Cq), 
137.0 (Cq), 135.2 (CH), 133.7 (Cq), 131.0 (CH), 130.7 (CH), 130.4 (CH), 129.3 (CH), 125.5 
(CH), 121.2 (CH), 113.5 (CH), 55.2 (CH3), 21.0 (CH3).  
IR (ATR): 2962, 2836, 1583, 1486, 1293, 1108, 1033, 891, 748, 568 cm-1.  
MS (EI) m/z (relative intensity) 275 (45) [M+], 274 (100), 231 (35), 152 (3), 78 (3).  
HR-MS (EI) m/z calcd for [C19H17NO] + 275.1310, found 275.1300.  
The spectral data were in accordance with those reported in the literature.86 
 
2-(4-Methyl-[1,1'-biphenyl]-2-yl)pyridine (52ab) 
                                                             





With aryl sulfamate: The general procedure E was followed using 3a (127 mg, 0.75 mmol) 
and 30ab (101 mg, 0.50 mmol). After purification by column chromatography (n-hexane/EtO
Ac 20:1) 52ab (85 mg, 70%) was obtained as a colorless oil.  
With aryl carbamate: The general procedure E was followed using 3a (127 mg, 0.75 mmol) 
and 30bb (83 mg, 0.50 mmol). After purification by column chromatography (n-hexane/EtOA
c 20:1) 52ab (87mg, 71%) was obtained as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.60-7.50 (m, 1H), 
7.40-7.06 (m, 9H), 6.86 (dt, J = 7.9, 1.1 Hz, 1H), 2.45 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ  = 159.3 (Cq), 149.4 (CH), 141.3 (Cq), 139.2 (Cq), 137.8 (Cq), 
137.4 (Cq), 135.1 (CH), 131.1 (CH), 130.4 (CH), 129.7 (CH), 129.3 (CH), 128.0 (CH), 126.5 
(CH), 125.5 (CH), 121.3 (CH), 21.1 (CH3).  
IR (ATR): 3023, 2918, 1585, 1442, 1283, 1149, 1094, 1008, 792, 573 cm-1.  
MS (EI) m/z (relative intensity) 245 (28) [M+], 244 (100), 202 (6), 121 (5), 77 (4).  
HR-MS (ESI) m/z calcd for [C18H15N+H] + 246.1277, found 246.1277.  




With aryl sulfamate: The general procedure E was followed using 3a (127 mg, 0.75 mmol) 
and 30ac (108 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 20:1) 52ac (103 mg, 80%) was obtained as a white solid (m.p. 75-76 °C ).  
With aryl carbamate: The general procedure E was followed using 3a (127 mg, 0.75 mmol) 
                                                             




and 30bc (90 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 20:1) 52ac (104 mg, 81%) was obtained as a white solid.  
 1H NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H), 7.52-7.48 (m, 1H), 7.3
6 (td, J = 7.7, 1.9 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H), 7.26-7.22 (m, 1H), 7.08 (ddd, J = 7.3, 4.8, 
1.1 Hz, 1H), 7.01 (m, 4H), 6.86 (dt, J = 7.9, 1.0 Hz, 1H), 2.42 (s, 3H), 2.29 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.5 (Cq), 149.4 (CH), 139.2 (Cq), 138.3 (Cq), 137.7 (Cq), 
137.2 (Cq), 136.1 (Cq), 135.1 (CH), 131.1 (CH), 130.5 (CH), 129.6 (CH), 129.3 (CH), 128.8 
(CH), 125.5 (CH), 121.2 (CH), 20.4 (2 CH3).  
IR (ATR): 3019, 2917, 1584, 1488, 1233, 1110, 1065, 1005, 785, 616 cm-1.  
MS (EI) m/z (relative intensity) 259 (30) [M+], 258 (100), 202 (3), 121 (4), 78 (2).  




With aryl sulfamate: The general procedure E was followed using 3a (127 mg, 0.75 mmol) 
and 30ag (115 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 20:1) 52ag (115 mg, 85%) was obtained as a colorless oil.  
With aryl carbamate: The general procedure E was followed using 3a (127 mg, 0.75 mmol) 
and 30bg (97 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 20:1) 52ag (117 mg, 86%) was obtained as a colorless oil.   
1H NMR (300 MHz, CDCl3): δ = 8.62 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H), 7.58-7.44 (m, 1H), 
7.36 (td, J = 7.8, 1.8 Hz, 1H), 7.31 (d, J = 7.8 Hz, 1H), 7.26-7.21 (m, 1H), 7.07 (ddd, J = 7.5, 
4.9, 1.2 Hz, 1H), 6.87 (dt, J = 7.9, 1.1 Hz, 1H), 6.84-6.80 (m, 1H), 6.78-6.68 (m, 2H), 2.42 (s, 
3H), 2.17 (s, 6H).  
13C NMR (75 MHz, CDCl3): δ = 159.7 (Cq), 149.3 (CH), 141.2 (Cq), 139.3 (Cq), 138.1 (Cq), 
137.4 (Cq), 137.1 (Cq), 134.9 (CH), 131.0 (CH), 130.4 (CH), 129.2 (CH), 128.1 (CH), 127.7 




IR (ATR): 3017, 2917, 1585, 1432, 1207, 1149, 1039, 851, 745, 583 cm-1.  
MS (EI) m/z (relative intensity) 273 (40) [M+], 272 (100), 258 (16), 121 (2), 69 (9).  




With aryl sulfamate: The general procedure E was followed using 3a (127 mg, 0.75 mmol) 
and 30aa (108 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 10:1) 52aa (105 mg, 81%) was obtained as a white solid (m.p. 100-101 °C ).  
With aryl carbamate: The general procedure E was followed using 3a (127 mg, 0.75 mmol) 
and 30ba (90 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 10:1) 52aa (100 mg, 77%) was obtained as a white solid.  
1H NMR (300 MHz, CDCl3): δ = 8.62 (ddd, J = 5.0, 1.9, 1.0 Hz, 1H), 7.63 (s, 1H), 7.33-7.24 
(m, 2H), 7.23-7.11 (m, 4H), 7.11-7.01 (m, 2H), 6.77 (dt, J = 8.0, 1.1 Hz, 1H), 2.47 (s, 3H), 
1.88 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 158.8 (Cq), 149.4 (CH), 141.1 (Cq), 139.5 (Cq), 137.4 (Cq), 
137.3 (Cq), 136.1 (Cq), 135.0 (CH), 130.1 (3 CH), 129.9 (CH), 129.0 (CH), 127.1 (CH), 
125.5 (CH), 124.5 (CH), 121.2 (CH), 21.1 (CH3), 20.0 (CH3).  
IR (ATR): 2917, 2835, 1583, 1480, 1433, 1260, 1152, 1065, 791, 617 cm-1.  
MS (EI) m/z (relative intensity) 259 (8) [M+], 244 (100), 165 (6), 122 (3), 79 (4).  







The general procedure E was followed using 3a (127 mg, 0.75 mmol) and 30ah (123 mg, 0.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1) 52ah (120 mg, 
83%) was obtained as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 8.61 (dt, J = 4.9, 0.9 Hz, 1H), 7.55 (s, 1H), 7.32 (td, J = 7.7, 
1.8 Hz, 1H), 7.26-7.24 (m, 2H), 7.10-6.98 (m, 2H), 6.88 (d, J = 7.9 Hz, 1H), 6.72 (dt, J = 7.6, 
0.7 Hz, 1H), 6.51 (s, 1H), 3.31 (s, 3H), 2.42 (s, 3H), 2.32 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.8 (Cq), 156.0 (Cq), 149.1 (CH), 140.1 (Cq), 138.5 (Cq), 
137.2 (Cq), 134.9 (CH), 134.1 (Cq), 131.2 (CH), 131.1 (CH), 130.3 (CH), 129.0 (CH), 127.5 
(Cq), 123.6 (CH), 121.3 (CH), 120.9 (CH), 111.6 (CH), 54.8 (CH3), 21.6 (CH3)，21.1 (CH3). 
IR (ATR): 2919, 2835, 1584, 1489, 1433, 1277, 1163, 1004, 791, 618 cm-1.  
MS (EI) m/z (relative intensity) 289 (1) [M+], 258 (100), 242 (7), 129 (4), 78 (2).  




The general procedure E was followed using 3b (116 mg, 0.75 mmol) and 30ad (116 mg, 0.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1) 52bd (82 mg, 
63%) was obtained as a white solid (m.p. 72-73 °C ).  
1H NMR (300 MHz, CDCl3): δ = 8.62 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.71-7.61 (m, 1H), 
7.46-7.34 (m, 4H), 7.12-7.01 (m, 3H), 6.88 (dt, J = 8.0, 1.0 Hz, 1H), 6.80-6.71 (m, 2H), 3.77 
(s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.7 (Cq), 158.7 (Cq), 149.5 (CH), 140.3 (Cq), 139.6 (Cq), 
135.1 (CH), 133.9 (Cq), 130.8 (CH), 130.5 (CH), 130.4 (CH), 128.5 (CH), 127.3 (CH), 125.4 
(CH), 121.2 (CH), 113.7 (CH), 55.2 (CH3).  
IR (ATR): 3067, 2969, 2839, 1607, 1582, 1440, 1148, 1037, 830, 561 cm-1.  
MS (EI) m/z (relative intensity) 261 (42) [M+], 260 (100), 217 (50), 191 (10), 78 (2).  







With aryl sulfamate: The general procedure E was followed using 3c (127 mg, 0.75 mmol) 
and 30ad (116 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 10:1) 52cd (74 mg, 55%) was obtained as a colorless oil.  
With aryl carbamate: The general procedure E was followed using 3c (127 mg, 0.75 mmol) 
and 30bd (98 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 10:1) 52cd (86 mg, 63%) was obtained as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.61 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H), 7.45 (td, J = 7.8, 
1.9 Hz, 1H), 7.32 (t, J = 7.5 Hz, 1H), 7.26-7.21 (m, 2H), 7.07 (ddd, J = 7.3, 4.9, 1.2 Hz, 1H), 
7.00-6.94 (m, 2H), 6.86 (dt, J = 7.9, 1.1 Hz, 1H), 6.68-6.62 (m, 2H), 3.71 (s, 3H), 2.15 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 160.0 (Cq), 158.2 (Cq), 148.9 (CH), 140.9 (Cq), 139.5 (Cq), 
136.7 (Cq), 135.6 (CH), 134.3 (Cq), 130.7 (CH), 129.1 (CH), 128.0 (CH), 127.6 (CH), 125.6 
(CH), 121.2 (CH), 113.2 (CH), 55.1 (CH3), 20.4 (CH3).  
IR (ATR): 2955, 2835, 1608, 1584, 1510, 1423, 1244, 1177, 1028, 674 cm-1.  
MS (EI) m/z (relative intensity) 275 (42) [M+], 274 (100), 231 (18), 152 (4), 78 (2).  




With aryl sulfamate: The general procedure E was followed using 3d (137 mg, 0.75 mmol) 
and 30ad (116 mg, 0.50 mmol). After purification by column chromatography 




With aryl carbamate: The general procedure E was followed using 3d (137 mg, 0.75 mmol) 
and 30bd (98 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 10:1→5:1) 52dd (122 mg, 84%) was obtained as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.48 (d, J = 4.9, 1H), 7.47 (s, 1H), 7.33-7.21 (m, 2H), 
7.12-7.00 (m, 2H), 6.91 (dd, J = 5.0, 1.0 Hz, 1H), 6.80-6.71 (m, 3H), 3.78 (s, 3H), 2.42 (s, 
3H), 2.11 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.3 (Cq), 158.3 (Cq), 149.0 (CH), 146.2 (Cq), 139.1 (Cq), 
137.7 (Cq), 136.9 (Cq), 133.8 (Cq), 131.0 (CH), 130.7 (CH), 130.3 (CH), 129.1 (CH), 126.3 
(CH), 122.3 (CH), 113.4 (CH), 55.2 (CH3), 21.0 (CH3)，20.9 (CH3).  
IR (ATR): 2920, 2835, 1599, 1559, 1463, 1242, 1176, 1036, 887, 578 cm-1.  
MS (EI) m/z (relative intensity) 289 (11) [M+], 288 (100), 245 (25), 137 (3), 63 (2).  




With aryl sulfamate: The general procedure E was followed using 3e (134 mg, 0.75 mmol) 
and 30ad (116 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 10:1) 52ed (132 mg, 95%) was obtained as a light yellow solid (m.p. 
123-124 °C ).  
With aryl carbamate: The general procedure E was followed using 3e (134 mg, 0.75 mmol) 
and 30bd (98 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 10:1) 52ed (134 mg, 96%) was obtained as a light yellow solid. 
1H NMR (300 MHz, CDCl3): δ = 8.46 (dd, J = 4.3, 1.9 Hz, 1H), 8.06 (dd, J = 7.8, 1.9 Hz, 
1H), 7.88 (dd, J = 7.8, 1.4 Hz, 1H), 7.83 (d, J = 8.9 Hz, 1H), 7.69-7.62 (m, 2H), 7.53 (dd, 




13C NMR (75 MHz, CDCl3): δ = 158.0 (Cq), 147.0 (Cq), 146.9 (CH), 141.4 (Cq), 138.9 (Cq), 
135.2 (CH), 135.1 (Cq), 131.7 (CH), 129.8 (CH), 129.1 (Cq), 128.3 (CH), 127.7 (CH), 127.2 
(Cq), 127.0 (CH), 125.9 (CH), 121.0 (CH), 112.8 (CH), 55.3 (CH3).  
IR (ATR): 3030, 2967, 1879, 1568, 1435, 1234, 1171, 1044, 848, 579 cm-1.  
MS (EI) m/z (relative intensity) 285 (20) [M+], 284 (100), 241 (38), 120 (7), 43 (6).  




With aryl sulfamate: The general procedure E was followed using 3e (134 mg, 0.75 mmol) 
and 30ac (108 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 10:1) 52ec (119 mg, 88%) was obtained as a colorless oil.  
With aryl carbamate: The general procedure E was followed using 3e (134 mg, 0.75 mmol) 
and 30bc (90 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 10:1) 52ec (115 mg, 86%) was obtained as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.44 (dd, J = 4.3, 1.9 Hz, 1H), 8.07 (dd, J = 7.9, 1.8 Hz, 
1H), 7.89 (dd, J = 7.9, 1.0 Hz, 1H), 7.83 (d, J = 8.7 Hz, 1H), 7.71-7.61 (m, 2H), 7.52 (dd, 
J = 7.3, 1.3 Hz, 1H), 7.30 (dd, J = 7.9, 4.3 Hz, 1H), 7.26-7.16 (m, 4H), 2.45 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 146.9 (Cq), 146.8 (CH), 143.4 (Cq), 141.7 (Cq), 135.2 (CH), 
135.1 (Cq), 135.0 (Cq), 131.6 (CH), 129.1 (Cq), 128.6 (CH), 128.3 (CH), 128.1 (CH), 127.8 
(CH), 127.2 (Cq), 127.0 (CH), 125.9 (CH), 121.0 (CH), 21.3 (CH3).  
IR (ATR): 3044, 2917, 1620, 1588, 1418, 1210, 1131, 1040, 973, 556 cm-1.  
MS (EI) m/z (relative intensity) 269 (25) [M+], 268 (100), 133 (5), 91 (2), 43 (4).  







With aryl sulfamate: The general procedure was E followed using 3e (134 mg, 0.75 mmol) 
and 30ae (110 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 10:1) 52ee (115 mg, 84%) was obtained as a yellow solid (m.p. 
115-116 °C ).  
With aryl carbamate: The general procedure was E followed using 3e (134 mg, 0.75 mmol) 
and 30be (92 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 10:1) 52ee (112 mg, 82%) was obtained as a yellow solid. 
1H NMR (300 MHz, CDCl3): δ = 8.45 (dd, J = 4.3, 1.9 Hz, 1H), 8.10 (dd, J = 8.0, 2.0 Hz, 
1H), 7.93 (dd, J = 8.0, 1.4 Hz, 1H), 7.87 (d, J = 8.8 Hz, 1H), 7.74-7.64 (m, 2H), 7.53 (dd, 
J = 7.3, 1.5 Hz, 1H), 7.38-7.25 (m, 3H), 7.15-7.04 (m, 2H).  
13C NMR (75 MHz, CDCl3): δ = 161.5 (Cq, 1JC-F = 243.7 Hz), 146.8 (CH), 146.7 (Cq), 142.2 
(Cq, 4JC-F = 3.8 Hz), 140.6 (Cq), 135.2 (CH), 135.0 (Cq), 131.5 (CH), 130.5 (CH, 3JC-F = 8.4 
Hz ), 129.0 (Cq), 128.3 (CH ), 128.1 (CH), 127.2 (Cq), 127.0 (CH), 126.0 (CH), 121.1 (CH), 
114.1 (CH, 2JC-F = 21.1 Hz).  
19F-NMR (282 MHz, CDCl3): δ = -118.1 ― -118.3 (m).  
IR (ATR): 3046, 2925, 1603, 1567, 1420, 1214, 1156, 1015, 828, 570 cm-1.  
MS (EI) m/z (relative intensity) 273 (28) [M+], 272 (100), 252 (8), 136 (9), 44 (7).  




The general procedure E was followed using 3a (127 mg, 0.75 mmol) and 30bi (120 mg, 




(116 mg, 72%) was obtained as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 8.34 (ddd, J = 4.8, 1.6, 0.9 Hz, 1H), 7.46-7.17 (m, 8H), 
7.16-6.94 (m, 4H), 6.74-6.62 (m, 3H), 2.40 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 158.2 (Cq), 148.9 (CH), 140.9 (Cq), 140.5 (Cq), 139.7 (Cq), 
139.3 (Cq), 137.1 (Cq), 137.0 (Cq), 134.8 (CH), 131.5 (CH), 130.5 (CH), 129.9 (CH), 129.1 
(CH), 129.0 (CH), 127.4 (2 CH), 127.3 (CH), 127.3 (CH), 126.2 (CH), 124.1 (CH), 120.6 
(CH), 21.0 (CH3).  
IR (ATR): 3054, 3018, 1713, 1585, 1472, 1150, 1007, 824, 767, 616 cm-1.  
MS (EI) m/z (relative intensity) 321 (40) [M+], 244 (100), 152 (6), 79 (10), 43 (7).  




The general procedure E was followed using 3a (127 mg, 0.75 mmol) and 30bj (119 mg, 
0.50 mmol). After purification by column chromatography (n-hexane/EtOAc 25:1) 52aj 
(118 mg, 76%) was obtained as a colorless oil.  
1H NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.8, 1.9, 0.9 Hz, 1H), 7.71-7.67 (m, 1H), 
7.57 (dd, J = 7.3, 1.5 Hz, 1H), 7.31-7.13 (m, 5H), 7.02 (ddd, J = 7.5, 4.9, 1.1 Hz, 1H), 
6.99-6.95 (m, 1H), 6.76 (dd, J = 8.1, 1.0 Hz, 1H), 2.47 (s, 3H), -0.04 (s, 9H).  
13C NMR (75 MHz, CDCl3): δ = 158.1 (Cq), 149.1 (CH), 147.6 (Cq), 139.5 (Cq), 138.9 (Cq), 
138.6 (Cq), 137.4 (Cq), 134.8 (2 CH), 131.1 (CH), 130.6 (CH), 130.6 (CH), 128.3 (CH), 
128.0 (CH), 125.9 (CH), 124.7 (CH), 121.0 (CH), 21.0 (CH3), 0.36 (CH3).  
IR (ATR): 3049, 2952, 1586, 1426, 1248, 1121, 1085, 837, 687, 621 cm-1.  
MS (EI) m/z (relative intensity) 317 (2) [M+], 244 (100), 202 (2), 73 (3), 43 (4).  







The general procedure E was followed using 3f (167 mg, 0.75 mmol) and 30bc (90 mg, 0.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 52fc (136 mg, 
87%) was obtained as a white solid (m.p. 77-78 °C ). 
1H NMR (300 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H), 7.95 (dd, J = 1.2, 
0.6 Hz, 1H), 7.67 (ddd, J = 8.0, 2.0, 0.6 Hz, 1H), 7.51 (d, J = 8.0, 1H), 7.40 (td, J = 7.8, 
1.8 Hz, 1H), 7.13 (ddd, J = 7.8, 4.8, 1.2 Hz, 1H), 7.08-7.00 (m, 4H), 6.88 (td, J = 7.9, 
1.1 Hz, 1H), 2.31 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 158.1 (Cq), 149.7 (CH), 144.1 (Cq), 140.1 (Cq), 137.7 (Cq), 
137.2 (Cq), 135.4 (CH), 131.0 (CH), 129.8 (Cq, 2JC-F = 31.9 Hz), 129.4 (CH), 129.0 (CH), 
127.6 (CH , 3JC-F = 3.8 Hz), 125.3 (CH), 125.1 (CH, 3JC-F = 3.7 Hz), 124.3 (Cq, 1JC-F = 271.5 
Hz), 121.8 (CH), 21.1 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = -62.4 (s).  
IR (ATR): 2925, 1612, 1587, 1439, 1254, 1164, 1078, 1059, 748, 585 cm-1.  
MS (EI) m/z (relative intensity) 313 (35) [M+], 312 (100), 242 (4), 155 (2), 78 (2).  




The general procedure E was followed using 3f (167 mg, 0.75 mmol) and 30bd (98 mg, 0.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1) 52fd (148 mg, 
93%) was obtained as a white solid (m.p. 77-78 °C ). 
1H NMR (300 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H), 7.94 (dd, J = 1.2, 




1.8 Hz, 1H), 7.13 (ddd, J = 7.8, 4.9, 1.2 Hz, 1H), 7.09-7.03 (m, 2H), 6.88 (td, J = 7.9, 
1.1 Hz, 1H), 6.81-6.75 (m, 2H), 3.23 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.1 (Cq), 158.1 (Cq), 149.7 (CH), 143.6 (Cq), 139.8 (Cq), 
135.5 (CH), 132.3 (Cq), 130.7 (CH), 129.5 (Cq, 2JC-F = 32.8 Hz), 127.7 (CH), 127.6 (CH , 3JC-F 
= 3.7 Hz), 125.3 (CH), 124.1 (Cq, 1JC-F = 271.5 Hz), 125.1 (CH, 3JC-F = 3.7 Hz), 121.9 (CH), 
113.8 (CH), 55.2 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = -62.4 (s).  
IR (ATR): 2938, 1610, 1587, 1401, 1276, 1123, 1083, 1061, 828, 553 cm-1.  
MS (EI) m/z (relative intensity) 329 (26) [M+], 328 (100), 285 (32), 142 (2), 78 (2).  




The general procedure E was followed using 3g (130 mg, 0.75 mmol) and 30bd (98 mg, 0.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 52gd 
(126 mg, 90%) was obtained as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.60 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.48 (ddd, J = 7.8, 1.4, 
0.4 Hz, 1H), 7.41-7.32 (m, 2H), 7.22-7.13 (m, 1H), 7.11-7.04 (m, 3H), 6.86-6.75 (m, 3H), 
3.76 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 160.0 (Cq, 1JC-F = 245.1 Hz), 158.8 (Cq), 158.1 (Cq, 3JC-F = 
3.3 Hz), 149.4 (CH), 142.1 (Cq, 3JC-F = 3.1 Hz), 135.2 (CH), 131.8 (CH, 4JC-F = 1.7 Hz ), 
128.6 (CH, 3JC-F = 9.0 Hz), 127.8 (Cq, 2JC-F = 17.1 Hz), 126.1 (Cq), 125.9 (CH, 4JC-F = 3.3 Hz), 
125.3 (CH), 121.5 (CH), 115.5 (CH, 2JC-F = 23.4 Hz), 113.5 (CH), 55.2 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = -115.8 (dd, J = 9.6, 5.4 Hz ).  
IR (ATR): 3003, 2835, 1606, 1586, 1425, 1177, 1036, 832, 748, 584 cm-1.  
MS (EI) m/z (relative intensity) 279 (45) [M+], 278 (100), 235 (50), 117 (7), 78 (2).  







The general procedure E was followed using 3h (137 mg, 0.75 mmol) and 30bd (98 mg, 0.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 52hd 
(118 mg, 82%) was obtained as a white solid (m.p. 114-115 °C ). 
1H NMR (300 MHz, CDCl3): δ = 8.54-8.41 (m, 1H), 7.55-7.45 (m, 1H), 7.35-7.13 (m, 3H), 
7.12-7.01 (m, 2H), 6.84-6.69 (m, 3H), 3.78 (s, 3H), 2.42 (s, 3H), 2.29 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 158.3 (Cq), 156.6 (Cq), 149.7 (CH), 139.0 (Cq), 137.3 (Cq), 
136.9 (Cq), 135.8 (CH), 133.8 (Cq), 131.0 (CH), 130.7 (CH), 130.5 (Cq), 130.3 (CH), 129.0 
(CH), 124.9 (CH), 113.4 (CH), 55.1 (CH3), 21.0 (CH3)，18.1 (CH3).  
IR (ATR): 2919, 1607, 1560, 1471, 1241, 1134, 1032, 878, 725, 589 cm-1.  
MS (EI) m/z (relative intensity) 289 (41) [M+], 288 (100), 245 (25), 137 (4), 58 (6).  




The general procedure E was followed using 3i (128 mg, 0.75 mmol) and 30bd (98 mg, 0.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1) 52id (131 mg, 
95%) was obtained as a white solid. 
1H NMR (300 MHz, CDCl3): δ = 8.62 (d, J = 5.1 Hz, 2H), 7.55 (s, 1H), 7.35-7.25 (m, 2H), 
7.10-6.97 (m, 3H), 6.78-6.69 (m, 2H), 3.76 (s, 3H), 2.42 (s, 3H).  




136.8 (Cq), 133.9 (Cq), 131.0 (CH), 130.5 (CH), 130.1 (2 CH), 118.3 (CH), 113.4 (CH), 55.2 
(CH3), 21.0 (CH3).  
IR (ATR): 3029, 2921, 2852, 1606, 1552, 1436, 1240, 1108, 1031, 583 cm-1.  
MS (EI) m/z (relative intensity) 276 (52) [M+], 275 (100), 232 (32), 152 (8), 43 (10).  




With aryl sulfamate: The general procedure E was followed using 82a (146 mg, 0.75 mmol) 
and 30ae (110 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 20:1) 83ae (83 mg, 55%) was obtained as a white solid (m.p. 147-148 °C ). 
With aryl carbamate: The general procedure E was followed using 82a (146 mg, 0.75 mmol) 
and 30be (92 mg, 0.50 mmol). After purification by column chromatography 
(n-hexane/EtOAc 20:1) 83ae (130 mg, 90%) was obtained as a white solid. 
1H NMR (300 MHz, CDCl3): δ = 8.68-8.55 (m, 1H), 7.74-7.56 (m, 3H), 7.26-7.17 (m, 5H), 
7.00-6.92 (m, 2H), 6.90 (dd, J = 8.0, 0.8 Hz, 1H), 6.75 (s, 1H).  
13C NMR (75 MHz, CDCl3): δ = 162.1 (Cq, 1JC-F = 247.4 Hz), 151.9 (Cq), 149.3 (CH), 138.9 
(Cq), 138.4 (Cq), 137.9 (CH), 130.4 (CH, 3JC-F = 8.2 Hz), 128.8 (Cq, 4JC-F = 3.4 Hz), 128.6 (Cq), 
123.1 (CH), 121.9 (CH), 121.7 (CH), 121.4 (CH), 120.5 (CH), 115.4 (CH, 2JC-F = 21.5 Hz), 
111.4 (CH), 105.5 (CH).  
19F-NMR (282 MHz, CDCl3): δ = -114.1 ― -114.3 (m).  
IR (ATR): 3052, 2840, 1584, 1436, 1261, 1179, 1154, 1045, 838, 586 cm-1.  
MS (EI) m/z (relative intensity) 288 (68) [M+], 287 (100), 183 (10), 143 (11), 78 (9).  







The general procedure E was followed using 82a (146 mg, 0.75 mmol) and 30bc (90 mg, 0.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1) 83ac (134 mg, 
91%) was obtained as a light yellow solid (m.p. 82-83 °C ). 
1H NMR (300 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.73-7.58 (m, 3H), 
7.27-7.15 (m, 5H), 7.09 (d, J = 8.5 Hz, 2H), 6.90 (dd, J = 8.0, 0.7 Hz, 1H), 6.78 (s, 1H), 2.34 
(s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 152.2 (Cq), 149.1 (CH), 140.0 (Cq), 138.4 (Cq), 137.7 (CH), 
137.3 (Cq), 129.8 (Cq), 129.0 (CH), 128.8 (Cq), 128.6 (CH), 122.8 (CH), 122.1 (CH), 121.5 
(CH), 121.3 (CH), 120.4 (CH), 111.5 (CH), 105.1 (CH), 21.2 (CH3).  
IR (ATR): 3027, 2922, 1578, 1469, 1434, 1261, 1148, 1043, 850, 588 cm-1.  
MS (EI) m/z (relative intensity) 284 (95) [M+], 283 (100), 268 (18), 134 (6), 78 (10).  




The general procedure E was followed using 82a (146 mg, 0.75 mmol) and 30bd (98 mg, 0.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1) 83ad (137 mg, 
91%) was obtained as a white solid (m.p. 122-123 °C ). 
1H NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.72-7.53 (m, 3H), 
7.27-7.13 (m, 5H), 6.94-6.67 (m, 4H), 3.78 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 159.3 (Cq), 152.4 (Cq), 149.2 (CH), 140.0 (Cq), 138.5 (Cq), 
137.7 (CH), 130.1 (CH), 128.9 (Cq), 125.4 (Cq), 122.7 (CH), 122.1 (CH), 121.5 (CH), 121.3 
(CH), 120.3 (CH), 113.9 (CH), 111.5 (CH), 104.8 (CH), 55.3 (CH3).  




MS (EI) m/z (relative intensity) 300 (100) [M+], 285 (18), 256 (33), 128 (9), 78 (14).  




The general procedure E was followed using 82b (156 mg, 0.75 mmol) and 30bd (98 mg, 0.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1→5:1) 83bd 
(146 mg, 93%) was obtained as a white solid (m.p. 136-137 °C ). 
1H NMR (300 MHz, CDCl3): δ = 8.64-8.54 (m, 1H), 7.79-7.69 (m, 1H), 7.67-7.58 (m, 1H), 
7.53 (dd, J = 7.7, 2.1 Hz, 1H), 7.25-7.10 (m, 5H), 6.91-6.81 (m, 2H), 6.74 (dt, J = 8.0, 0.9 Hz, 
1H), 3.81 (s, 3H), 2.38 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 158.8 (Cq), 152.4 (Cq), 148.9 (CH), 137.4 (CH), 137.1 (Cq), 
135.5 (Cq), 131.5 (CH), 129.7 (Cq), 124.8 (Cq), 122.9 (CH), 121.5 (CH), 120.8 (CH), 120.7 
(CH), 118.7 (CH), 113.7 (CH), 112.0 (Cq), 111.5 (CH), 55.2 (CH3), 9.5 (CH3).  
IR (ATR): 2928, 2840, 1505, 1435, 1288, 1149, 1070, 1040, 836, 578 cm-1.  
MS (EI) m/z (relative intensity) 314 (100) [M+], 299 (14), 236 (12), 128 (3), 78 (9).  




The general procedure E was followed using 82b (156 mg, 0.75 mmol) and 30be (92 mg, 0.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 83be (147 mg, 
92%) was obtained as a white solid (m.p. 151-152 °C ). 




7.29-7.12 (m, 5H), 7.06-6.96 (m, 2H), 6.78 (dd, J = 8.0, 0.8 Hz, 1H), 2.38 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 161.8 (Cq, 1JC-F = 247.1 Hz), 152.0 (Cq), 149.0 (CH), 137.5 
(CH), 137.1 (Cq), 134.6 (Cq), 131.9 (CH, 3JC-F = 8.7 Hz), 129.5 (Cq), 128.4 (Cq, 4JC-F = 3.4 Hz), 
123.3 (CH), 121.4 (CH), 121.0 (CH), 120.9 (CH), 118.9 (CH), 115.4 (CH, 2JC-F = 21.5 Hz), 
112.6 (Cq), 111.4 (CH), 9.44 (CH3).  
19F-NMR (282 MHz, CDCl3): δ = -114.2 ― -114.4 (m).  
IR (ATR): 2919, 2839, 1672, 1580, 1432, 1213, 1145, 1071, 846, 576 cm-1.  
MS (EI) m/z (relative intensity) 302 (100) [M+], 287 (18), 224 (20), 143 (14), 78 (26). 




The general procedure E was followed using 82b (156 mg, 0.75 mmol) and 30ba (90 mg, 0.50 
mmol). After purification by column chromatography (n-hexane/EtOAc 10:1) 83ba (128 mg, 
86%) was obtained as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.55 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.93-7.86 (m, 1H), 
7.71-7.63 (m, 1H), 7.50-7.41 (m, 1H), 7.31-7.17 (m, 6H), 7.07 (ddd, J = 7.4, 4.9, 1.0 Hz, 1H), 
6.69 (dt, J = 8.0, 0.9 Hz, 1H), 2.24 (s, 3H), 2.03 (s, 3H).  
13C NMR (75 MHz, CDCl3): δ = 152.0 (Cq), 148.7 (CH), 138.3 (Cq), 137.3 (CH), 136.6 (Cq), 
135.2 (Cq), 132.1 (Cq), 131.6 (CH), 130.0 (CH), 129.4 (Cq), 128.3 (CH), 125.5 (CH), 122.9 
(CH), 120.7 (CH), 120.5 (CH), 119.9 (CH), 118.6 (CH), 112.5 (Cq), 111.9 (CH), 19.8 (CH3), 
9.3 (CH3).  
IR (ATR): 2916, 2840, 1587, 1435, 1254, 1148, 1072, 1013, 845, 575 cm-1.  
MS (EI) m/z (relative intensity) 298 (100) [M+], 220 (28), 167 (7), 128 (4), 78 (10).  







The general procedure E was followed using 82a (146 mg, 0.75 mmol) and 84 (122 mg, 
0.50mmol) at ambient temperature. After purification by column chromatography (n-hexane/
EtOAc 20:1) 85 (92 mg, 65%) was obtained as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 8.69-8.60 (m, 1H), 7.78 (td, J = 7.7, 2.1 Hz, 1H), 7.56 (dd, 
J = 5.7, 3.4 Hz, 1H), 7.34-7.23 (m, 3H), 7.22-7.00 (m, 7H), 6.40-6.34 (m, 1H), 4.25 (s, 2H).  
13C NMR (75 MHz, CDCl3): δ = 151.3 (Cq), 149.5 (CH), 140.1 (Cq), 138.7 (Cq), 138.1 (CH), 
137.4 (Cq), 128.8 (CH), 128.4 (Cq), 128.1 (CH), 126.1 (CH), 122.0 (CH), 121.9 (CH), 121.2 
(CH), 120.6 (CH), 120.1 (CH), 110.0 (CH), 104.1 (CH), 34.0 (CH2).  
IR (ATR): 2971, 1565, 1494, 1441, 1230, 1145, 1024, 966, 842, 575 cm-1.  
MS (EI) m/z (relative intensity) 284 (100) [M+], 206 (95), 178 (20), 128 (9), 78 (40).  




The general procedure F was followed using 3b (78 mg, 0.50 mmol) and 12aa (90 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53ba (106 mg, 
90%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.69 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.74 (td, J = 7.8, 1.8 
Hz, 1H), 7.38 (dt, J = 7.8, 1.1 Hz, 1H), 7.35−7.21 (m, 5H), 2.69 (t, J = 7.8 Hz, 2H), 1.53−1.35 
(m, 2H), 1.26−1.10 (m, 6H), 0.81 (t, J = 6.9 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 160.4 (Cq), 149.1 (CH), 140.8 (Cq), 140.3 (Cq), 136.0 (CH), 
129.7 (CH), 129.7 (CH), 128.2 (CH), 125.7 (CH), 124.1 (CH), 121.6 (CH), 32.9 (CH2), 31.5 




IR (neat): 2954, 2924, 2855, 1585, 1466, 1377, 1023, 746 cm-1.  
MS (EI) m/z (relative intensity) 239 (15) [M+], 182 (100), 167 (65), 115 (3), 43 (33).  
HR-MS (EI) m/z calcd for [C17H21N] + 239.1674, found 239.1666.  




The general procedure F was followed using 3b (78 mg, 0.50 mmol) and 12ab (111 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53bb (110 mg, 
83%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.69 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.74 (td, J = 7.8, 1.9 
Hz, 1H), 7.38 (dt, J = 7.8, 1.0 Hz, 1H), 7.36−7.22 (m, 5H), 2.69 (t, J = 7.9 Hz, 2H), 1.52−1.35 
(m, 2H), 1.32−1.09 (m, 10H), 0.86 (t, J = 6.7 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 160.4 (Cq), 149.1 (CH), 140.8 (Cq), 140.3 (Cq), 136.0 (CH), 
129.7 (CH), 129.7 (CH), 128.2 (CH), 125.7 (CH), 124.1 (CH), 121.5 (CH), 32.9 (CH2), 31.8 
(CH2), 31.2 (CH2), 29.4 (CH2), 29.2 (CH2), 29.1 (CH2), 22.6 (CH2), 14.1 (CH3).  
IR (neat): 2922, 2853, 1585, 1424, 1148, 1023, 989, 747 cm-1.  
MS (EI) m/z (relative intensity) 267 (11) [M+], 182 (100), 167 (55), 78 (3), 41 (8).  




The general procedure F was followed using 3j (93 mg, 0.50 mmol) and 12aa (90 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53ja (107 mg, 
                                                             




80%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.69 (td, J = 7.8, 1.9 
Hz, 1H), 7.32 (dt, J = 7.8, 1.1 Hz, 1H), 7.27 (d, J = 8.3 Hz, 1H), 7.19 (ddd, J = 7.5, 4.9, 1.1 
Hz, 1H), 6.84−6.75 (m, 2H), 3.82 (s, 3H), 2.68 (t, J = 7.7 Hz, 2H), 1.50−1.35 (m, 2H), 
1.27−1.06 (m, 6H), 0.80 (t, J = 6.9 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 160.1 (Cq), 159.5 (Cq), 149.1 (CH), 142.5 (Cq), 136.0 (CH), 
133.2 (Cq), 131.0 (CH), 124.1 (CH), 121.2 (CH), 115.2 (CH), 110.9 (CH), 55.2 (CH3), 33.2 
(CH2), 31.5 (CH2), 31.1 (CH2), 29.1 (CH2), 22.4 (CH2), 14.0 (CH3).  
IR (neat): 2954, 2925, 2855, 1586, 1463, 1377, 1091, 785 cm-1.  
MS (EI) m/z (relative intensity) 269 (38) [M+], 212 (100), 197 (46), 154 (28), 41 (8).  




The general procedure F was followed using 3j (93 mg, 0.50 mmol) and 12ab (111 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53jb (122 mg, 
82%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.69 (td, J = 7.8, 1.9 
Hz, 1H), 7.32 (dt, J = 7.8, 1.1 Hz, 1H), 7.27 (d, J = 8.3 Hz, 1H), 7.19 (ddd, J = 7.5, 4.9, 1.1 
Hz, 1H), 6.84−6.76 (m, 2H), 3.82 (s, 3H), 2.68 (t, J = 7.7 Hz, 2H), 1.52−1.33 (m, 2H), 
1.31−1.04 (m, 10H), 0.84 (t, J = 6.9 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 160.1 (Cq), 159.5 (Cq), 149.1 (CH), 142.5 (Cq), 136.0 (CH), 
133.2 (Cq), 131.0 (CH), 124.1 (CH), 121.2 (CH), 115.2 (CH), 110.9 (CH), 55.2 (CH3), 33.2 
(CH2), 31.8 (CH2), 31.2 (CH2), 29.4 (CH2), 29.2 (CH2), 29.1 (CH2), 22.6 (CH2), 14.1 (CH3). 
IR (neat): 2923, 2853, 1586, 1463, 1277, 1128, 1059, 747 cm-1.  
MS (EI) m/z (relative intensity) 297 (14) [M+], 212 (100), 197 (32), 154 (24), 43 (15). 







The general procedure F was followed using 3j (93 mg, 0.50 mmol) and 12ac (52 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53jc (95 mg, 
79%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.69 (td, J = 7.8, 1.9 
Hz, 1H), 7.33 (dt, J = 7.8, 1.1 Hz, 1H), 7.27 (d, J = 8.3 Hz, 1H), 7.19 (ddd, J = 7.5, 4.9, 1.1 
Hz, 1H), 6.85−6.74 (m, 2H), 3.82 (s, 3H), 2.69 (t, J = 7.7 Hz, 2H), 1.50−1.36 (m, 2H), 
1.29−1.11 (m, 2H), 0.77 (t, J = 7.2 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 160.1 (Cq), 159.5 (Cq), 149.1 (CH), 142.4 (Cq), 136.0 (CH), 
133.2 (Cq), 131.0 (CH), 124.1 (CH), 121.2 (CH), 115.2 (CH), 110.9 (CH), 55.2 (CH3), 33.4 
(CH2), 32.8 (CH2), 22.5 (CH2), 13.8 (CH3).  
IR (neat): 2954, 2929, 1586, 1462, 1378, 1128, 1017, 747 cm-1.  
MS (EI) m/z (relative intensity) 241 (24) [M+], 212 (100), 197 (25), 154 (17), 41 (3).  




The general procedure F was followed using 3k (112 mg, 0.50 mmol) and 12aa (90 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53ka (140 mg, 
91%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.69 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.76 (td, J = 7.8, 1.9 




J = 7.6, 4.9, 1.2 Hz, 1H), 2.71 (t, J = 7.9 Hz, 2H), 1.54−1.35 (m, 2H), 1.33−1.02 (m, 6H), 
0.80 (t, J = 6.9 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 159.0 (Cq), 149.4 (CH), 143.6 (Cq), 141.8 (Cq), 136.3 (CH), 
130.3 (Cq, 2JC-F = 32.5 Hz), 130.1 (CH), 126.4 (CH, 3JC-F = 3.8 Hz), 124.6 (Cq, 1JC-F = 271.3 
Hz), 124.0 (CH), 122.5 (CH, 3JC-F = 3.8 Hz), 122.2 (CH), 32.9 (CH2), 31.4 (CH2), 30.9 (CH2), 
29.0 (CH2), 22.4 (CH2), 14.0 (CH3).  
19F-NMR (283 MHz, CDCl3): δ = −62.56 (s).  
IR (neat): 2927, 2857, 1587, 1467, 1267, 1091, 990, 748 cm-1.  
MS (EI) m/z (relative intensity) 307 (12) [M+], 250 (100), 235 (72), 167 (10), 43 (12).  




The general procedure F was followed using 3k (112 mg, 0.50 mmol) and 12ab (111 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53kb (135 mg, 
81%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.68 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.76 (td, J = 7.8, 1.9 
Hz, 1H), 7.58−7.39 (m, 3H), 7.36 (dt, J = 7.8, 1.0 Hz, 1H), 7.28 (ddd, J = 7.6, 4.9, 1.2 Hz, 
1H), 2.71 (t, J = 7.9 Hz, 2H), 1.52−1.36 (m, 2H), 1.32−1.07 (m, 10H), 0.84 (t, J = 6.9 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 159.0 (Cq), 149.4 (CH), 143.6 (Cq), 141.8 (Cq), 136.3 (CH), 
130.3 (Cq, 2JC-F = 32.1 Hz), 130.1 (CH), 126.4 (CH, 3JC-F = 3.8 Hz), 124.5 (Cq, 1JC-F = 271.3 
Hz), 124.0 (CH), 122.5 (CH, 3JC-F = 3.8 Hz), 122.2 (CH), 32.9 (CH2), 31.8 (CH2), 31.0 (CH2), 
29.3 (CH2), 29.1 (CH2), 29.1 (CH2), 22.6 (CH2), 14.1 (CH3).  
19F-NMR (283 MHz, CDCl3): δ = −62.55 (s).  
IR (neat): 2923, 2853, 1586, 1463, 1277, 1128, 1059, 747 cm-1.  
MS (EI) m/z (relative intensity) 335 (12) [M+], 250 (100), 235 (50), 69 (8), 43 (23).  







The general procedure F was followed using 3k (112 mg, 0.50 mmol) and 12ad (92 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53kd (101 mg, 
65%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.68 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.75 (td, J = 7.8, 1.9 
Hz, 1H), 7.46−7.31 (m, 4H), 7.25 (ddd, J = 7.8, 1.9, 1.1 Hz, 1H), 2.48 (s, 2H), −0.22 (s, 9H). 
13C-NMR (75 MHz, CDCl3): δ = 159.5 (Cq), 149.2 (CH), 142.0 (Cq), 140.2 (Cq), 136.4 (CH), 
130.5 (CH), 130.1 (Cq, 2JC-F = 33.4 Hz), 126.5 (CH, 3JC-F = 4.3 Hz), 124.4 (CH), 124.2 
(Cq, 1JC-F = 271.3 Hz), 122.1 (CH), 120.9 (CH, 3JC-F = 4.3 Hz), 23.8 (CH2), −1.6 (CH3). 
19F-NMR (283 MHz, CDCl3): δ = −62.73 (s).  
IR (neat): 2955, 2856, 1587, 1406, 1248, 1120, 991, 746 cm-1.  
MS (EI) m/z (relative intensity) 309 (3) [M+], 294 (100), 216 (18), 167 (15), 73 (37).  




The general procedure F was followed using 3l (87 mg, 0.50 mmol) and 12aa (90 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53la (78 mg, 
61%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.67 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.74 (td, J = 7.6, 1.9 
Hz, 1H), 7.37−7.22 (m, 3H), 7.05−6.89 (m, 2H), 2.68 (t, J = 7.9 Hz, 2H), 1.53−1.36 (m, 2H), 




13C-NMR (75 MHz, CDCl3): δ = 162.6 (Cq, 1JC-F = 243.7 Hz), 159.4 (Cq), 149.2 (CH), 143.5 
(Cq, 3JC-F = 7.7 Hz), 136.4 (Cq, 4JC-F = 2.9 Hz), 136.2 (CH), 131.4 (CH, 3JC-F = 8.5 Hz), 124.1 
(CH), 121.7 (CH), 116.1 (CH, 2JC-F = 21.3 Hz), 112.5 (CH, 2JC-F = 21.3 Hz), 32.9 (CH2, 4JC-F = 
1.3 Hz), 31.4 (CH2), 30.8 (CH2), 29.0 (CH2), 22.4 (CH2), 14.0 (CH3).  
19F-NMR (283 MHz, CDCl3): δ = −(114.6－114.4) (m).  
IR (neat): 2955, 2856, 1608, 1564, 1427, 1150, 953, 747 cm-1.  
MS (EI) m/z (relative intensity) 257 (17) [M+], 200 (100), 185 (62), 133 (4), 41 (8).  




The general procedure F was followed using 3m (85 mg, 0.50 mmol) and 12aa (90 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53ma (92 mg, 
72%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.51 (dd, J = 5.0, 0.5 Hz, 1H), 7.36−7.15 (m, 5H), 7.05 
(ddd, J = 5.0, 1.6, 0.7 Hz, 1H), 2.66 (t, J = 7.9 Hz, 2H), 2.38 (s, 3H), 1.51−1.35 (m, 2H), 
1.26−1.06 (m, 6H), 0.80 (t, J = 7.0 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 160.2 (Cq), 148.8 (CH), 147.0 (Cq), 140.8 (Cq), 140.4 (Cq), 
129.6 (CH), 129.6 (CH), 128.1 (CH), 125.6 (CH), 125.0 (CH), 122.6 (CH), 32.9 (CH2), 31.5 
(CH2), 31.2 (CH2), 29.1 (CH2), 22.5 (CH2), 21.1 (CH3), 14.0 (CH3).  
IR (neat): 2954, 2923, 2854, 1599, 1467, 1291, 1040, 749 cm-1.  
MS (EI) m/z (relative intensity) 253 (14) [M+], 196 (100), 181 (43), 91 (2), 43 (8).  







The general procedure F was followed using 3a (85 mg, 0.50 mmol) and 12aa (90 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53aa (63 mg, 
50%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.69 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.73 (td, J = 7.8, 1.9 
Hz, 1H), 7.37 (dt, J = 7.8, 1.0 Hz, 1H), 7.28−7.10 (m, 4H), 2.66 (t, J = 7.8 Hz, 2H), 2.35 (s, 
3H), 1.51−1.34 (m, 2H), 1.30−1.06 (m, 6H), 0.82 (t, J = 6.8 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 160.4 (Cq), 149.1 (CH), 140.2 (Cq), 137.6 (Cq), 135.9 (CH), 
135.1 (Cq), 130.4 (CH), 129.6 (CH), 129.0 (CH), 124.1 (CH), 121.5 (CH), 32.5 (CH2), 31.5 
(CH2), 31.3 (CH2), 29.1 (CH2), 22.5 (CH2), 20.9 (CH3), 14.0 (CH3).  
IR (neat): 2954, 2923, 2855, 1587, 1425, 1287, 1109, 747 cm-1.  
MS (EI) m/z (relative intensity) 253 (16) [M+], 196 (100), 181 (44), 167 (2), 41 (10).  
HR-MS (EI) m/z calcd for [C18H23N] + 253.1830, found 253.1834.  




The general procedure F was followed using 3n (85 mg, 0.50 mmol) and 12aa (90 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53na (107 mg, 
85%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.69 (td, J = 7.8, 1.9 
Hz, 1H), 7.34 (dt, J = 7.8, 1.0 Hz, 1H), 7.27−7.16 (m, 2H), 7.13−7.00 (m, 2H), 2.65 (t, J = 7.9 
Hz, 2H), 2.36 (s, 3H), 1.50−1.33 (m, 2H), 1.28−1.04 (m, 6H), 0.80 (t, J = 6.9 Hz, 3H).  
                                                             




13C-NMR (75 MHz, CDCl3): δ = 160.4 (Cq), 149.1 (CH), 140.6 (Cq), 137.9 (Cq), 137.5 (Cq), 
136.0 (CH), 130.4 (CH), 129.7 (CH), 126.4 (CH), 124.1 (CH), 121.3 (CH), 32.9 (CH2), 31.5 
(CH2), 31.3 (CH2), 29.1 (CH2), 22.5 (CH2), 21.2 (CH3), 14.0 (CH3).  
IR (neat): 2954, 2923, 2856, 1613, 1561, 1296, 1091, 747 cm-1.  
MS (EI) m/z (relative intensity) 253 (23) [M+], 196 (100), 181 (48), 167 (14), 41 (9).  




The general procedure F was followed using 3b (78 mg, 0.50 mmol) and 12ae (116 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53be (101 mg, 
74%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.69 (td, J = 7.7, 1.9 
Hz, 1H), 7.41−6.97 (m, 11H), 2.73 (t, J = 7.8 Hz, 2H), 2.50 (t, J = 7.6 Hz, 2H), 1.77 (tt, J = 
7.8, 7.6 Hz, 2H).  
13C-NMR (75 MHz, CDCl3): δ = 159.9 (Cq), 148.8 (CH), 142.2 (Cq), 140.2 (Cq), 140.0 (Cq), 
136.4 (CH), 129.8 (CH), 129.8 (CH), 128.4 (CH), 128.3 (CH), 128.2 (CH), 125.9 (CH), 125.6 
(CH), 124.1 (CH), 121.7 (CH), 35.6 (CH2), 32.7 (CH2), 32.5 (CH2).  
IR (neat): 3024, 2929, 2858, 1585, 1495, 1264, 1090, 745 cm-1.  
MS (EI) m/z (relative intensity) 273 (3) [M+], 182 (100), 167 (57), 91 (6), 43 (5).  








mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53je (112 mg, 
74%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.61 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.64 (td, J = 7.7, 1.9 
Hz, 1H), 7.36−6.99 (m, 8H), 6.86−6.75 (m, 2H), 3.82 (s, 3H), 2.75 (t, J = 7.9 Hz, 2H), 2.51 (t, 
J = 7.6 Hz, 2H), 1.79 (tt, J = 7.9, 7.6 Hz, 2H).  
13C-NMR (75 MHz, CDCl3): δ = 159.9 (Cq), 159.5 (Cq), 149.1 (CH), 142.2 (Cq), 141.9 (Cq), 
136.0 (CH), 133.2 (Cq), 131.1 (CH), 128.3 (CH), 128.2 (CH), 125.6 (CH), 124.0 (CH), 121.2 
(CH), 115.3 (CH), 111.1 (CH),  55.2 (CH3), 35.6 (CH2), 32.8 (CH2), 32.6 (CH2).  
IR (neat): 3025, 2932, 2857, 1604, 1495, 1234, 988, 745 cm-1.  
MS (EI) m/z (relative intensity) 303 (3) [M+], 212 (100), 197 (30), 91 (21), 51 (3).  




The general procedure F was followed using 3k (112 mg, 0.50 mmol) and 12ae (116 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53ke (109 mg, 
64%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.70 (td, J = 7.8, 1.9 
Hz, 1H), 7.57−7.46 (m, 2H), 7.43 (d, J = 7.8 Hz, 1H), 7.36−7.08 (m, 5H), 7.08−6.97 (m, 2H), 
2.77 (t, J = 7.8 Hz, 2H), 2.51 (t, J = 7.6 Hz, 2H), 1.79 (tt, J = 7.8, 7.6 Hz, 2H).  
13C-NMR (75 MHz, CDCl3): δ = 158.8 (Cq), 149.4 (CH), 143.7 (Cq), 141.8 (Cq), 141.3 (Cq), 
136.4 (CH), 130.3 (Cq, 2JC-F = 32.5 Hz), 130.2 (CH), 128.3 (CH), 128.2 (CH), 126.5 (CH, 3JC-F 
= 4.0 Hz), 125.7 (CH), 124.2 (Cq, 1JC-F = 271.3 Hz), 123.9 (CH), 122.7 (CH, 3JC-F = 4.2 Hz), 
122.2 (CH), 35.6 (CH2), 32.5 (CH2), 32.4 (CH2).  
19F-NMR (283 MHz, CDCl3): δ = −62.55 (s).  




MS (EI) m/z (relative intensity) 341 (3) [M+], 250 (100), 235 (92), 91 (21), 51 (7).  




The general procedure F was followed using 3e (90 mg, 0.50 mmol) and 12ab (111 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53eb (124 mg, 
85%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 9.00 (dd, J = 4.3, 1.9 Hz, 1H), 8.13 (dd, J = 8.0, 1.9 Hz, 
1H), 7.82−7.71 (m, 2H), 7.66−7.50 (m, 3H), 7.46 (dd, J = 8.0, 4.3 Hz, 1H), 3.85 (t, J = 7.6 Hz, 
2H), 1.85−1.65 (m, 2H), 1.60−1.15 (m, 10H), 0.87 (t, J = 6.9 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 148.4 (Cq), 147.2 (CH), 143.8 (Cq), 135.5 (Cq), 135.4 (CH), 
130.9 (CH), 129.3 (Cq), 129.0 (CH), 127.4 (CH), 127.3 (Cq), 126.8 (CH), 125.3 (CH), 120.6 
(CH), 38.4 (CH2), 32.0 (CH2), 31.8 (CH2), 30.2 (CH2), 29.6 (CH2), 29.4 (CH2), 22.7 (CH2), 
14.1 (CH3).  
IR (neat): 3047, 2921, 2850, 1621, 1567, 1319, 1058, 757 cm-1.  
MS (EI) m/z (relative intensity) 291 (21) [M+], 206 (100), 191 (43), 98 (3), 43 (17).  




The general procedure F was followed using 3e (90 mg, 0.50 mmol) and 12aa (90 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 53ea (104 mg, 
79%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 9.00 (dd, J = 4.3, 1.9 Hz, 1H), 8.12 (dd, J = 8.0, 1.9 Hz, 




2H), 1.86−1.67 (m, 2H), 1.64−1.28 (m, 6H), 0.91 (t, J = 7.0 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 148.4 (Cq), 147.2 (CH), 143.8 (Cq), 135.5 (Cq), 135.3 (CH), 
130.9 (CH), 129.3 (Cq), 129.0 (CH), 127.4 (CH), 127.3 (Cq), 126.8 (CH), 125.3 (CH), 120.6 
(CH), 38.4 (CH2), 31.9 (CH2), 31.7 (CH2), 29.9 (CH2), 22.8 (CH2), 14.2 (CH3).  
IR (neat): 3024, 2919, 2850, 1591, 1421, 1319, 1029, 747 cm-1.  
MS (EI) m/z (relative intensity) 263 (12) [M+], 206 (100), 191 (52), 131 (4), 41 (8).  
HR-MS (EI) m/z calcd for [C19H21N] + 263.1674, found 263.1669.  




The general procedure F was followed using 82a (97 mg, 0.50 mmol) and 12aa (90 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 86aa (134 mg, 
97%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.65 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.88 (td, J = 7.9, 2.0 
Hz, 1H), 7.61−7.50 (m, 1H), 7.41 (dt, J = 7.9, 0.9 Hz, 1H), 7.35−7.26 (m, 2H), 7.18−7.02 (m, 
2H), 6.43 (s, 1H), 2.82 (t, J = 7.7 Hz, 2H), 1.65−1.45 (m, 2H), 1.39−1.10 (m, 6H), 0.83 (t, J = 
6.9 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 151.5 (Cq), 150.0 (CH), 141.8 (Cq), 138.3 (CH), 137.3 (Cq), 
128.7 (Cq), 122.0 (CH), 121.5 (CH), 121.2 (CH), 120.6 (CH), 119.8 (CH), 110.0 (CH), 102.1 
(CH), 31.5 (CH2), 29.0 (CH2), 28.5 (CH2), 27.4 (CH2), 22.5 (CH2), 14.0 (CH3).  
IR (neat): 3053, 2926, 2856, 1584, 1468, 1315, 1095, 737 cm-1.  
MS (EI) m/z (relative intensity) 278 (22) [M+], 221 (20), 207 (100), 130 (10), 78 (7).  
HR-MS (EI) m/z calcd for [C19H22N2] + 278.1783, found 278.1782. 
 
2-n-Hexyl-1-(pyrimidin-2-yl)-1H-indole (86ca) 
                                                             





The general procedure F was followed using 82c (98 mg, 0.50 mmol) and 12aa (90 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 86ca (115 mg, 
82%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.78 (d, J = 4.9 Hz, 2H), 8.24−8.13 (m, 1H), 7.57−7.45 (m, 
1H), 7.22−7.09 (m, 3H), 6.45 (s, 1H), 3.13 (t, J = 7.8 Hz, 2H), 1.70−1.51 (m, 2H), 1.45−1.17 
(m, 6H), 0.86 (t, J = 6.9 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 158.3 (Cq), 158.1 (CH), 142.4 (Cq), 136.9 (Cq), 129.4 (Cq), 
122.3 (CH), 121.7 (CH), 119.6 (CH), 117.0 (CH), 113.5 (CH), 105.4 (CH), 31.7 (CH2), 29.3 
(CH2), 29.1 (CH2), 29.0 (CH2), 22.6 (CH2), 14.1 (CH3).  
IR (neat): 2925, 2855, 1558, 1454, 1348, 1152, 929, 739 cm-1.  
MS (EI) m/z (relative intensity) 279 (38) [M+], 221 (24), 208 (100), 130 (12), 43 (4).  




The general procedure F was followed using 82c (98 mg, 0.50 mmol) and 12ab (111 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 86cb (109 mg, 
71%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.78 (d, J = 4.9 Hz, 2H), 8.25−8.10 (m, 1H), 7.57−7.45 (m, 
1H), 7.22−7.09 (m, 3H), 6.45 (s, 1H), 3.13 (t, J = 7.8 Hz, 2H), 1.68−1.50 (m, 2H), 1.44−1.14 
(m, 10H), 0.85 (t, J = 6.8 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 158.3 (Cq), 158.1 (CH), 142.4 (Cq), 136.9 (Cq), 129.4 (Cq), 
122.3 (CH), 121.7 (CH), 119.6 (CH), 117.0 (CH), 113.5 (CH), 105.4 (CH), 31.9 (CH2), 29.5 




IR (neat): 2923, 2852, 1558, 1454, 1347, 1082, 985, 739 cm-1.  
MS (EI) m/z (relative intensity) 307 (38) [M+], 221 (27), 209 (100), 130 (9), 43 (11).  
HR-MS (EI) m/z calcd for [C20H25N3] + 307.2048, found 307.2055.  




The general procedure F was followed using 82a (97 mg, 0.50 mmol) and 12ae (116 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 86ae (138 mg, 
89%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.64 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.93−7.80 (m, 1H), 
7.65−7.52 (m, 1H), 7.46−7.03 (m, 10H), 6.48 (s, 1H), 2.90 (t, J = 7.7 Hz, 2H), 2.63 (t, J = 7.9 
Hz, 2H), 1.90 (tt, J = 7.9, 7.7 Hz, 2H).  
13C-NMR (75 MHz, CDCl3): δ = 151.5 (Cq), 149.6 (CH), 142.0 (Cq), 141.1 (Cq), 138.2 (CH), 
137.3 (Cq), 128.6 (Cq), 128.4 (CH), 128.3 (CH), 125.7 (CH), 122.0 (CH), 121.6 (CH), 121.0 
(CH), 120.6 (CH), 119.9 (CH), 110.1 (CH), 102.4 (CH), 35.4 (CH2), 30.3 (CH2), 28.0 (CH2). 
IR (neat): 3024, 2933, 2859, 1584, 1468, 1346, 1051, 735 cm-1.  
MS (EI) m/z (relative intensity) 312 (23) [M+], 221 (35), 208 (100), 130 (8), 44 (8).  




The general procedure F was followed using 82c (98 mg, 0.50 mmol) and 12ae (116 mg, 0.75 
                                                             




mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 86ce (135 mg, 
86%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.71 (d, J = 4.9 Hz, 2H), 8.30−8.14 (m, 1H), 7.58−7.43 (m, 
1H), 7.30−7.07 (m, 8H), 6.47 (s, 1H), 3.20 (t, J = 7.1 Hz, 2H), 2.68 (t, J = 7.7 Hz, 2H), 1.95 
(tt, J = 7.7, 7.1 Hz, 2H).  
13C-NMR (75 MHz, CDCl3): δ = 158.2 (Cq), 158.1 (CH), 142.2 (Cq), 141.8 (Cq), 136.9 (Cq), 
129.3 (Cq), 128.5 (CH), 128.3 (CH), 125.7 (CH), 122.5 (CH), 121.7 (CH), 119.6 (CH), 
117.0 (CH), 113.7 (CH), 105.8 (CH), 35.6 (CH2), 30.9 (CH2), 28.9 (CH2).  
IR (neat): 3024, 2931, 1558, 1495, 1348, 1206, 1152, 738 cm-1.  
MS (EI) m/z (relative intensity) 313 (32) [M+], 222 (18), 208 (100), 130 (16), 91 (11). 




The general procedure F was followed using 82d (113 mg, 0.50 mmol) and 12ab (111 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 86db (123 
mg, 73%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.74 (d, J = 4.9 Hz, 2H), 8.16 (d, J = 9.0 Hz, 1H), 7.09 (t, J 
= 4.9 Hz, 1H), 6.99 (d, J = 2.8 Hz, 1H), 6.81 (dd, J = 9.0, 2.8 Hz, 1H), 6.37 (s, 1H), 3.84 (s, 
3H), 3.13 (t, J = 7.3 Hz, 2H), 1.69−1.51 (m, 2H), 1.44−1.14 (m, 10H), 0.86 (t, J = 6.8 Hz, 3H). 
13C-NMR (75 MHz, CDCl3): δ = 158.4 (Cq), 158.0 (CH), 155.4 (Cq), 143.2 (Cq), 131.9 (Cq), 
130.2 (Cq), 116.7 (CH), 114.8 (CH), 111.2 (CH), 105.5 (CH), 102.2 (CH), 55.7 (CH3), 31.9 
(CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 29.2 (CH2), 29.1 (CH2), 22.7 (CH2), 14.1 (CH3). 
IR (neat): 2923, 2853, 1614, 1557, 1292, 1139, 985, 736 cm-1.  
MS (EI) m/z (relative intensity) 337 (28) [M+], 252 (20), 238 (100), 195 (22), 41 (8).  







The general procedure F was followed using 82b (104 mg, 0.50 mmol) and 12ab (111 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 86bb (121 
mg, 67%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.63 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.86 (td, J = 7.9, 1.9 
Hz, 1H), 7.56−7.46 (m, 1H), 7.41 (d, J = 8.1 Hz, 1H), 7.33−7.25 (m, 2H), 7.18−7.04 (m, 2H), 
2.87 (t, J = 7.7 Hz, 2H), 2.29 (s, 3H), 1.40−1.02 (m, 12H), 0.83 (t, J = 6.9 Hz, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 151.9 (Cq), 149.5 (CH), 138.2 (CH), 137.3 (Cq), 136.5 (Cq), 
129.5 (Cq), 121.7 (CH), 121.6 (CH), 121.1 (CH), 120.1 (CH), 118.1 (CH), 109.8 (Cq), 109.7 
(CH), 31.8 (CH2), 29.4 (CH2), 29.2 (CH2), 29.1 (CH2), 29.1 (CH2), 24.7 (CH2), 22.6 (CH2), 
14.1 (CH3), 8.8 (CH3).  
IR (neat): 2922, 2853, 1585, 1458, 1361, 1222, 1014, 736 cm-1.  
MS (EI) m/z (relative intensity) 320 (38) [M+], 221 (100), 207 (30), 144 (17), 43 (24). 




The general procedure F was followed using 82e (112 mg, 0.50 mmol) and 12ab (111 mg, 
0.75 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 86eb (135 
mg, 81%) was obtained as a colorless oil.  
1H-NMR (300 MHz, CDCl3): δ = 8.85 (d, J = 4.9 Hz, 2H), 7.40 (d, J = 6.9 Hz, 1H), 7.32 (d, J 
= 4.9 Hz, 1H), 7.08 (t, J = 7.6 Hz, 1H), 6.97 (d, J = 7.6 Hz, 1H), 6.40 (s, 1H), 2.62 (t, J = 7.5 
Hz, 2H), 2.24 (q, J = 7.5 Hz, 2H), 1.59−1.43 (m, 2H), 1.36−1.11 (m, 10H), 0.94 (t, J = 7.5 Hz, 
3H), 0.85 (t, J = 6.9 Hz, 3H).  




127.8 (Cq), 122.4 (CH), 121.2 (CH), 119.2 (CH), 117.8 (CH), 102.9 (CH), 31.8 (CH2), 29.3 
(CH2), 29.3 (CH2), 29.2 (CH2), 28.4 (CH2), 27.5 (CH2), 25.6 (CH2), 22.6 (CH2), 14.1 (CH3), 
13.9 (CH3).  
IR (neat): 2924, 2853, 1559, 1415, 1347, 1218, 1095, 741 cm-1.  
MS (EI) m/z (relative intensity) 335 (47) [M+], 236 (100), 222 (72), 156 (7), 41 (11).  




The general procedure F was followed using 3k (112 mg, 0.50 mmol) and 22ba (89 mg, 0.75 
mmol). After purification by column chromatography (n-hexane/DCM 2:1) 87ka (98 mg, 64%) 
was obtained as a white solid (m.p. 75−76 °C).  
1H-NMR (300 MHz, CDCl3): δ = 8.69 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.75 (td, J = 7.9, 1.9 
Hz, 1H), 7.61(s, 1H), 7.52−7.44 (m, 1H), 7.42 (dt, J = 7.9, 0.7 Hz, 1H), 7.32 (dt, J = 7.9, 1.0 
Hz, 1H), 7.28 (ddd, J = 7.9, 4.9, 1.2 Hz, 1H), 2.78 (tt, J = 11.9, 3.2 Hz, 1H), 1.86−1.58 (m, 
5H), 1.53−1.32 (m, 2H), 1.30−1.04 (m, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 159.0 (Cq), 149.4 (CH), 146.5 (Cq), 143.3 (Cq, 4JC-F = 1.6 
Hz), 136.2 (CH), 130.4 (Cq, 2JC-F = 32.5 Hz), 130.2 (CH), 124.3 (Cq, 1JC-F = 271.3 Hz), 124.0 
(CH), 123.3 (CH, 3JC-F = 3.9 Hz), 122.3 (CH, 3JC-F = 3.9 Hz), 122.2 (CH), 39.9 (CH), 34.2 
(CH2), 26.6 (CH2), 26.0 (CH2).  
19F-NMR (283 MHz, CDCl3): δ = −62.5 (s).  
IR (neat): 2926, 2852, 1587, 1429, 1272, 989 cm-1.  
MS (EI) m/z (relative intensity) 305 (50) [M+], 304 (100), 248 (35), 235 (18), 161 (7). 







The general procedure F was followed using 82a (97 mg, 0.50 mmol) and 22ba (89 mg, 0.75 
mmol). The mixture was stirred at 60 °C  for 16 h. After purification by column 
chromatography (n-hexane/EtOAc 20:1) 88aa (72 mg, 52%) was obtained as a white solid 
(m.p. 89−90 °C).  
1H-NMR (300 MHz, CDCl3): δ = 8.66 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.88 (td, J = 7.9, 2.0 
Hz, 1H), 7.63−7.53 (m, 1H), 7.42 (dt, J = 7.9, 0.9 Hz, 1H), 7.32 (ddd, J = 7.9, 4.9, 0.9 Hz, 
1H), 7.29−7.21 (m, 1H), 7.17−7.04 (m, 2H), 6.45 (t, J = 0.8 Hz, 1H), 2.82 (tt, J = 11.5, 3.3 Hz, 
1H), 2.00−1.83 (m, 2H), 1.81−1.61 (m, 3H), 1.50−1.32 (m, 2H), 1.31−1.11 (m, 3H).  
13C-NMR (75 MHz, CDCl3): δ = 151.7 (Cq), 149.6 (CH), 147.2 (Cq), 138.3 (CH), 137.3 (Cq), 
128.5 (Cq), 122.1 (CH), 121.5 (CH), 121.4 (CH), 120.4 (CH), 119.9 (CH), 109.9 (CH), 99.8 
(CH), 35.6 (CH), 33.2 (CH2), 26.4 (CH2), 26.2 (CH2).  
IR (neat): 2925, 2852, 1585, 1436, 1264, 997 cm-1.  
MS (EI) m/z (relative intensity) 276 (100) [M+], 219 (78), 130 (16), 78 (18).  
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